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ABSTRACT 
 
Nucleos(t)ide reverse transcriptase inhibitors (N(t)RTI) are essential components of combination 
antiretroviral therapy for treatment of human immunodeficiency virus type-1 (HIV-1) infection. 
N(t)RTI are analogs of natural 2’-deoxyribonucleos(t)ides that lack a 3’-hydroxyl. Once 
metabolized by host kinases to the active form, their incorporation into viral DNA by HIV-1 
reverse transcriptase (RT) results in chain termination of DNA synthesis. N(t)RTI efficacy is 
undermined primarily by rapid selection of resistant/cross-resistant HIV-1 variants. 
Consequently, the development of novel N(t)RTI with activity against a broad range of N(t)RTI-
resistant HIV-1 is of critical importance. Rational design of novel N(t)RTI with knowledge of 
analog structure-activity-resistance relationships with the RT target enzyme is the most 
promising approach. We hypothesized that uncovering knowledge of how N(t)RTI base, sugar, 
and phosphate structures influence activity and resistance phenotypes would aid in the rational 
design of new N(t)RTI with improved activity and resistance profiles. Therefore, a combination 
of biochemical, antiviral, molecular modeling, and cellular pharmacology analyses provided a 
 v 
detailed characterization of structure-activity-resistance relationships for inhibition of wild-type 
and NRTI-resistant HIV-1 by novel N(t)RTI. First, we studied two novel nucleoside phosphonate 
NtRTI, (R)-6-[2-phosphonylmethoxy]propoxy]-2,4-diaminopyrimidine (PMEO-DAPym) and (5-
(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosphonate (GS-9148). We 
showed the diphosphate (-DP) form, PMEO-DAPym-DP acts as a purine mimetic that is 
recognized by RT as an adenosine analog and unambiguously incorporated across from thymine 
(DNA) or uracil (RNA). Studies indicated that PMEO-DAPym-DP and GS-9148-DP were 
superior to tenofovir-DP against both discrimination and excision RT resistance mechanisms. 
Next, we examined structure-activity-resistance relationships of 6-modified, 3’-azido-2’,3’-
dideoxyguanosine (3’-azido-ddG) NRTI analogs. In RT-mediated DNA synthesis assays the 
triphosphate (-TP) form of each analog behaved as an adenosine mimetic for incorporation by 
HIV-1 RT. Importantly, the structure-activity relationships for incorporation and ATP-mediated 
excision were different, suggesting that new analogs can be designed that are efficiently 
incorporated but poorly excised by RT. RS-788, a 5’-monophosphate prodrug of 3’-azido-2’,3’-
dideoxy-2,6-diaminopurine (3’-azido-2,6-DA-P), displayed potent activity against multi-NRTI-
resistant HIV-1 and unique cellular metabolism. RS-788 was metabolized ~1:1 to both 3’-azido-
2,6-DA-P and 3’-azido-ddG, thus delivering two distinct metabolites, each of which are potent 
RT chain-terminators that are incorporated opposite different bases, thymine and cytosine, 
respectively. Combinations of 3’-azido-2,6-DA-P+3’-azido-ddG synergistically inhibited multi-
NRTI-resistant RT DNA synthesis.  
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1 
1.0  INTRODUCTION 
In 1983, the human immunodeficiency virus (HIV) was independently discovered by research 
groups led by Robert Gallo and Luc Montagnier as the etiologic agent of acquired 
immunodeficiency syndrome (AIDS) (1, 2). Only two years later, Samuel Broder and colleagues 
showed that the nucleoside analog 3’-azido-thymidine (AZT, zidovudine) had inhibitory activity 
against HIV replication targeting the viral enzyme reverse transcriptase (RT) (3-5). This seminal 
discovery demonstrated that HIV replication could be suppressed by small molecule 
chemotherapeutic agents, and provided the basis for the field of antiviral therapeutics. However, 
the rapid development of viral resistance to antiviral medications remains a significant challenge 
to successful antiviral therapy. Therefore, there is a continued need to develop novel drugs. This 
introductory chapter will discuss key aspects of HIV virology, RT structure and function, 
antiretroviral therapeutics focusing on nucleoside/nucleotide inhibitors of HIV-1 reverse 
transcriptase (NRTI), and antiviral drug resistance. 
1.1   HIV CLASSIFICATION 
HIV is a Lentivirus from the family Retroviridae that originated in West and Central sub-Saharan 
Africa from closely related non-human primate simian immunodeficiency viruses (SIV) (2, 6, 7). 
HIV is classified into two groups, type 1 (HIV-1) and type 2 (HIV-2). HIV-1 is most closely 
2 
related to SIV endemic in chimpanzees (SIVcpz) and is believed to have entered the human 
population through multiple primate to human zoonotic transmissions (7, 8). HIV-2 likely 
originated from viruses carried by the sooty mangabey (SIVsmm) (9, 10).  
The more virulent HIV-1 is responsible for worldwide human infections while HIV-2 is 
largely confined to sub-Saharan Africa (11). HIV-1 is divided into three groups M (major), O 
(outlier), and N (non-major/non-outlier) based on the viral envelope (env) gene (12, 13). Group 
M HIV-1 is the most prevalent worldwide and is genetically subdivided into nine clades (clades 
A-K) which are largely geographically distinct (13).  
 
1.2 EPIDEMIOLOGY 
HIV-1 infection has grown to a worldwide pandemic. As of 2010, the WHO estimates 34 million 
people are living with HIV-1 (11). Of those, 16 million are women and 2.5 million are children 
under the age of 15. Approximately 2.6 million people were newly infected with HIV in 2010 
and more than 30 million people have died from HIV/AIDS-related disease since the beginning 
of the pandemic. 
Sub-Saharan Africa is the most heavily affected region, accounting for more 68% of 
HIV-1 infections and 66% of AIDS-related deaths (11). Approximately 5% of the population in 
sub-Saharan Africa was living with HIV-1 in 2009. The second most afflicted region is south and 
south-east Asia with approximately 12% of worldwide infections. India alone accounts for more 
than 2.4 million cases. The most heavily impacted regions occur in the developing world where 
low income countries have limited access to antiviral medications. In 2003, it was estimated that 
3 
> 7% of HIV-1 infected individuals in sub-Saharan Africa had access to antiretroviral drugs. 
Initiatives by the World Health Organization, UNAIDS, and PEPFAR have increase access to 
37% of those in need by 2010 (11).  
The lowest prevalence of HIV infection is in west and central Europe with about 0.2% of 
the population infected. In the United States and Canada, approximately 1.5 million people are 
infected with HIV-1, representing ~ 0.5% of the adult population. In 2009, there were ~ 70,000 
people newly infected with HIV-1 in the United States and Canada and about 26,000 AIDS-
related deaths (11).  
1.3 HIV-1/AIDS TRANSMISSION AND PATHOGENESIS 
HIV-1 is transmitted through direct contact with blood, semen, vaginal fluid, or breast milk of 
infected persons (14, 15). The most common route of infection is through sexual contact with an 
infected person (15). Infections also result from intravenous drug use, blood transfusions, and 
mother-to-child-transmission (intrapartum, peripartum, or via breast feeding). Instances of these 
infections have decreased substantially due to greater awareness, blood bank screening, and 
improved prenatal treatment, respectively (11).  
Following exposure, HIV-1 infects host lymphocytic cells harboring the cell surface 
protein CD4. HIV-1 infection proceeds through three clinical stages of disease (Figure 1.1): 
acute infection, secondary infection (clinical latency), and AIDS (15, 16). Acute HIV-1 infection 
(also referred to as primary infection) lasts approximately 2-4 weeks post-transmission and is 
characterized by influenza-like illness. Common symptoms include fever, lymphadenopathy, 
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Figure 1.1 A generalized graph of HIV-1 disease progression showing the relationship of 
CD4+ T lymphocyte decay and plasma viral load over time.  
The CD4+ T lymphocyte count is indicated in blue of the left axis, while the number of HIV-1 
RNA copies per milliliter of plasma is indicated in red on the right axis. The landmarks of 
clinical disease progression are indicated in black. This figure was adapted from references (15, 
16). 
 
pharyngitis, rash, myalgia, and malaise. Acute infection is associated with a sharp spike in viral 
load (up to > 1 million HIV-1 RNA copies / ml of plasma) with a concurrent drop in target CD4+ 
T cells (14, 15). Acute symptoms wane as the host immune system elicits a cytotoxic T cell 
response, resulting in viral load reduction and partial recovery of CD4+ T cell counts. Recent 
studies suggest that it is during the initial acute phase of infection that viral reservoirs of latently 
infected cells are established (17, 18). The specific cell types or tissue compartments that harbor 
latent HIV-1 are not fully recognized and there is currently substantial debate about how these 
reservoirs contribute to persistent viremia. HIV-1 replication continues during asymptomatic 
infection, resulting in a steady decrease in CD4+ T cells over a period of 1 to 10 years (15). 
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Without intervention, the clinical development of AIDS occurs once CD4+ T cell counts drop 
below 200 cells per mL. The severe impairment of the immune system renders the individual 
highly susceptible to opportunistic infections or cancer. Following the onset of AIDS, patients 
succumb to opportunistic infections which commonly include pneumocystis pneumonia, 
tuberculosis, and candidiasis or cancers such as Kaposi’s sarcoma and lymphoma (15, 19).  
1.4 HIV-1 STRUCTURE AND VIRAL LIFE CYCLE 
The roughly spherical 110 nM HIV-1 virions are composed of a conical capsid core surrounded 
by a host cell membrane-derived lipid envelope (Figure 1.2) (20). The capsid core is composed 
of approximately 1500 molecules of the viral p24 capsid (CA) protein (21). The HIV-1 capsid 
core encloses two copies of the positive-sense single-stranded RNA genome that are 5’-methyl-
GDP capped and 3’-polyadenylated (20). The RNA genomes are tightly bound and stabilized by 
the nucleocapsid (NC) protein. The virion also contains cellular components, the essential viral 
enzymes protease (PR), reverse transcriptase (RT), and integrase (IN), and the accessory proteins 
Vif, Vpr, Nef, and Vpu. The matrix (MA) protein coats the interior of the viral envelope, which 
is studded with envelope glycoproteins composed of trimers of the gp120 surface protein (SU) 
and gp41 transmembrane protein (TM) complex.  
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Figure 1.2 HIV-1 genome organization, viral proteins, and mature virion structure. 
The genome structure and protein products were adapted from reference (20). The virion 
structure was adapted from reference (18). 
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The 9.2 kb HIV-1 RNA genome encodes three primary genes gag, pol, and env, as well 
as six accessory genes tat, rev, vif, vpr, vpu, and nef (Figure 1.2) (20). In the proviral form, the 
HIV-1 genome, like all retroviruses, contains two copies of the long terminal repeat (LTR) at the 
5’- and 3’- ends of the genome. The LTRs are composed of the segments U3 (derived from a 
unique sequence at the 3’ end), R (repeated sequence at both ends), and U5 (derived from a 
unique sequence at the 5’ end) (20).  
The HIV-1 replication cycle begins when the virion gp120 envelope glycoprotein 
recognizes and binds the cell surface protein CD4 on host lymphocytes (22, 23). Viral entry 
requires additional binding to one co-receptor molecules (24). The seven-transmembrane, G-
protein-coupled, receptors CCR5 and CXCR4 are most commonly used as HIV-1 entry 
coreceptors, however others such as CCR8 have also been identified (25-27). Early in HIV-1 
infection, viruses predominantly infect CD4+ cells expressing the co-receptor CCR5. During the 
course of infection, viruses often switch cell entry tropism to infect cells expressing the co-
receptor CXCR4 (26, 27). Tight binding of gp120 to CD4 and a co-receptor triggers a 
conformational change exposing the gp41 viral fusion protein which inserts into the host cell 
membrane. The resulting fusion of the virus and host membranes releases the viral core into the 
host cell cytoplasm (24-27).  
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Although evidence suggests reverse transcription may begin within the virion, the 
availability of host cytoplasmic dNTP pools facilitates the completion of reverse transcription. 
(described in detail below) (28). The full-length double-stranded DNA product of reverse 
transcription together with viral integrase, MA and Vpr and various cellular proteins form the 
pre-integration complex (PIC) (29). The PIC is transported into the cell nucleus where the viral 
DNA is inserted into a host chromosome through the action of viral integrase and several host 
factors (30).  
Viral genes are expressed from the integrated proviral DNA by the host transcription 
machinery including RNA polymerase II (31). Proviral transcription is initiated at the U3 region 
of the 5’ LTR that contains numerous binding sites for viral regulators such as Tat (trans-
activator of transcription), Rev (regulator of viral gene expression), and Nef (negative factor) as 
well as host transcription factors, including Sp1, NFκB, AP-1, and NFAT. Following 
transcription initiation, Tat binds the stem-loop TAR element at the 5’ end of the nascent mRNA 
and promotes transcription elongation (31).  Proviral transcription results in the production of a 
genome length mRNA which can serve as the message for viral polyprotein translation or can be 
modified to serve as a new RNA genome to be incorporated into a virion (31). The full length 
mRNA transcript contains multiple splice sites to allow for the generation of over 40 unique viral 
transcripts for the expression of the nine viral genes. The full length (unspliced) mRNA serves as 
the message for translation of the Gag and Gag- Pol precursor polyproteins by host ribosomes. 
During Gag translation, a -1 ribosomal frameshifting mechanism allows for the production of the 
Gag- Pol polyprotein (31, 32). This mechanism produces approximately one Gag- Pol 
polyprotein for every 10-20 Gag polyproteins.  
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The Env polyprotein undergoes multiple glycosylation events in the endoplasmic 
reticulum and is then trafficked to and inserted into the cellular membrane (33). Full-length RNA 
genomes interact with the Gag polyprotein through packaging sequences to be transported to the 
assembling virion at the cell membrane (33, 34). The Gag- Pol polyprotein is also transported via 
interactions with Gag (33). Virion budding is promoted when RNA/Gag complexes bind the 
cytoplasmic tail of membrane associated Env proteins. Assembled immature viral particles are 
released from the cell membrane and the action of the HIV-1 protease begins the maturation 
process (33). The viral protease first auto-cleaves from the Gag- Pol precursor polyprotein. 
Further proteolysis of the Gag- Pol precursor liberates the mature RT and IN enzymes. 
Proteolytic cleavage of the Gag precursor polyprotein yields the mature structural proteins CA, 
MA, and NC, while cleavage of the Env polyproteins produces the gp41 and gp120 envelope 
proteins (20, 33). The proteolytic liberation of the mature HIV-1 structural proteins promotes the 
condensation of the core into its characteristic bullet shape, thus producing mature, infectious 
viral progeny.  
1.5 ANTIRETROVIRAL THERAPY 
At the beginning of the AIDS epidemic in the early 1980s, HIV-1 infection meant near certain 
mortality within 1 year from the onset of AIDS. The grave need to curtail this rapidly 
progressing epidemic led to the development of the RT inhibitor 3’-azido-3’-deoxythymidine 
(zidovudine, AZT) in 1985 (3-5). This was only two years after the identification of HIV-1 as the 
etiologic agent of AIDS. AZT, the first drug for the treatment of any viral infection, became 
clinically available as a monotherapy in 1987 (35). Since then 24 additional antiretroviral drugs 
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have been approved by the United States FDA, rendering HIV-1 a chronic manageable infection, 
in which patients receiving therapy can now live many healthy years before the onset of AIDS 
(19, 35).  
1.5.1 Antiretroviral drug targets and classes  
The FDA-approved antiretrovirals are divided into 6 classes that target 4 key steps in the HIV-1 
life cycle: viral entry, reverse transcription, integration, and protein processing/maturation (35, 
36).  
The first steps in the HIV-1 life cycle, viral attachment and membrane fusion are targeted 
by two classes of drugs known collectively as entry inhibitors. The first class of entry inhibitors 
are CCR5 antagonists, represented by one FDA approved antiretroviral, maraviroc.  Maraviroc 
binds the viral chemokine co-receptor CCR5, thus preventing gp120 mediated viral attachment 
(37). Maraviroc, however, has no efficacy against CXCR4-tropic viruses and susceptible viruses 
can easily become resistant via point mutations in gp120. The viral envelope fusion inhibitor 
enfuvirtide (T-20) represents the second class of entry inhibitors. Enfuvirtide acts as a 
peptidomimetic of the HIV-1 gp41 fusion peptide to prevent fusion of the viral and cell 
membranes (36, 38). Enfuvirtide is reserved for treatment experienced patients because 
proteolysis of the drug in the gastrointestinal tract requires administration by twice daily 
intravenous injections. 
Reverse transcription is inhibited by 12 FDA approved drugs from two classes (36, 39): 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse 
transcriptase inhibitors (NNRTI).  The FDA approved NRTI (Figure 1.3) include one 
monophosphate nucleotide, tenofovir (TFV; [FDA approved as the prodrug tenofovir disoproxil  
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Figure 1.3 Structures of the FDA approved NRTI. 
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fumarate, TDF]), and 7 nucleosides; zidovudine (AZT), stavudine (d4T), lamivudine (3TC), 
emtricitabine (FTC), zalcitabine (ddC), didanosine (ddI), and abacavir (ABC). For the remainder 
of this work the abbreviation “NRTI” will refer to both nucleoside and nucleotide analogs while 
the abbreviation “NtRTI” will be used when specifically referring to nucleotide analogs. NRTI 
are analogs of natural 2’-deoxribonucleotides that must be metabolized by host cell enzymes to 
their active triphosphate forms. NRTI-triphosphates (NRTI-TP) compete with cellular dNTPs for 
incorporation by RT into HIV-1 DNA. Once incorporated into DNA, NRTI result in chain-
termination of viral DNA synthesis due to the lack of a 3’-OH group (39). NRTI mechanisms of 
action and resistance will be described in detail below.  
The five NNRTI, efavirenz (EFV), etravirine (ETV), nevirapine (NVP), delavirdine 
(DLV), and rilpivirine (RPV) are allosteric, non-competitive inhibitors that bind RT in a specific 
hydrophobic pocket near the polymerase active site (40, 41). NNRTI binding perturbs active site 
residues, resulting in decreased nucleotide incorporation (41). Single amino acid substitutions in 
RT can induce resistance and broad cross-resistance to each member of this drug class (42). 
Following reverse transcription, the viral cDNA must be integrated into the host 
chromosome. Integration is blocked by inhibitors of the HIV-1 encoded integrase enzyme. The 
integrase inhibitor raltegravir was FDA approved in 2007 for treatment-experienced patients and 
has been subsequently approved for treatment-naïve patients (36, 43). Raltegravir competitively 
inhibits the strand transfer step of integration by binding the divalent metal cations in the 
integrase active site. Integrase inhibitors result in decreased HIV-1 DNA integration. The 
discovery of novel integrase inhibitors with improved efficacy is an active area of investigation.  
The final step in producing infectious HIV-1 particles is viral maturation through the 
proteolytic processing of precursor polypeptides by the virally encoded protease. Protease 
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inhibitors (PI) mimic natural protease substrates and block the action of HIV-1 protease (35, 36, 
44). Protease inhibition thus prevents the maturation of infectious virions. FDA approved 
protease inhibitors include indinavir, saquinavir, fosamprenavir, ritonavir, darunavir, atazanavir, 
tipranovir, lopinavir, and nelfinavir. Most protease inhibitors cause adverse side effects and have 
poor bioavailability (36, 44). The PI ritonavir also inhibits the cytochrome P-450 CYP3A4 
enzyme which is responsible for metabolism of most PI (45). Thus, current FDA guidelines 
suggest the co-administration of ritonavir with other PIs to minimize metabolism and improve 
bioavailability and half-life.  
1.5.2 Combination antiretroviral therapy 
The initial use of AZT as monotherapy quickly led to the development of viral populations with 
decreased drug susceptibility (46, 47). Multiple studies have shown that treatment regimens 
including two NRTIs with an NNRTI or a PI suppress HIV-1 replication without the emergence 
of drug resistance (36, 48, 49). Thus, the use of three or more antiretrovirals from different drug 
classes in combination, termed highly active antiretroviral therapy (HAART) became the 
treatment standard in 1996. HAART decreased resistance development, reduced patient 
morbidity, and improved survival (36, 39). To this day, standard antiretroviral treatment 
regimens include two NRTIs with at least one NNRTI, PI, or integrase inhibitor.  
The requirement of multiple drug combination therapy provides a heavy pill burden on 
HIV-1 patients that often require multiple daily doses at various intervals. To ease patient pill 
burden and increase regimen adherence several fixed-dose combination pill formulations have 
been developed (36). These include Combivir (AZT+3TC), Trizivir (ABC+3TC+AZT), Truvada 
(TDF+FTC), Epzicom (ABC+3TC), and Kaletra (lopinavir boosted with ritonavir).  The three 
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drug combination Atripla (TDF+FTC+EFV) was the first once daily antiretroviral pill including 
2 NRTIs and an NNRTI that can fully suppress HIV-1 replication in some patients. Atripla was 
followed by the approval in 2011 of the multi-class triple combination Complera 
(TDF+FTC+RPV). The recently developed 4-drug combination Quad pill containing the novel 
integrase inhibitor elvitegravir, the novel pharmacoenhancer cobicistat (a CYP3A4 inhibitor that 
boosts levels of other drugs but has no antiviral activity itself), tenofovir, and emtricitabine 
represents the first once daily dual-target combination pill (50). The Quad pill is expected to be 
approved by the FDA in the summer of 2012. 
1.6 HIV-1 REVERSE TRANSCRIPTASE 
Successful retrovirus replication requires the conversion of the positive sense, single-stranded 
RNA genome to double stranded cDNA that is competent for incorporation into the host 
chromosome (51). The RNA-directed DNA synthesis or reverse transcription activity necessary 
for this process is not required for the growth of eukaryotic cells. Therefore, this step provides a 
unique viral characteristic that can be targeted for inhibition of viral replication. Reverse 
transcription was first observed in Rous sarcoma virus by Baltimore and Temin in 1970 (52, 53). 
In order to complete the complex reverse transcription process, the HIV-encoded reverse 
transcriptase enzyme is capable of both RNA- directed and DNA-directed DNA synthesis, 
ribonuclease H cleavage (RNase H, ‘H’ for hybrid), and strand transfer activity.  
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1.6.1 Steps of HIV-1 reverse transcription 
The multi-step process of HIV-1 reverse transcription will be described in detail here  
(Figure 1.4):  
1) Reverse transcription begins with minus strand DNA synthesis by RNA-dependent 
DNA polymerase (RDDP) activity of RT (54). A host tRNALys3 hybridized to the RNA 
genome at a primer binding site (PBS) near the 5’ end serves as the initial primer (55).  
RT elongates the minus strand to the 5’ end of the genome, producing a product termed 
minus strand strong stop DNA (-ssDNA). The RNA template of the subsequent 
RNA/DNA heteroduplex is simultaneously removed by the RNase H activity of RT.  
2) RNase H removal of template RNA and subsequent dissociation of -ssDNA is 
essential for minus strand DNA transfer and annealing to a homologous repeat region 
near the 3’ end of the genomic RNA template (56, 57). This strand transfer may occur 
intra- or inter-molecularly (58). Intermolecular strand transfer provides a source of 
recombination and genetic diversity during reverse transcription (59).  
3) Minus strand elongation with concurrent RNase H cleavage results in a complete 
cDNA. RNase H cleavages during cDNA synthesis leave 3’ and central polypurine tract 
(PPT) sequences uncleaved which serve as primers for plus strand DNA initiation (60). 
Highly specific RNase H cleavages occur at the 3’ and 5’ ends of the PPT through 
specific RNase H primer grip contacts with mismatched and unpaired residues in the PPT 
(61-66) . Correct cleavage of the 3’ PPT is essential to properly produce the integrase 
recognition site for proviral integration (65).  
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Figure 1.4 Mechanism of HIV-1 reverse transcription. 
The steps required to produce the full length integration competent HIV-1 double-stranded viral 
DNA are described in detail in Section 1.6.1. This figure was adapted from (51).  
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4) Initiation of plus strand DNA synthesis proceeds from the PPT (65-67). After 
incorporation of exactly 12 nucleotides, the PPT RNA:DNA junction resides in the 
RNase H primer grip, which promotes RT pausing and dissociation (67, 68). RT then 
rebinds the substrate in polymerase-independent manner (described below) to specifically 
cleave the PPT RNA:DNA junction. The enzyme can then dissociate once again and re-
associate in a polymerase-dependent confirmation to continue plus strand elongation to 
the to the 5’ cDNA template end and the attached tRNALys3 primer. The first 18 
ribonucleotides of the tRNALys3 primer serve as the template for the plus strand PBS 
sequence (67). RT pausing at a modified tRNALys3 ribonucleotide at position 19 allows 
specific RNase H cleavage at the DNA/tRNALys3 interface to release tRNALys3 (68, 69). 
5) The complementary PBS sequences at the ends of the plus and minus strands facilitate 
a second strand transfer event (69, 70). If this transfer occurs in an intramolecular fashion 
the complex becomes circularized.  
6) Bidirectional DNA synthesis elongates the plus strand ultimately resulting in a 
complete double stranded genome with identical LTR sequences on each end (51). Due to 
the presence of internally primed DNA fragments (such as from the central PPT), plus 
strand elongation occurs in a discontinuous fashion (67-69). A combination of RT 
mediated strand displacement synthesis and gap repair/ligation by cellular enzymes 
results in the full length, double stranded, integration-competent DNA genome (51). 
1.6.2 RT Structure 
The requirement of reverse transcription for HIV-1 replication and the lack of reverse 
transcriptase activity in host cells make RT an ideal drug target. The structure and function of  
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Figure 1.5 Structure of HIV-1 in complex with a DNA/DNA template/primer substrate. 
The fingers (orange), palm (green), and thumb (red) subdomains make up the polymerase 
domain of the p66 subunit of RT. The p66 connection and RNase H domains are colored in 
yellow and blue, respectively. The RT p51 subunit is lacking the C-terminal RNase H 
domain and is colored in grey. The structure was drawn using PyMol based on the PDB 
Coordinates 1RTD from Huang et al. 1998 (77). 
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HIV-1 RT has been intensely studied to inform antiretroviral drug discovery. RT is expressed as 
part of the Gag- Pol precursor polyprotein and is cleaved by HIV-1 protease to release the 
polymerase (31, 33). HIV-1 RT is a large multidomain heterodimer of 66 kDa (p66) and 51 kDa 
(p51) subunits comprised of 560 and 440 amino acids, respectively (Figure 1.5) (71-74). Early 
studies revealed that the 51 kDa subunit is a C-terminal proteolytic truncation of the p66 subunit 
(73, 75, 76).  
RT was first crystallized in 1992 by the laboratory of Thomas Steitz, shedding light on 
the structure and function of each subunit (76). This study revealed that p51 is structurally 
distinct from p66 and that it may serve primarily as a structural scaffold for the catalytic domains 
of p66. Furthermore, the crystal structure identified spatially distinct polymerase (residues 1-
318) and RNase H (residues 427-560) domains of p66 linked by a connection domain (residues 
319-426). The RT polymerase domain is structurally homologous to other polymerases, 
including the previously crystallized E. coli DNA Pol I Klenow fragment (71, 76). This structure 
is described as a “right hand” containing “palm, finger, and thumb” subdomains, which form a 
nucleic acid binding cleft at the polymerase active site. The RNase H domain, resembles the E. 
coli RNase HI enzyme (71, 76). The polymerase and RNase H catalytic active sites are 
approximately 60 Å apart, spanning 18 nucleotides of a bound nucleic acid substrate (63, 71). 
Numerous additional studies of the three dimensional structure of HIV-1 RT co-crystallized with 
various nucleic acid substrates and inhibitors have helped to elucidate RTs catalytic mechanisms 
of action (63, 71, 76-85). 
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Figure 1.6 Steps required for nucleotide addition (A) and the molecular mechanism of nucleotide incorporation (B). 
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1.6.3 Nucleic acid substrate binding 
In order for polymerase or RNase H catalysis to occur, RT must first bind its RNA/DNA or 
DNA/DNA nucleic acid substrate (Figure 1.6A). Upon substrate binding, the thumb subdomain 
rotates outward to an open conformation (71, 83). RT preferentially binds most nucleic acid 
substrates in a conformation (polymerase competent) in which the primer 3’-OH is situated 
adjacent to the polymerase active site, termed the priming site (P-site). Specific contacts between 
the polymerase domain and the primer and template strands are essential for proper substrate 
positioning during catalysis (71). The p66 palm subdomain forms a “primer grip” region 
composed of residues 227-235 that form the β12 and β13 sheets (62, 71, 83, 86). The p51 subunit 
also makes contact with the primer near the base of the palm in p66. The template strand is 
stabilized through contacts in the fingers and palm subdomains (71, 83).  The bound nucleic acid  
substrate spans the polymerase and RNase H domains therefore important contacts are also made 
by the connection and RNase H domains of p66 as wells as by p51 (87). An “RNase H primer 
grip” region makes multiple contacts with an RNA/DNA hybrid substrate to allow cleavage of 
the RNA template (87).  
To facilitate the variety of RNase H cleavage activities required during reverse 
transcription, RT is capable of binding nucleic acid substrates in multiple conformations (88, 89). 
As described above, the polymerase competent (or polymerase dependent) binding mode has the 
primer 3’-OH situated in the polymerase P-site with the RNase active site 18 nucleotides 
downstream. This binding mode allows for polymerase dependent RNase H activity during 
processive DNA synthesis (83, 88). Alternatively, RT can bind an RNA/DNA hybrid with the 
RNA template 5’ end in the polymerase active site thus positioning the RNase H active site 13-
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19 nucleotides from the 5’ end (89-91). This binding mode, called RNase H competent (or 
polymerase independent) binding is responsible for the highly specific RNase cleavages at both 
ends of the PPT during reverse transcription. RT can also bind the nucleic acid substrate 
irrespective of the primer 3’- or template 5’-termini (92). Template/primer binding in this 
manner results in random internal cleavage of the RNA template. Certain HIV-1 sequences and 
RNA secondary structures lead to directed cleavage events when RT is bound in this mode (92).  
Multiple biochemical and kinetic studies have examined the binding affinity of RT for 
nucleic acid substrates (57, 83, 86-89, 91, 93). Binding affinity was dependent on several factors 
including hybrid structure (DNA/DNA or RNA/DNA), substrate length, and template sequence. 
Generally, the kinetic binding constants (Kd) for RT binding to RNA/DNA and DNA/DNA 
substrates were approximately 5-20 nM (93, 94).   
1.6.4 Mechanism of nucleotide binding and incorporation 
RT binding to a template/primer substrate (in the polymerase competent mode) situates the 
primer 3’-OH terminus in the P-site and exposes the binding site for an incoming dNTP, called 
the N-site, or nucleotide site. (Figures 1.6 and 1.7).  Multiple structural studies of [RT-
template/primer/dNTP or NRTI] complexes have elucidated the molecular mechanisms of dNTP 
binding and incorporation (76, 77, 83-85). The RT polymerase active site in the palm subdomain 
contains the catalytic triad residues D110, D185, and D186 (Figure 1.7). Residues D185 and 
D186 are part of the YXDD motif conserved among all retroviruses, with X being methionine for 
HIV-1 (83). The catalytic triad aspartate residues coordinate two divalent metal cations (likely  
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Figure 1.7 Molecular model of the RT active site showing the pre-incorporation complex of 
a bound dNTP substrate (red). 
The positions of the priming site (P-site) with the primer 3’-residue (P-3’, blue) and the 
nucleotide binding site (N-site) with a bound dNTP (red) are indicated. The catalytic triad 
residues D110, D185, and D186 (green) coordinate the two magnesium ions shown in purple. 
Residues K65 L74, Y115, Q151, and M184, shown in yellow, contact the incoming dNTP and 
are often mutated to confer resistance through the discrimination mechanism. The template 
residues (T) that are base paired with the primer 3’-residue and the incoming dNTP are shown in 
orange. The structure was drawn using PyMol based on the PDB Coordinates 1RTD from Huang 
et al. 1998 (77). 
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Mg2+ in vivo) supporting the proposed two metal ion model for the phosphoryl transfer reaction 
by RT and other polymerases (77, 79). Residues K65, R72, L74, Y115, Q151 and M184 form the 
N-site for dNTP binding and base pairing with the corresponding template base. Residues K65 
and R72 interact with the incoming dNTP β and γ phosphates, respectively, while residue Q151 
contacts the 3’-OH of the incoming dNTP.  The 2’-position of the dNTP is in particularly close 
proximity to residue Y115, which is believed to confer specificity for dNTP over rNTP (95, 96). 
Structural and kinetic studies support an induced fit model where dNTP binding at the N-
site and appropriate template base pairing causes a conformational change where the fingers 
subdomain clamps down on the template/primer and dNTP (77, 97-99). The resulting “closed” 
polymerase complex has the dNTP α phosphate aligned for nucleophilic attack by the primer 3’-
hydroxyl (Figure 1.6B). This reaction forms the phosphodiester bond between the primer and 
dNTP while producing pyrophosphate. The opening of the fingers subdomain allows 
pyrophosphate release, template/primer translocation for processive polymerization, or RT 
dissociation (77, 83). Incorporation fidelity has been attributed to the conformational change 
dependence on correct dNTP binding and base pairing (96, 98, 100). 
1.6.5 Pre-steady state kinetics of nucleotide incorporation 
Steady state kinetic assays demonstrate that RT dissociation and template/primer rebinding is 
rate limiting during DNA synthesis (83). However, pre-steady state or transient kinetic studies, 
where RT is pre-bound with the template/primer substrate, allow for the measurement of the 
kinetic binding constant (Kd) and incorporation rate (kpol) of single nucleotide addition (98, 100). 
These studies demonstrate that the rate limiting step of single nucleotide incorporation is the 
conformational change to a closed ternary complex rather than dNTP binding or catalysis.  
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The binding constants of dNTP vary with respect to base. However, in general dNTPs 
bind with Kd values in the low micromolar range. Studies have shown that dNTPs may bind 
more efficiently with DNA/DNA substrates than with RNA/DNA substrates (98, 100). However, 
the incorporation rates of bound dNTP are approximately 2-fold higher for incorporation in 
RNA/DNA hybrids compared to DNA/DNA hybrids. Pre-steady state analyses of NRTI-TP 
incorporation compared to the analogous dNTP are used to evaluate the relative ability of NRTI-
TP to compete for binding and incorporation by RT.  
1.7 NRTI PHOSPHORYLATION AND MECHANISM OF RT INHIBITON 
In order to be orally bioavailable and readily transported across cell membranes, NRTI are 
administered as prodrugs in the form of nucleosides (lacking phosphates) or chemically shielded 
monophosphate nucleotides in the case of NtRTI. NRTI and NtRTI must undergo successive 
phosphorylation by host enzymes to produce the NRTI-TP substrate required for incorporation 
by RT (36, 39, 101). Some NRTI prodrugs (e.g. ddI and ABC) also require additional 
modification by other cellular enzymes to produce the nucleotide form active against RT 
(discussed with respect to each NRTI below). Therefore, NRTI antiviral activity is not only 
dependent on activity against HIV-1 RT but also on their ability to serve as substrates for host 
phosphorylating enzymes.  
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1.7.1 NRTI Phosphorylation 
The general phosphorylation scheme required to produce the NRTI-TP RT substrate is presented 
in Figure 1.8.  NRTI-MP is usually produced through the action of the constitutively active 
deoxynucleoside kinases responsible for endogenous nucleotide salvage or through 
phosphotransfer from 5’-nucleotidase (101-106). Addition of the second phosphate to produce 
NRTI-DP is carried out by the nucleotide monophosphate kinases: thymidylate kinase, uridylate-
cytidylate kinase, adenylate kinases 1–5 and guanylate kinase (107). Production of NRTI-TP 
from NRTI-DP is readily catalyzed by many cellular enzymes but most commonly by nucleotide 
diphosphate kinase, phosphoglycerate kinase, pyruvate kinase and creatine kinase (108, 109). 
Conversely, many cellular dephosphorylating enzymes also act on mono-, di-, and tri-phosphate 
forms of NRTI (36). Therefore, the equilibrium of phosphorylation and dephosphorylation 
greatly influences intracellular NRTI-TP pools and subsequent antiviral activity. 
 
 
 
 
Figure 1.8 General scheme of NRTI phosphorylation to the NRTI-MP, NRTI-DP, and 
NRTI-TP forms. 
The NRTI-TP form acts as a competitive substrate with respect to the analogous dNTP for 
incorporation by HIV-1 RT. A generic NRTI base (B) is depicted.  
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1.7.2 Mechanism of NRTI Inhibition 
Once metabolized by host cell enzymes to their triphosphate forms, NRTI-TP inhibit RT-
catalyzed proviral DNA synthesis by two mechanisms (83). First, they are competitive inhibitors 
for binding and/or catalytic incorporation with respect to the analogous dNTP substrate. Second, 
they terminate further viral DNA synthesis due to the lack of a 3’-OH group. Obligate chain 
termination is the principal mechanism of NRTI antiviral action. NRTI-TP binding affinity and 
incorporation rate are generally similar to their analogous dNTP counterparts (83). Notable 
exceptions will be discussed with regard to the specific NRTI. 
In theory, NRTI-TPs should be ideal antivirals. Each HIV virion carries only two copies 
of genomic RNA. There are about 20,000 nucleotide incorporation events catalyzed by RT 
during the synthesis of complete viral DNA, thus providing approximately 5000 chances for 
chain-termination by any given NRTI (20). Since HIV-1 RT lacks a formal proof-reading 
activity (51, 110), a single NRTI incorporation event should effectively terminate reverse 
transcription. In reality, however, NRTIs are less potent than might be expected. The two 
primary reasons responsible for this are: (i) HIV-1 RT can effectively discriminate between the 
natural dNTP and NRTI-TP, and the extent of this discrimination can be increased dramatically 
by nucleic acid sequence; and (ii) HIV-1 RT can excise the chain-terminating NRTI-MP by 
using either pyrophosphate (pyrophosphorolysis) or ATP as a substrate (83). These two RT 
characteristics can be selectively enhanced by single amino acid substitutions thus providing the 
mechanisms for NRTI resistance (111). 
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1.8 NRTI RESISTANCE SELECTION AND MECHANISMS 
Populations of HIV-1 circulating within individual patients are highly diverse. Genetic diversity 
is driven by both replication errors resulting in mutation and genome recombination during 
reverse transcription (58, 59, 110). Mutations are easily generated in HIV-1 genomes for two key 
reasons; the high rate of viral replication and the lack of a formal proofreading activity in RT. 
Approximately 10.3 × 109 virions per day are produced in a typical patient and estimates of RT 
error rate are as high as 5-10 misincorporations per genome per replication cycle (111-113). 
Under selective pressure, such as from antiretroviral drugs, mutated species that provide a 
replication advantage quickly become dominant viral populations. Antiviral resistance is 
conferred by mutations that decrease the effectiveness of a drug to inhibit viral replication. 
Mutations in RT confer resistance to NRTI through two distinct molecular mechanisms: 
nucleotide discrimination (Figure 1.9) and the phosphorolytic removal (excision; Figure 1.10) 
of a chain-terminating NRTI-MP (111). 
1.8.1 Nucleotide discrimination 
The nucleotide discrimination mechanism of NRTI resistance involves the preferential 
incorporation of natural dNTP substrates over NRTI-TP substrates (Figure 1.9). NRTI-resistant 
viruses maintain the ability to complete reverse transcription in the presence of drug by 
excluding NRTI-TP substrates while retaining the ability to incorporate natural dNTP substrates  
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Figure 1.9 Molecular mechanism of NRTI discrimination by HIV-1 RT. 
Mutations that confer resistance to NRTI by the discrimination mechanism maintain the ability to incorporate natural dNTP while 
selectively excluding NRTI-TP. NRTI-TP exclusion occurs by decreased NRTI-TP binding affinity (Kd) for the RT active site or 
decreased rate of NRTI incorporation (kpol).  
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Figure 1.10 Molecular mechanisms of HIV-1 RT primer unblocking by ATP-mediated 
NRTI-MP excision. 
Nucleophilic attack of the chain-terminating NRTI-MP from an ATP pyrophosphate donor 
results in the release of an adenosine-NRTI dinucleoside tetraphosphate and restores the primer 
3’-OH for subsequent nucleotide incorporation.  
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with reasonable efficiency (39, 83, 111). Mutations conferring enhanced NRTI-TP 
discrimination selectively decrease NRTI binding efficiency or rate of catalysis while preserving 
binding and incorporation of the analogous dNTP. NRTI discrimination mutations occur at 
residues in the fingers or palm of the polymerase active site including L74V, K65R, Q151M (in 
complex with other mutations) and M184V/I, some of which form the dNTP binding pocket (80, 
114-127). These mutations affect NRTI and dNTP binding and incorporation through direct 
interaction or via conformational distortions of the active site. These mutations and their 
discrimination phenotypes and mechanism toward specific NRTI will be discussed below.  
1.8.2 NRTI-MP excision 
Although RT does not possess a distinct exonucleolytic proofreading mechanism, RT does have 
an innate ability to catalyze the reverse reaction to nucleotide incorporation, the 
pyrophosphorolytic removal of an incorporated nucleotide monophosphate (Figure 1.10), 
typically referred to as excision (128-132). When a newly incorporated nucleotide-
monophosphate sits in the N-site prior to RT translocation, it is susceptible to nucleophilic attack 
by an incoming pyrophosphate donor molecule such as inorganic pyrophosphate (PPi) or ATP 
(129, 130). This reaction results in the removal of incorporated nucleotide monophosphate from 
the primer. When PPi or ATP act as the pyrophosphate donor, a dNTP or a dinucleotide-
tetraphosphate product is released, respectively. Nucleotide monophosphate removal, however, 
is greatly disfavored for wild-type RT during normal DNA synthesis due to the low binding 
affinity of PPi or ATP and the slow rate of pyrophosphorolysis compared to nucleotide 
incorporation (83, 128). Mutations in the RT polymerase domain primarily selected by AZT and 
d4T can enhance the ATP-mediated excision phenotype (46, 47, 133, 134). These mutations are 
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termed thymidine analog mutations (TAMs), or alternatively excision enhancing mutations, and 
will be discussed in detail below with regard to AZT and d4T resistance. TAMs selectively 
increase the ATP-mediated NRTI-MP excision from a chain-terminated primer (82-84, 135). 
Although slight discrimination has been observed in some cases, mutant RTs containing TAMs 
generally incorporate NRTI with similar efficiency as dNTP (136). The primary mechanism by 
which TAMs confer resistance is through increased NRTI-MP removal from chain-terminated 
primers. In absence of the next complimentary dNTP, most NRTI can be excised from the chain-
terminated primer (137). The mechanism of excision enhancement has been under considerable 
debate, but is now believed to be primarily due to increased binding affinity of the ATP 
pyrophosphate donor for most TAMs (82, 135, 138). The T215F/Y mutation in particular 
increases ATP binding because the F or Y side chains facilitate Pi-Pi stacking with the ATP 
adenine ring.  
Excision can only occur prior to RT translocation, while the incorporated NRTI-MP 
remains in the N-site. Cellular concentrations of dNTP can promote RT translocation such that 
the terminating NRTI-MP moves to the P-site, thus freeing the N-site (83, 137, 139, 140). 
Binding of the next correct dNTP to the N-site results in a stable closed conformation dead-end 
complex (Figure 1.11): the lack of a 3’-hydroxyl prevents incorporation of the incoming dNTP, 
the terminating NRTI-MP cannot be excised from the primer, and the dNTP bound at the N-site 
prevents retrograde translocation. The dead-end complex model may explain why cellular 
concentrations of the next complementary dNTP inhibit the excision of most terminating NRTI-
MP except AZT. It has been suggested that the bulky 3’-azido group of AZT protrudes into the 
N-site preventing dNTP binding (82). Some studies have also suggested that primers terminated  
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Figure 1.11 Formation of a stable, dead-end RT/T-P-NRTI-MP/dNTP complex. 
Following NRTI-MP incorporation, translocation and binding of the next correct dNTP results in 
a stable dead-end complex, in which further nucleotide incorporation and NRTI-MP excision are 
not possible.  
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with AZT-MP preferentially bind in the N-site (137). These explanations are not complete, 
however, because not all 3’-azido containing analogs are readily excised, suggesting that NRTI 
base and sugar moieties must also influence excision capacity (141-143). The selection of 
multiple amino acid insertions following position 69 as well as several dipeptide insertions in the 
fingers subdomain in addition to TAMs (described in detail below) also destabilizes the dead-end 
ternary complex, thus allowing for improved excision of most chain-terminating NRTI-MP in 
the presence of the next dNTP (144-146).   
1.8.3 Antagonism between the discrimination and excision mechanisms 
The use of two NRTI together with an antiretroviral drug from another class is recommended for 
combination antiretroviral therapy because several studies have shown synergy between NRTI 
combinations, such as AZT/ddI and AZT/3TC (147-152). The observed antiviral synergy of 
these combinations has been attributed to antagonism between the discrimination mutations 
K65R, L74V, and M184V and TAMs (81, 120, 153-160). K65R, K70E, L74V, or M184V when 
present in combination with TAMs reverse the AZT resistance observed with TAMs alone. The 
rate of primer unblocking by ATP-mediated excision is decreased by the addition of K65R, 
K70E, L74V, and M184V in the background of TAMs (156, 158, 160, 161). Multiple hypotheses 
have been proposed to explain how these residues diminish excision activity. K65R and M184V 
may reposition or limit the flexibility of the chain-terminated primer in the active site (81, 155).  
L74V may alter the base pairing interaction of the NRTI with the template (77, 81). Additionally, 
TAMs also negatively affect the ability of K65R to discriminate between NRTI-TP and dNTP by 
partially restoring the rate of incorporation (160).  
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The poor excision and discrimination phenotypes observed with viruses carrying both 
TAMs and discrimination mutations can be partially restored by the accumulation of additional 
mutations (152, 162-166). These mutations, some of which are in the connection and RNase H 
domains, include E44A/D, T69D, V75M/T, V118I, H208Y, R211K, K219R, N348I, and G333D.  
1.9 FDA-APPROVED NRTI 
NRTI remain an invaluable component of combination antiviral therapy that suppresses viral 
replication to undetectable levels, thus dramatically improving patient survival and quality of 
life. However, the rapid selection of NRTI resistance mutations that often confer cross-resistance 
to multiple NRTI remains the greatest challenge to their success. Much research effort has 
focused on understanding NRTI activity and resistance. This section will: i) provide a detailed 
review of the properties of the FDA-approved NRTI, including cellular phosphorylation and 
metabolism, inhibition of RT, and resistance mutations/mechanisms; and ii) discuss the 
limitations of the current NRTI to highlight the need for novel NRTI development.  
1.9.1 Zidovudine (AZT) and Stavudine (d4T) 
Zidovudine (3’-azido-2’,3’-dideoxythymidine, AZT) and stavudine (2’,3’-didehydro-3’-
deoxythymidine, d4T)  were first synthesized in the 1960s as potential anticancer drugs, but were 
abandoned due to toxicity concerns (167). However, both were found to have potent and 
selective anti-HIV-1 activity at much lower concentrations (3-5). AZT was approved by the FDA 
for clinical use in 1987, thus becoming the first available antiviral drug. FDA approval of d4T 
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followed in 1994. AZT and d4T are both thymidine analogs that lack a 3’-hydroxyl group. The 
ribose ring 3’-hydroxyl of AZT has been replaced with an azido (-N3) group, whereas d4T 
contains an unsaturated 2’,3’-didehyro ribose ring.  AZT and d4T are both activated by 
sequential phosphorylation by thymidine kinase, dTMP kinase, and nucleotide diphosphate 
kinase to produce the nucleotide mono-, di-, and triphosphate forms (168). AZT is also subject to 
metabolism in the liver, kidney, and intestinal mucosa to produce the 5’-glucuronide and 3’-
amino-thymidine which is highly toxic (169, 170). AZT-TP and d4T-TP also act as substrates for 
incorporation by mitochondrial polymerase γ resulting in a reduction of mitochondrial DNA and 
subsequent mitochondrial poisoning (171).  
AZT-TP and d4T-TP are incorporated by RT into viral DNA across from adenosine 
bases, resulting in chain-termination with submicromolar 50 % inhibitory concentrations (IC50) 
(141).  Pre-steady state studies show that AZT-TP and d4T-TP are good substrates for 
incorporation by RT (136). The binding affinities of AZT-TP and d4T-TP are similar to that of 
TTP with Kd values of 2.0 μM, 2.7 μM, and 2.2 μM, respectively (172). The kpol values for TTP, 
AZT-TP, and d4T-TP are 9.2 sec-1, 8.8 sec-1, and 4.3 sec-1, respectively.  
Soon after its introduction, AZT monotherapy was shown to lead to rapid resistance 
development and subsequent therapeutic failure. (46, 47, 133, 134). Decreased AZT 
susceptibility was associated with the selection of the K70R mutation, which was followed by 
D67N and K219E/Q. Clinical isolates from patients failing AZT or d4T therapy were found to 
contain similar TAMs (173, 174). TAMs are typically selected in two patterns i) M41L, D67N, 
L210W, T215Y, and K219E/Q; and ii) M41L, D67N, K70R, T215F, and K219E/Q (174). These 
patterns are not exclusive, however, and the reasons they are selected together are not clear. The 
presence of each TAM in either pattern is not required for substantial resistance, but additional 
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TAMs usually results in increased resistance (83). The selection of TAMs is associated with very 
high levels of viral resistance resulting in up to a three log reduction in AZT or d4T 
susceptibility. TAMs also confer cross-resistance to all other NRTI (46). The selection of TAMs 
is often followed by the selection of additional mutations (E44D, A62V, V118I, H208Y, R211K, 
L214F, multiple insertions following T69, and multiple dipeptide insertions in the fingers 
subdomain) that further increase resistance and cross-resistance (144, 145, 162, 175). As 
described above, TAMs confer resistance by selectively increasing the excision of NRTI-MP 
from chain-terminated primers. RT containing TAMs are significantly more efficient at 
unblocking AZT-MP- and d4T-MP-terminated primers than WT RT (130-132, 141). The 
efficiency with which TAM-containing RTs excise incorporated AZT-MP or d4T-MP varies 
with the number of TAMs present and the template sequence (39, 83).  
1.9.2 Didanosine (ddI) 
Didanosine (ddI, 2’,3’-dideoxyinosine) is a prodrug that is converted to ddATP, the active 
metabolite recognized by RT. Initially, 2’,3’-dideoxyadenosine (ddA) was evaluated as a clinical 
candidate but was ultimately discovered to cause nephrotoxicity (176, 177). Interestingly, ddA 
was shown to be metabolized to ddI by adenosine deaminase and that the ddI metabolite is 
responsible for much of the antiviral activity of ddA. Therefore, the administration of ddI avoids 
the ddA associated nephrotoxicity (176, 178). Didanosine is phosphorylated to didanosine-MP 
by cytosolic 5'-nucleotidase, which uses either inosine monophosphate (IMP) or guanosine 
monophosphate (GMP) as phosphate donors (179). Didanosine-MP is then converted to ddAMP 
by adenylosuccinate synthetase and 5' adenosine monophosphate-activated protein (AMP) kinase 
(178). The enzymes involved in phosphorylation of ddAMP to ddADP and ddATP have not been 
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identified, although AMP kinase and NDP kinase have been proposed to play a role. Didanosine 
can be hydrolyzed by purine nucleoside phosphorylase (PNP) to release the hypoxanthine base 
(180). 
After metabolism and activation, ddATP can be incorporated by HIV-1 RT into the 
nascent viral DNA causing chain-termination. In cell culture assays, the concentrations of ddI 
required to inhibit HIV-1 replication by 50 % (EC50) were between 0.1 μM and 4 μM depending 
on the assay system and cell type (178).  ddATP binds RT with similar affinity as dATP 
however, the rate of incorporation is > 5-fold slower for ddATP compared to dATP (126).  
Clinical isolates from patients that received didanosine monotherapy for 1-2 years 
harbored the mutations L74V, K65R, M184V, as well as some TAMs with L74V being most 
prevalent (116). The L74V mutation confers at least 5-fold resistance to ddI compared to WT 
HIV-1 (116, 151). Pre-steady state incorporation assays with L74V RT indicate that the 
incorporation rate for ddATP is severely decreased (10-fold) compared to WT RT, indicating a 
discrimination phenotype (126, 181). The L74V mutation also causes reduced viral fitness due to 
decreased ability to incorporate natural dNTPs (126, 181).  
Additionally, AZT+ddI combination treatment can select a cluster of mutations with 
Q151M appearing first followed by A62V, V75I, F77L, and F116Y (182). Together these 
mutations are referred to as the Q151M complex (Q151Mc). This complex results in high level 
resistance to most NRTI (tenofovir is the exception) by the discrimination mechanism (183, 
184). The rate of incorporation of each NRTI was significantly decreased compared to that of its 
counterpart dNTP. It is believed that a loss of interaction between Q151 and the 3’-OH of the 
incoming dNTP or NRTI is responsible for this mechanism (183).  
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1.9.3  Abacavir (ABC) 
Abacavir (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-
yl]methanol) is a prodrug of carbovir (2-Amino-1,9-dihydro-9-[(1R,4S)-4-(hydroxymethyl)-2-
cyclopenten-1-yl]-6H-purin-6-one), a deoxyguanosine analog (185). Abacavir is phosphorylated 
to abacavir-MP by adenosine phosphotransferase (186). A yet unidentified cytosolic deaminase 
then converts abacavir-MP to carbovir-MP. Phosphorylation to the diphosphate derivative occurs 
via guanidinylate monophosphate kinase. The final phosphorylation step can be catalyzed by a 
number of cellular enzymes including 5’-nucleotide diphosphate kinase, pyruvate kinase, and 
creatine kinase (186). Abacavir is extensively catabolized in the liver and only 1.2% is excreted 
as unchanged abacavir in urine (187). Abacavir oxidation by alcohol dehyrogenases produces a 
5’-carboxylic acid derivative and UDP glucuronosyltransferase yields the 5’-O-glucronide (187).  
Abacavir demonstrated equivalent activity to AZT against HIV-1 clinical isolates in 
peripheral blood lymphocytes with EC50 values of 0.26 μM and 0.23 μM, respectively (185). 
CBV-TP potently and selectively inhibited HIV-1 RT with a Ki value of 21 nM.  
Both cell culture selection experiments and clinical isolates from patients treated with 
ABC identified the similar resistance mutations as those selected by ddI (188). The most 
frequent mutations selected by ABC were M184V and the combination of L74V+M184V. Both 
of these mutations alone conferred low-level resistance (2- to 4-fold over WT) to ABC. In 
combination, L74V+M184V conferred 11-fold ABC resistance over WT (188). Like L74V, 
M184V confers resistance to ABC and other NRTI through the discrimination mechanism(189-
191). Discrimination by M184V has been more thoroughly characterized for 3TC and FTC so 
the molecular mechanism by which M184V discriminates NRTI will be discussed further below.  
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1.9.4 Zalcitabine (ddC), lamivudine (3TC), and emtricitabine (FTC)  
Zalcitabine (2’,3’-dideoxycytidine; ddC), lamivudine ((-)-3’-thia-2’,3’-dideoxycytidine;  3TC) 
and emtricitabine ((-)-3’-thia-5-flouro-2’,3’-dideoxycytidine;  FTC) are the three cytidine analog 
NRTI and were FDA approved in 1992, 1994, and 1995, respectively (192). Zalcitabine never 
saw widespread application due to delayed peripheral neuropathy that progressed with 
cumulative dose and did not resolve with stoppage of use (193). Neuropathic cytotoxicity was 
later associated with potent inhibition of mitochondrial polymerase γ (194). ddC was 
subsequently removed from the market in 2006 (153).  
Like ddC, 3TC and FTC are cytidine analogs. However, both contain the unnatural L-
enantiomer ribose with a sulfur atom replacing the C3’ position. Emtricitabine has an additional 
5-flouro modification to the cytosine ring. The modified sugar ring results in decreased affinity 
of 3TC-TP and FTC-TP compared to ddCTP for polymerase γ (171).  Lamivudine and 
emtricitabine are both metabolized to their respective 5'-mono- and di- and triphosphate 
derivatives by deoxycytidine kinase, deoxycytidine monophosphate kinase, and 5’-nucleoside 
diphosphate kinase, respectively (195-198).  
3TC and FTC demonstrate antiviral activity against HIV-1 in cell culture and their 5’-
triphosphate forms are potent chain-terminators of DNA synthesis upon incorporation by HIV-1 
RT (199-201). Cell culture selection as well as sequencing of patient isolates identified the 
mutations M184V or I to confer decreased susceptibility to 3TC and FTC (202-205). M184I is 
selected within two weeks in patients receiving 3TC which is replaced with M184V within two 
months (205). M184V conferred greater than 1400-fold resistance to 3TC and FTC and cross-
resistance to ddI and ABC (203).  
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The mechanism of M184V resistance has been extensively characterized with structural 
and kinetic studies. Multiple kinetic studies have demonstrated a severely reduced catalytic 
efficiency of incorporation of 3TC-TP and FTC-TP by HIV-1 RT containing the M184V 
mutation (189-191). 3TC-TP and FTC-TP demonstrated drastically impaired binding to M184V 
RT (Kd values increased 76- and 19- fold, respectively) compared to WT enzyme with relatively 
unchanged incorporation rates. The catalytic efficiencies of dCTP binding and incorporation for 
M184V and WT RT were similar, indicating that M184V can effectively discriminate between 
dCTP and 3TC-TP or FTC-TP (189-191). A crystal structure of RT containing the M184I 
mutation revealed that branched side chains at position 184 (i.e. I and V) cause a steric clash 
with the L-enantiomer ribose of 3TC-TP or FTC-TP but not with the natural D- ribose of dCTP 
(80). This explains why 3TC-TP and FTC-TP binding is diminished while dCTP binding is 
maintained. Together, these findings describe the molecular mechanism of discrimination by 
which the M184V/I mutations confer resistance to 3TC and FTC. 
1.9.5 Tenofovir (TFV)  
The acyclic nucleoside phosphonate tenofovir (R-9-(2-phosphonylmethoxypropyl)-adenine; 
(R)PMPA) has no sugar ring structure but contains an acyclic methoxypropyl linker between the 
base N9 atom and a non-hydrolyzable C-P phosphonate bond (206). Thus TFV represents the 
only currently approved NtRTI. Tenofovir is poorly absorbed by the oral route and is therefore 
administered as a lipophilic orally bioavailable prodrug, tenofovir disoproxil fumarate (TDF), a 
fumaric acid salt of the bis-isopropoxycarbonyloxymethyl ester of tenofovir (206). Degradation 
of TDF to its monoester and, subsequently, to tenofovir occurs readily in the intestinal mucosa 
by the action of carboxylesterases and phosphodiesterases, respectively (207). Tenofovir is 
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rapidly converted intracellularly to tenofovir-monophosphate (TFV-MP) and the active 
tenofovir-diphosphate (TFV-DP) forms by adenylate monophosphate kinase and 5’-nucleoside 
diphosphate kinase, respectively (208).  
Cell culture selection experiments identified K65R as the predominant resistance 
mutation which conferred 3- to 4- fold resistance to TFV compared to WT HIV-1 (209). It has 
been reported that the K70E mutation is also selected in HIV-1 patients receiving tenofovir in 
combination with other NRTI (210). However, the K65R and K70E mutations are antagonistic to 
one another and are not believed to exist on the same genome (211). 
The K65R mutation provides some level of cross-resistance to all approved NRTI except 
AZT (212). Both K65R and K70E mutations confer resistance to tenofovir via the discrimination 
mechanism (122, 160, 161, 212, 213). Unlike the discrimination of 3TC-TP and FTC-TP by 
M184V, the discrimination phenotype conferred by K65R and K70E toward TFV-DP is driven 
by decreased kpol, and not by significantly altered binding (122, 160, 161, 212, 213).   
1.9.6 Limitations of the currently approved NRTI  
Despite their important contribution to the success of combination antiretroviral therapy, the 
currently approved NRTI have significant limitations that include adverse events associated with 
drug toxicity, pharmacokinetic limitations (e.g. short intracellular half-life) or interactions with 
other antiretroviral drugs, and the selection of drug-resistant variants that are cross-resistant to 
other NRTI (36). The development of novel NRTI with considerations for these shortcomings is 
necessary for the continued success of the NRTI drug class.  
Treatment with NRTI is associated with both short- and long-term toxicities resulting in 
occasionally life-threatening adverse events (214). Toxicity associated adverse events often 
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result in lower drug regimen adherence by patients, thus reducing their anti-HIV-1 efficacy. 
Examples of acute toxicity from NRTI include: fatigue, dizziness and dyspepsia common with 
treatment of most NRTI, hypersensitivity reaction from ABC, nausea and vomiting with ddI and 
ZDV, anemia and neutropenia observed with ZDV treatment, pancreatitis and lactic acidosis in 
patients treated with ddI or d4T, acute renal failure and drug induced hepatitis are rare but have 
been observed with treatment of most NRTI (214-219). Long term NRTI adverse events include: 
cardiovascular disease with ABC and ddI, peripheral and central neuropathy with d4T, ddI, ddC, 
ZDV, diabetes with ZDV, d4T, and DDI, Dyslipidemia with ZDV, d4T, and ABC, various 
hepatic pathologies with most NRTI, lipodystrophy with d4T and ZDV (214, 218-222). It has 
been suggested that mitochondrial toxicity from inhibition of mitochondrial DNA polymerase γ 
represents a common mechanism responsible for many NRTI associated toxicities (223). 
Mitochondrial toxicity has been directly linked to myopathy and cardiomyopathy resulting from 
treatment with AZT (224, 225). Indeed, polymerase γ is potently inhibited by the active 
triphosphate forms of ddC, ddI (metabolized to ddATP), and d4T, however, the active forms of 
AZT, ABC, and TFV were found to be poor substrates for incorporation by polymerase γ (226). 
Recent evidence suggests that mitochondrial toxicity may also be due to inhibition of the 
thymidine phosphorylating enzymes causing indirect inhibition of mitochondrial DNA 
replication through reduction in mitochondrial TTP pools (227). Mitochondrial toxicity via 
polymerase γ inhibition or other mechanisms does not explain adverse events from treatment of 
NRTI such as by ABC and TDF that do not deplete mitochondrial DNA (228). Other 
mechanisms of NRTI toxicity include the involvement of the major histocompatability complex 
class 1 human leukocyte antigen 57.1 haplotype in ABC hypersensitivity and TFV accumulation 
in renal proximal tubules due to influx transport via the human organic anion transporter 1 in 
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TDF-associated renal toxicity. (215, 222). The previously identified mechanisms of NRTI 
toxicity do not explain all NRTI-related adverse events (214). As such, there is much to be 
learned about the mechanisms of NRTI-induced toxicity in order to inform the development of 
novel NRTI with improved safety. However, all novel NRTI under current development should 
be thoroughly evaluated with respect to their propensity to cause cellular and tissue toxicity via 
known mechanisms such as mitochondrial toxicity and bone marrow depletion.   
Antiretroviral combination therapy regimens often require patients to take 3 or more 
drugs daily, which often require multiple pills and multiple doses per day (229). This high 
therapeutic burden can lead to low patient adherence to antiretroviral regimens thus decreasing 
the antiretroviral effectiveness. As such, simplifying antiretroviral regimens through fixed-dose 
combinations that limit pill count and the development of drugs with pharmacokinetic properties 
amenable to once daily dosing (i.e. long half-life) is an important concern. The requirement of 
NRTI for intracellular phosphorylation to the active NRTI-TP form suggests that the intracellular 
concentration of NRTI-TP is more important for antiviral effectiveness than plasma half-life 
(230, 231). It has been demonstrated that intracellular concentrations of the active triphosphate 
metabolites of 3TC, FTC, and d4T, rather than levels of unchanged drugs in plasma, correlated 
with virologic response in HIV-infected patients (230, 232). The intracellular kinetics of 
activation and half-life of any NRTI-TP is subject to many cellular factors such as: cell 
activation state; cellular kinase expression levels, activation, and efficiency of NRTI substrate 
phosphorylation; cell cycle; activity of cellular dephosphorylating enzymes; and intracellular 
ratios of NRTI/deoxynucleoside, NRTI-MP/dNMP, NRTI-DP/dNDP, and NRTI-TP/dNTP (229) 
(233). For example, ZDV and d4T are phosphorylated to a greater extent and yield higher 
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ZDV-TP/dTTP and d4T/dTTP ratios in activated lymphocytes, thus exerting more potent 
antiretroviral activity in activated cells than in resting cells (234, 235). Conversely, ddI, ddC, and 
3TC produce higher NRTI-TP/dNTP ratios and exert more potent antiretroviral activity in resting 
cells (234, 235). Thus, characterization of the NRTI activation by cellular phosphorylating 
enzymes and other factors that influence NRTI-TP intracellular half-life must be considered in 
the development of novel NRTI. To facilitate once or twice daily dosing, novel NRTI should 
maintain the minimally antiviral effective intracellular NRTI-TP concentration over a period a 
12-24 hours. 
Another factor that restricts patient antiretroviral regimen options and effectiveness is 
intra- and inter-antiretroviral class drug-drug interactions. The shared and overlapping 
phosphorylation pathways for activation of many NRTI leads to intra-NRTI drug class 
pharmacokinetic interactions by competition for phosphorylating enzymes when some NRTI are 
co-administered (233). For example, AZT and d4T are both phosphorylated to their –MP and –
DP forms by thimidine kinase 1 and thymidylate kinase, respectively, however, AZT-and AZT-
MP have stronger affinities for these enzymes (105). This pharmacokinetic interaction results in 
reduced cellular d4T-TP levels when AZT and d4T are co-administered in cell culture and 
antagonistic anti-HIV-1 activity in patients receiving AZT and d4T co-therapy  (105, 236). A 
similar interaction has been observed for 3TC and ddC due to their common phosphorylation by 
deoxycitidine kinase (237). However, not all pharmacokinetic interactions between NRTI are 
detrimental. Despite competition between TFV and ddA for the same phosphorylating enzymes, 
co-administration of TDF and ddI leads to higher intracellular and plasma levels, and a longer 
half-life of the active ddI metabolite ddATP (238). This is due to TFV-mediated inhibition of 
ddI/ddA catabolism by purine nucleoside phosphorylase. NRTI are also subject to 
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pharmacokinetic interactions with drugs from other antiretroviral classes. For example, when 
ABC is co-administered with some PIs (e.g. atazanavir and lopinavir), ABC exposure is 
decreased up to 32 % via increased glucuronidation of ABC by uridine diphosphate 
glucuronyltransferase and subsequence ABC clearance (239, 240). Similarly, co-administration 
of TDF with some PIs (notably fosamprenavir and atazanavir) cause changes in TFV plasma and 
cellular levels, however the mechanism of this interaction is currently under debate (241). These 
studies illustrate the complex pharmacokinetic interactions of NRTI that must be given careful 
consideration when choosing which combination of NRTI to include in antiretroviral regimens.  
Possibly the most important factor affecting the efficacy of the currently approved NRTI 
is the rapid selection of drug-resistance mutations that can lead to regimen failure. The 
mechanisms of HIV-1 resistance to NRTI and the specific mutations conferring resistance have 
been described in detail in the previous sections. Here, I will describe why NRTI resistance 
posses a significant hurdle to the continued success of the NRTI drug class that must be 
overcome when developing novel NRTI.  
The increased access of NRTI-containing antiretroviral regimens along with the 
successful extension of life span of HIV-1 infected individuals has led to the increasing 
prevalence of resistance development to some NRTI within infected individuals as well as 
transmitted NRTI resistance (242). For example, in developing countries, where regimens 
containing 3TC, FTC, and ABC have become increasing available, the M184V mutation has 
been observed in 40 % to 85 % of patients failing antiretroviral therapy (243-245). Transmitted 
drug resistance was evident in recent drug resistance surveys of antiretroviral naïve HIV-1 
infected patients in America and Europe, where antiretroviral therapy is widely available. These 
studies identified HIV-1 drug resistance mutations (including resistance to NRTI) in 8 % to 20 % 
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of the untreated population (246-249). In antiretroviral experienced patients complex 
combinations of mutations have been identified that confer broad spectrum resistance across 
multiple drug classes including NRTI, NNRTI, and PI (242, 250-252).  Furthermore, patient non-
adherence to therapy regimens (often due to adverse events and the high therapy burden 
discussed above) leads to sub-inhibitory drug levels that promote the selection and survival of 
drug-resistant variants. In order to stay ahead of the complex and constantly changing antiviral 
resistance problem, novel NRTI development efforts must focus on analogs that have a low 
potential for cross-resistance from the current circulating resistant viruses.  
 
 
1.10 NOVEL NRTI DEVELOPMENT 
Despite substantial investment and research, there is no vaccine for the prevention of HIV-1 
infection (253). Efforts to prevent HIV-1 transmission using pre-exposure chemoprophylaxis, as 
well as research into strategies to cure HIV-1 infected individuals, are in their infancy (254, 255). 
Thus, combination antiretroviral therapy remains the best means to curtail the HIV-1 epidemic 
and improve patient quality of life. Potent combination antiretroviral therapy containing at least 
two NRTI has drastically decreased death rates and HIV-1 associated morbidities among infected 
individuals, and has contributed to decreased transmission rates by suppressing viral replication 
within infected persons (11, 250, 256). The limitations of current NRTI described in the previous 
section demonstrate the critical need to develop new NRTI that have excellent activity and safety 
profiles and exhibit little or no cross-resistance with existing drugs. This section will: i) illustrate 
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how a comprehensive mechanistic understanding of the molecular interactions of NRTI with RT 
can guide efforts to identify novel NRTI that are potent against NRTI-resistant HIV-1 and ii) 
introduce two recent NRTI discovery efforts that will provide the background for the work in 
this dissertation.  
1.10.1 Novel NRTI design through structure-activity-resistance relationships 
The rational design of new drugs with considerations for target enzyme structural and specificity 
determinants has been a productive approach to drug discovery (257, 258). This approach has 
been employed in the development of novel HIV-1 protease inhibitors, however, a rational drug 
design approach has not been extensively applied to the development of novel NRTI (259, 260). 
The world-wide multidisciplinary research effort in the 27 years of the HIV-1 epidemic has 
provided a detailed molecular understanding of the mechanisms of HIV-1 reverse transcription, 
RT inhibition, and NRTI activity, resistance, and pharmacology (83). This extraordinary wealth 
of knowledge provides a distinct advantage for the development of novel NRTI using a rational 
design approach.  
The primary focus of this work is understanding NRTI structure-activity-resistance 
relationships in order to inform the development of novel NRTI that demonstrate low-cross 
resistance and potent activity against NRTI-resistant HIV-1. In order to develop new NRTI with 
little or no cross-resistance with existing NRTI, novel drug candidates must have potent activity 
against viruses carrying mutations that confer resistance via both the discrimination and excision 
mechanisms. Previous NRTI discovery efforts have largely relied on an empirical approach in 
which novel analogs are synthesized and evaluated for antiviral activity and toxicity, with, 
initially, little regard for activity against drug-resistant HIV-1. This approach provides 
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unpredictable results in terms of the activity of an investigational NRTI against drug-resistant 
HIV-1. A rational design approach in which novel analogs are synthesized based on an 
understanding of NRTI structural components that influence activity towards drug-resistant virus 
may prove more successful. 
In 2005, Sluis-Cremer et al. and Parikh et al. described two of the first studies comparing 
the activity of structurally diverse NRTI against drug-resistant HIV-1 viral replication or RT 
DNA synthesis (141, 212). These studies provided the novel insight that identified the 3’-azido-
2’,3’-dideoxypurine nucleosides as a lead class of novel NRTI with potent activity against drug-
resistant HIV-1 and will be discussed in detail below. Structure-activity-resistance 
characterizations such as these may allow the optimization of lead investigational NRTI to 
overcome one or both of the RT resistance mechanisms. The following two sections provide the 
background for the work in this dissertation by introducing two classes of novel investigational 
NRTI and describe why their specific structure-activity-resistance profiles should be 
characterized. 
1.10.2 Second generation phosphonate NtRTIs: PMEO-DAPY derivatives and GS-9148.            
Nucleoside phosphonate analogs are a structurally distinct class of antiviral compounds that were 
first developed by De Clercq and colleagues in 1986 (206). Analogs such as the NtRTI tenofovir 
(TFV) that was discussed above and adefovir (PMEA; 9-(2-phosphonylmethoxyethyl)adenine), 
an antiviral approved for the treatment of hepatitis B virus, contain no sugar ring and are 
considered ‘acyclic’ nucleoside phosphonates (ANP) (206). 
A group of novel ‘second generation’ acyclic nucleoside phosphonates, the 6-[2-
(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines (PMEO-DAPy) was recently described by 
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Balzarini and colleagues (261, 262). These analogs differ from their parent compounds TFV and 
PMEA in that they contain a pyrimidine base with the phosphonate moiety linked via the C-6 
position, whereas TFV and PMEA have a phosphonate linkage at the N-9 position of an adenine 
base. Several 5-substituted PMEO-DAPy derivatives were characterized and reported to inhibit a 
broad range of HIV-1 clinical isolates. These compounds also demonstrated greater activity 
against drug-resistant clinical isolates than the parent compounds TFV and PMEA. One 
compound a 5-Me-substituted PMEO-DAPy (PMEO-DAPym) analog demonstrated the most 
potent inhibition of replication of all the clinical isolates tested (EC50 against WT = 0.062 
µg/mL) (262). Clinical isolates containing the K65R mutation demonstrated some resistance to 
PMEO-DAPym but to a lesser extent than for tenofovir. Additionally, PMEO-DAPym was more 
effective against HIV-1 isolates containing TAMs than TFV and PMEA (262). These 
encouraging activity and resistance phenotypes warrant a detailed characterization of the 
molecular mechanisms of RT inhibition and resistance of PMEO-DAPym-DP. The structure-
activity-resistance information obtained from these studies may allow further optimization of the 
promising qualities of this lead compound.  
Recently, the novel phosphonate NtRTI, (5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-
furan-2-yloxymethyl)phosphonic acid (GS-9148), was described by Cihlar and colleagues (263-
265). GS-9148 differs structurally from the acyclic analogs TFV, PMEA, and PMEO-DAPym in 
that it contains a fluoro-modified-didehydro-ribose sugar ring, as well as an alternative 
phosphonate linkage. TFV and PMEA, and GS-1948 share a common adenine base. The 
phosphonoamidate prodrug of GS-9148, called GS-9131, demonstrated potent antiviral activity 
against a broad group of clinical HIV-1 isolates in cell culture (mean EC50 = 37 nM) (263, 266). 
GS-9148, also had potent activity against purified WT RT (steady state inhibitory constant, Ki = 
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0.8 µM) (263).  GS-9148 displayed a favorable resistance profile against NRTI-resistant HIV-1 
strains. Notably, K65R, K70E, and M184V, individually and in every combination had no effect 
on the activity of GS-9148 compared to WT and TAMs conferred modest resistance to GS-9148 
(263). Cell culture selection experiments yielded resistant variants with the novel combination of 
resistance mutations K70E/D123N/T165I that are not selected by other NRTI and are 
infrequently observed in treatment-naïve and treatment-experience patients (267, 268). The low 
cross-resistance with existing NRTI and the selection of a unique resistance pattern warrant a 
mechanistic understanding of GS-9148-DP activity against WT and drug-resistant RT. Transient 
kinetic analyses will be used in this dissertation to examine the mechanisms of inhibition of GS-
9148-DP against WT RT and RT containing the novel resistant mutations K70E/D123N/T165I. 
 
 
1.10.3 The 3’-azido-2’,3’-dideoxypurine analogs 
Two studies published in 2005 provide the rationale for pursuing 3’-azdio-2’,3’-dideoxypurines 
as a lead class of novel NRTI with potent activity against viruses carrying discrimination 
mutations and those carrying excision enhancing mutations (i.e. TAMs) (141, 212). Parikh et al. 
examined the antiviral activity of a structurally diverse panel of approved and investigational 
NRTIs that differed by enantiomer, sugar/pseudosugar, and base against HIV-1 carrying the 
K65R mutation to determine how NRTI structure affects activity (212). The results indicated that 
NRTI sugar/pseudosugar structure and base identity but not enantiomer influenced antiviral 
activity against K65R HIV-1. Importantly, NRTIs containing 3’-azido-modified sugars remained 
active against K65R HIV-1 while NRTI with other sugar/pseudosugar structures demonstrated 
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up to 77-fold decreased susceptibility to K65R compared to WT HIV-1.  The 3’-azido-2’,3’-
dideoxynucleosides with thymine and adenine bases had similar activity against K65R HIV-1 as 
WT HIV-1 in MT-2 cells. The 3’-azido-2’,3’-dideoxynucleosides with guanine and cytosine 
bases had 2.0-fold and 2.5-fold reduced activity against K65R HIV-1 in MT-2 cells, respectively, 
but these reductions compared to WT were not significant (p-value = 0.09 for 3’-azido-2’,3’-
dideoxyguanosine) or borderline significant (p-value = 0.05 for 3’-azido-2’,3’-dideoxycytidine). 
This study demonstrates that NRTI base and sugar structure influence antiviral activity against 
drug-resistant HIV-1. Furthermore, these results suggest that novel NRTI with 3’-azido-sugars 
may also demonstrate superior activity against viruses carrying the multi-NRTI discrimination 
mutation K65R.  
In the second study, Sluis-Cremer et al. examined the 3’-azido-2’,3’-dideoxynucleosides 
containing the four DNA nucleobases for activity against AZT-resistant HIV-1 viral replication 
and RT DNA synthesis (141). In antiviral activity assays in MT-2 cells, 3’-azido-2’,3’-
dideoxycytidine and AZT demonstrated 10.7-fold and 11.7-fold reduced activity, respectively, 
against HIV-1 containing TAMs (D67N/K70R/T215F/K219Q) compared to WT HIV-1. 
However, 3’-azido-2’,3’-dideoxyadenosine and 3’-azido-2’,3’-dideoxyguanosine demonstrated 
only 1.2-fold and 1.3-fold reduced activity, respectively, against HIV-1 containing TAMs 
compared to WT HIV-1. Furthermore, RT DNA synthesis assays showed that TAMs increase the 
ATP-mediated pyrophosphorylytic excision of the monophosphate forms of AZT and 3’-azido-
2’,3’-dideoxycytidine but not the excision of the monophosphate forms of 3’-azido-2’,3’-
dideoxyadenosine and 3’-azido-2’,3’-dideoxyguanosine. These results clearly demonstrate that 
TAMs confer resistance to 3’-azido-2’,3’-dideoxypyrimidine nucleosides (i.e. thymine and 
cytosine bases) but not to 3’-azido-2’,3’-dideoxypurine nucleosides (i.e. adenine and guanine 
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bases). Contrary to the accepted dogma at the time, this study demonstrated that the 3’-azido 
group is not the sole determinant of the RT excision phenotype, but the NRTI base also 
influences activity against RT containing TAMs.  
Together these two structure-activity-resistance studies identified 3’-azido-2’,3’-
dideoxypurine analogs a novel lead class of NRTI with potent activity against HIV-1 containing 
the discrimination mutation K65R and HIV-1 containing multiple TAMs. A later study by Sluis-
Cremer et al. further demonstrated that 3′-azido-2′,3′-dideoxyguanosine (3′-azido-ddG) exhibits 
potent activity against HIV-1 variants that contain the discrimination mutations K65R, L74V or 
M184V and against HIV-1 that contains multiple thymidine analog mutations (TAMs) that 
enhance nucleotide excision (172). Furthermore, 3′-azido-ddG does not exhibit cytotoxicity in 
primary lymphocytes or epithelial and T-cell lines, and does not decrease the mitochondrial 
DNA content of HepG2 cells.  
With the exception of FTC that contains a 5–fluoro modification, the active metabolites 
of all FDA approved NRTI contain natural DNA nucleobases. Given that natural base identity 
can influence NRTI activity towards drug-resistant RT, it is expected that base modification will 
also impact NRTI activity. However, the molecular interactions of base-modified analogs with 
WT or NRTI-resistant HIV-1 RT have not been extensively studied. Accordingly, we 
synthesized a series of novel base modified 3′-azido-2′,3′-dideoxypurine analogs (143). In this 
dissertation, the structure-activity-resistance relationships of these analogs was characterized in 
order to identify base modifications that may further improve 3′-azido-2′,3′-dideoxypurine 
activity against NRTI-resistant HIV-1.  
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTI/NtRTI) remain an indispensible 
component of combination antiretroviral therapy. However, NRTI efficacy can be undermined 
by toxicity and the selection of resistance mutations, which often confer cross-resistance to other 
NRTI. Consequently, the development of novel NRTI with improved safety and resistance 
qualities is of critical importance. The rational design of novel therapeutics with considerations 
for target enzyme structural and specificity determinants has been the most productive approach 
to drug discovery.  Uncovering specific knowledge of how NRTI base, sugar, and phosphate 
structure influence activity, resistance, and toxicity will inform the rational design and 
development of new analogs that demonstrate favorable resistance and pharmacologic 
properties. This information will be obtained through the following specific aims: 
 
Specific Aims 
1. Use steady-state and transient kinetic analyses to examine the mechanism(s) of action and 
resistance of two second-generation phosphonate NtRTI-diphosphates against WT and 
drug-resistant HIV-1 RT.  
 
2. Identify structure-activity-resistance relationships of novel base modified 3’-azido-2’,3’-
dideoxypurine nucleosides using a combination of biochemical and antiviral assays.  
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3.1 PREFACE 
This chapter is adapted in part from a manuscript originally published in the Journal of 
Biological Chemistry; Herman, B. D., Votruba, I., Holý, A., Sluis-Cremer, N., and J. Balzarini. 
(2010). The Acyclic 2,4-Diaminopyrimidine Nucleoside Phosphonate Acts as a Purine Mimetic 
in HIV-1 Reverse Transcriptase DNA Polymerization.  J Biol Chem 285(16): pp. 12101–12108. 
© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. 
Furthermore, this work was presented in part as a poster at The 9th Annual Symposium on 
Antiviral Drug Resistance: Targets and Mechanisms, November 16-19, 2008 Richmond, VA. 
USA. Herman, B. D., Meteer, J., Balzarini, J., and N. Sluis-Cremer. Mechanism of action and 
resistance to PMEO-5-methyl-DAPy, a novel pyrimidine nucleotide reverse transcriptase 
inhibitor.  
The work presented in this chapter is in partial fulfillment of dissertation Aim 1. Brian 
Herman performed all work with the exception of the steady-state kinetic analyses on 
homopolymeric template/primers, which were performed by Ivan Votruba.  
3.2 ABSTRACT 
The acyclic pyrimidine nucleoside phosphonate (ANP) phosphonylmethoxyethoxy-diamino-
pyrimidine (PMEO-DAPym) differs from other ANPs in that the aliphatic alkyloxy linker is 
bound to the C-6 of the 2,4-diaminopyrimidine base through an ether bond, instead of the 
traditional alkyl linkage to the N-1 or N-9 of the pyrimidine or purine base. In this study, we 
have analyzed the molecular interactions between PMEO-DAPym-diphosphate (PMEO-
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DAPym-DP) and the active sites of WT and drug-resistant HIV-1 RT. Pre-steady-state kinetic 
analyses revealed that PMEO-DAPym-DP is a good substrate for WT HIV-1 RT: its catalytic 
efficiency of incorporation (kpol/Kd) is only 2- to 3-fold less than that of the corresponding 
prototype purine nucleotide analogs PMEA-DP or TFV-DP. HIV-1 RT recognizes PMEO-
DAPym-DP as a purine base instead of a pyrimidine base and incorporates it opposite to thymine 
(in DNA) or uracil (in RNA). Molecular modeling demonstrates that PMEO-DAPym-DP fits 
into the active site of HIV-1 RT without significant perturbation of key amino acid residues and 
mimics an open incomplete purine ring that allows the canonical Watson-Crick base pairing to 
be maintained. PMEO-DAPym-DP is incorporated more efficiently than TFV-DP by mutant 
K65R HIV-1 RT and is not as efficiently excised as TFV by HIV-1 RT containing TAMs. 
Overall, the data revealed that PMEO-DAPym represents the prototype compound of a novel 
class of pyrimidine acyclic nucleoside phosphonates that are recognized as a purine nucleotide 
and should form the rational basis for the design and development of novel purine nucleo(s)(t)ide 
mimetics as potential antiviral or antimetabolic agents. 
3.3 INTRODUCTION 
Acyclic nucleoside phosphonates (ANPs) are nucleotide analogs that are characterized by the 
presence of a phosphonate group linked to a pyrimidine or purine base through an aliphatic 
linker (269). ANPs can be functionally divided into different structural subclasses (Figure 3.1) 
that include: (i) the phosphonylmethoxyethyl (PME) derivatives  (e.g. PMEA (adefovir)); (ii) the 
phosphonylmethoxypropyl (PMP) derivatives (e.g. TFV ((R)PMPA) and (S)FPMPA); and (iii) 
the hydroxyphosphonylmethoxypropyl (HPMP) derivatives (e.g. (S)HPMPA and (S)HPMPC  
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Figure 3.1 Structures of select acyclic nucleoside phosphonate derivatives. 
The structures of PME (PMEA), PMP ((R)PMPA), and HPMP ((S)HPMPA, (S)FPMPA and 
(S)HPMPC) ANP derivatives and the corresponding PMEO-, (R)PMPO-, (S)HPMPO-, and 
(S)FPMPO-diamino pyrimidines (DAPym) are shown. 
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(cidofovir)) ( (269-273). Analogs of each subclass are endowed with a characteristic and specific 
antiviral activity spectrum (274). For example, the PME-purine derivatives are active against 
several DNA viruses (i.e. herpesviruses, poxviruses and hepatitis B virus (HBV)) and 
retroviruses (e.g.HIV-1), whereas the PMP-purine derivatives display antiviral activity against 
retroviruses and HBV only. The HPMP-purine derivatives are active against a broad variety of 
DNA viruses (i.e. herpesviruses, poxviruses, and adenoviruses), whereas the cytosine derivative 
(S)HPMPC represents the sole HPMP-pyrimidine derivative that shows selective activity against 
cytomegalovirus and poxviruses. Interestingly, the PME- and PMP-pyrimidine derivatives do not 
exhibit antiviral activity. Thus, minor structural modifications in the side chain and also the 
identity of the base have a marked impact on the ANP antiviral activity spectrum. All of the 
ANPs described above are metabolized to a diphosphate form in the cell and act as competitive 
inhibitors (alternative substrates) of the virus-encoded DNA polymerase (270, 275-279). The 
ANP-diphosphate binds to the active site of the viral polymerase and competes with the 
corresponding natural nucleotide (i.e. dATP for (S)HPMPA, PMEA,  (S)FPMPA and TFV and 
dCTP for (S)HPMPC) for subsequent incorporation into the growing DNA chain. 
Recently, a new structural subclass of ANP, the acyclic phosphonylmethoxyethoxy- and 
phosphonylmethoxypropoxy-diaminopyrimidines (designated PMEO- and PMPO-DAPym) 
derivatives, was identified (262, 280-282). These ANPs differ from the other subclasses by the 
presence of an aliphatic alkyloxy linker bound to the C-6 of a 2,4-diaminopyrimidine base 
through an ether bond instead of the traditional alkyl linker bond to the N-1 of a pyrimidine or 
the N-9 of a purine (Figures 3.1, 3.2). Interestingly, and in contrast to the PME- and PMP-
pyrimidines, the PMEO- and PMPO-pyrimidine ANP derivatives exhibit pronounced activity 
against both retroviruses and HBV (283). Of further interest, these analogs display an antiviral  
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Figure 3.2 Structural similarity between the PME-diaminopurine (DAP) derivative and 
PMEO-DAPym.  
 
activity spectrum that is similar to the PME- and PMP-purines. Therefore, it was speculated that 
there was structural similarity between the 2,6-diaminopurine (DAP) PME-derivative 
(PMEDAP) and the PMEO-DAPym derivatives (280). This was supported by molecular 
modeling and superimposition of their optimized three-dimensional structures which 
demonstrated that the 2,4-diamino-substituted pyrimidine could be regarded as an open-ring 
analog of the purine system in the 2,6-diaminopurine ANPs (Figure 3.2) (283).  
In this study, we have analyzed the molecular interactions between PMEO-DAPym-DP 
and the active site of HIV-1 reverse transcriptase (RT) using both steady-state and pre-steady-
state kinetic analyses. The in vitro activity of PMEO-DAPym-DP against WT and drug-resistant 
recombinant purified HIV-1 RT was also compared to the PME-purine (i.e. PMEA-DP) and 
PMP-purine (i.e. TFV-DP) analogs.  Importantly, we show for the first time that the acyclic 
pyrimidine nucleoside phosphonate derivative PMEO-DAPym-DP is incorporated into the 
growing DNA chain by HIV-1 RT as a purine nucleotide analog but not as a pyrimidine 
nucleotide analog. Therefore, PMEO-pyrimidine derivatives successfully mislead the viral DNA 
polymerase and act as purine nucleotide mimetics. Also, we obtained kinetic evidence that 
PMEO-DAPym may have a therapeutic edge over TFV in terms of its level of phenotypic drug 
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resistance. Additionally, we examined the ability of PMEO-DAPym-DP, PMEA-DP, and TFV-
DP to directly inhibit steady-state DNA polymerization in vitro by recombinant, purified human 
DNA polymerases alpha (Pol α), beta (Pol β), and gamma (Pol γ). Interestingly, PMEO-DAPym-
DP was recognized and incorporated by Pol α, resulting in chain-termination, but was not 
incorporated by Pol β or Pol γ. The identification of modified pyrimidine analogs opens new 
perspectives for developing novel types of such ambiguous pyrimidine nucleo(s)(t)ides with 
antiviral or antimetabolic potential.  
3.4 MATERIALS AND METHODS 
3.4.1 Reagents 
The WT HIV-1 RT EC 2.7.7.49 used in the steady-state kinetic experiments that utilized 
homopolymeric template/primers (T/Ps) was derived from an HIV-1 (SF2 strain) pol gene 
fragment coding for the RT (Pro156-Leu715). The stock solution was 0.36 mg/ml. The WT, 
K65R, K70E, M184V, M41L/L210W/T215Y (TAM41), and D67N/K70R/T215F/K219Q 
(TAM67) HIV-1 RTs used in the steady-state and pre-steady-state kinetic experiments that 
utilized heteropolymeric T/Ps were purified as described previously (284, 285). The protein 
concentration of these enzymes was determined spectrophotometrically at 280 nm using an 
extinction coefficient (ε280) of 260450 M−1 cm−1, and by Bradford protein assays (Sigma-
Aldrich, St. Louis, MO). The RNA- and DNA-dependent DNA polymerase activities of the 
purified WT and mutant enzymes were essentially identical (data not shown). Purified human 
DNA polymerases α. Β, and γ were purchased from CHIMERx (Milwaukee, WI). TFV 
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diphosphate (TFV-DP) and PMEA diphosphate (PMEA-DP) were purchased from Moravek 
Biochemicals (Brea, CA). PMEO-DAPym-DP was synthesized and provided by A. Holý 
(Prague, Czech Republic). ATP, dNTPs, and ddNTPs were purchased from GE Healthcare 
(Piscataway, NJ), and [γ-32P]ATP was acquired from PerkinElmer Life Sciences (Boston, MA). 
RNA and DNA heteropolymeric oligonucleotides were synthesized by IDT (Coralville, IA). The 
templates poly(rC), poly(rA),  poly(rI) and poly(rU) as well as the primers oligo(dG)12-18, 
oligo(dT)12-18, oligo(dC)12-18, and oligo(dA)12-18 were from Pharmacia (Uppsala, Sweden). 
The homopolymeric T/P substrates poly(rC)/oligo(dG), poly(rA)/oligo(dT), poly(rI)/oligo(dC) 
and poly(rU)/oligo(dA) were prepared by mixing 0.15 mM of template with an equal volume of 
0.0375 mM primer. 
3.4.2 Steady-state assays using homopolymeric T/Ps 
Reactions (50 µl in volume) were carried out in a 50 mM Tris-HC1 (pH 7.8) buffer that 
contained 5 mM dithiothreitol, 300 mM glutathione, 0.5 mM EDTA, 150 mM KC1, 5 mM 
MgC12 or 5 mM MnCl2, 1.25 µg of BSA, 0.06% Triton X-100, an appropriate concentration of 
[3H]-dTTP, [3H]-dGTP, [3H]-dCTP or [3H]-dATP (2 µCi/assay), varying concentrations of ANP 
analog, and a fixed concentration of poly(rA)/oligo(dT) (0.015 mM), poly(rC)/oligo(dG) (0.1 
mM), poly(rI)/oligo(dC) (0.015 mM) or poly(rU)/oligo(dA) (0.015 mM). Reactions were 
initiated by the addition of 1 µl of RT and were incubated for 15 min at 37°C. Reactions were 
then terminated by the addition of 100 µl of 150 µg/ml calf thymus DNA, 2 ml of 0.1 M 
Na4P2O7 (in 1 M HCl), and 2 ml of 10% (v/v) trichloroacetic acid. The solutions were kept on ice 
for 30 min after which the acid-insoluble material was washed and analyzed for radioactivity. 
For IC50 determinations, fixed concentrations of 1.25 µM [3H]dTTP, 2.5 µM [3H]dGTP, 1.75 µM 
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[3H]dATP, or 2.5 µM [3H]dCTP were used. For the Ki determinations with respect to the natural 
substrates, a fixed concentration of T/P was used (as indicated above).  For the Ki determinations 
with respect to T/P, varying concentrations of the T/P were used in the presence of a fixed 
concentration of 1.25 µM [3H]dTTP, 2.5 µM [3H]dGTP, 1.75 µM [3H]dATP or 2.5 µM 
[3H]dCTP. The steady state kinetic constants Ki and Km were calculated using the Michaelis-
Menten equation derived from double reciprocal (Lineweaver-Burke) plots.  
3.4.3 Steady-state assays using heteropolymeric T/P 
The ability of PMEO-DAPym-DP to inhibit HIV-1 RT DNA synthesis was also evaluated using 
heteropolymeric DNA/DNA and RNA/DNA T/Ps. Briefly, reactions were carried out in 50 mM 
Tris (pH 7.5), 50 mM KCl, 10 mM MgCl2 containing 20 nM T/P, 0.5 µM each dNTP and 
various concentrations of PMEO-DAPym-DP (0 to 40 µM). The sequences of the T/P substrates 
are provided in Figure 3.4, and the DNA primers were 5′-radiolabeled with [γ-32P]ATP as 
described previously (141). Reactions were initiated by the addition of 200 nM WT RT, 
incubated for 10 min at 37 °C and then quenched using 20 µL of gel loading buffer (98 % 
deionized formamide containing 1 mg/mL each of bromophenol blue and xylene cyanol). 
Control reactions included the addition of either TFV-DP or PMEA-DP. Samples were then 
denatured at 95 °C for 10 min and polymerization products were separated from substrates by 
denaturing gel electrophoresis using 14 % acrylamide containing 7 M urea. Gels were analyzed 
using phosphorimaging with a GS525 Molecular Imager and Quantity One Software (Biorad 
Laboratories, Inc., Hercules, CA). The concentrations required to inhibit the formation of final 
product by 50 % were calculated using non-linear regression from three independent 
experiments.  
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3.4.4 Pre-steady-state assays 
A rapid quench instrument (Kintek RQF-3 instrument, Kintek Corporation, Clarence, PA) was 
used for pre-steady-state experiments with reaction times ranging from 20 ms to 60 s. The typical 
experiment was performed at 37 °C in 50 mM Tris-HCl (pH 7.5) containing 50 mM KCl, 10 mM 
MgCl2 and varying concentrations of nucleotide. All concentrations reported refer to the final 
concentrations after mixing. HIV-1 RT (200 nM) was pre-incubated with 20 nM T/P substrate, 
prior to rapid mixing with nucleotide and divalent metal ions to initiate the reaction that was 
quenched with 50 mM EDTA. The sequences of the template and 5’-radiolabeled primer were 
5’-
CTCAGACCCTTTTAGTCAGAATGGAAATTCTCTAGCAGTGGCGCCCGAACAGGGACA
-3’ and 5’-TCGGGCG CCACTGCTAGAGA-3’, respectively. The quenched samples were then 
mixed with an equal volume of gel loading buffer and products were separated from substrates as 
described above. The disappearance of substrate (20mer) and the formation of product (21mer) 
were quantified using a Bio-Rad GS525 Molecular Imager (Bio-Rad Laboratories, Inc., 
Hercules, CA). Data were fitted by nonlinear regression with Sigma Plot software (Systat 
Software, Inc., San Jose, CA) using the appropriate equations (286). The apparent burst rate 
constant (kobs) for each particular concentration of dNTP was determined by fitting the time 
courses for the formation of product (21mer) using the following equation: [21mer] = A[1-exp(-
kobst)], where A represents the burst amplitude. The turnover number (kpol) and apparent 
dissociation constant for dNTP (Kd) were then obtained by plotting the apparent catalytic rates 
(kobs) against dNTP concentrations and fitting the data with the following hyperbolic equation: 
kobs = (kpol[dNTP])/([dNTP] + Kd). Catalytic efficiency was calculated as the ratio of turnover 
number over dissociation constant ([kpol/Kd]). Selectivity for natural dNTP versus ANP was 
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calculated as the ratio of catalytic efficiency of dNTP over that of ANP 
([(kpol/Kd)dNTP/(kpol/Kd)ANP]). Resistance was calculated as the ratio of selectivity of the mutant 
over that of WT ([(selectivity)Mutant/(selectivity)WT]).  
3.4.5 Excision assays 
A 26 nucleotide DNA primer (P; 5′-CCTGTTCGGGCGCCACTGCTAGAGAT-3′) was 5′-
radiolabeled with [γ-32P]ATP and chain-terminated with either PMEO-DAPym-DP, TFV-DP or 
PMEA-DP as reported previously (141).  
This chain-terminated primer was then annealed to a DNA template (5’-
CTCAGACCCTTTTAGTCAGAATGGAAATTCTCTAGCAGTGGCGCCCGAACAGGGACA
-3’). ATP-mediated excision assays were carried out by first incubating 20 nM T/P with 3 mM 
ATP, 10 mM MgCl2, 1 μM dATP, and 10 μM ddGTP in a buffer containing 50 mM Tris-HCl 
(pH 7.5) and 50 mM KCl. Reactions were initiated by the addition of 200 nM WT or mutant RT. 
Aliquots were removed at defined times, quenched with sample loading buffer, denatured at 95 
°C for 10 min, and then the product was resolved from substrate by denaturing polyacrylamide 
gel electrophoresis and analyzed, as described above. Dead-end complex formation was 
evaluated using the same assay set-up described above. However, the concentration of the next 
correct dNTP (i.e. dATP) was varied from 0-100 µM and reactions were quenched after 60 min. 
3.4.6 Molecular modeling 
Molecular models were constructed using the X-ray crystallographic coordinates for the 
RT/T/P/TFV-DP ternary complex (PDB, 1T05) (85). PMEO-DAPym-DP was docked into the 
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DNA polymerization active site and energy minimization experiments were carried out using 
Molecular Operating Environment (Chemical Computing Group, Montreal, Quebec, Canada). 
Charges were calculated using the Gasteiger method, and iterative minimizations were carried 
out using the AMBER 99 force field until the energy difference between iterations was less than 
0.0001 kcal/mol per Å. 
3.4.7 Steady state DNA synthesis by human DNA polymerases α, β, and γ 
The ability of PMEO-DAPym-DP to inhibit DNA synthesis by human polymerases α, β, and γ 
was evaluated using the heteropolymeric DNA/DNA T/Ps indicated in Figure 3.7. The DNA 
primers were 5′-radiolabeled with [γ-32P]ATP and annealed to the template as described 
previously (141). Preliminary experiments were performed to identify the T/P substrate and 
reaction conditions that provided the best activity from each human polymerase (data not 
shown). DNA synthesis reactions for Pol α were carried out in a reaction buffer containing 60 
mM Tris (pH 8.0), 5 mM Mg Acetate, 1mM DTT, 0.1 mM spermine, and 0.3 mg/mL BSA. DNA 
synthesis reactions for Pol β and Pol γ were carried out in the same reaction buffer but in the 
absence of spermine and with 10 mM MgCl2 instead of 5 mM Mg Acetate. A solution of the 
appropriate reaction buffer containing 20 nM T/P, 10 µM each dNTP and various concentrations 
of PMEO-DAPym-DP (0 to 60 µM) was mixed with 3 units of Pol α, 2 units of Pol β, or 2 units 
of Pol γ to initiate the reaction. One unit is defined as the amount of enzyme required to 
incorporate 1 nmol (Pol α and Pol β) or 1 pmol (Pol γ) total nucleotide into the acid-insoluble 
form in 60 min at 37 °C. Control reactions included the addition of either TFV-DP or PMEA-
DP. Reactions were incubated for 60 min at 37 °C and then quenched using 20 µL of gel loading 
buffer (98 % deionized formamide containing 1 mg/mL each of bromophenol blue and xylene 
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cyanol). Samples were then denatured at 95 °C for 10 min and polymerization products were 
separated from substrates by denaturing gel electrophoresis using 14 % acrylamide containing 7 
M urea. Gels were analyzed using phosphorimaging with a GS525 Molecular Imager and 
Quantity One Software (Biorad Laboratories, Inc., Hercules, CA). The concentrations required to 
inhibit the formation of final product by 50 % were calculated using non-linear regression from 
three independent experiments. 
3.5 RESULTS 
3.5.1 Inhibition of HIV-1 RT-mediated DNA synthesis by PMEO-DAPym-DP in the 
presence of homopolymeric T/Ps 
The ability of PMEO-DAPym-DP to inhibit HIV-1 RT mediated DNA synthesis was first 
evaluated using four different homopolymeric T/Ps (Table 3.1). PMEA-DP and the 2’,3’-
dideoxynucleotide derivatives ddATP, ddTTP and AZT-TP were included as controls in these 
experiments. Reactions were carried out using either MgCl2 or MnCl2 as the divalent metal ion. 
In general, MgCl2-mediated DNA polymerization reactions proceeded 10- to 100-fold more 
efficiently than MnCl2-mediated reactions when poly(rC)/oligo(dG), poly(rA)/oligo(dT) or 
poly(rI)/oligo(dC) were used as the T/P substrate. By contrast, efficient DNA synthesis on the 
poly(rU)/oligo(dA) T/P was only observed when MnCl2 was used as the divalent metal ion (data 
not shown). PMEO-DAPym-DP showed pronounced submicromolar inhibitory activity (IC50 = 
0.26 µM), that was similar to PMEA-DP (IC50 = 0.12 µM) or ddATP (IC50 = 0.23 µM), when 
poly(rU)/oligo(dA) and MnCl2-dATP were used as substrates. By contrast, AZT-TP and ddTTP  
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Table 3.1 Inhibition of HIV-1 RT mediated DNA synthesis by PMEO-DAPym-DP and other nucleoside analogs using 
hompolymeric T/Ps. 
 
 IC50 (µM) a 
 Poly(rC)/oligo(dG) [3H]dGTP  
Poly(rU)/oligo(dA) 
[3H]dATP  
Poly(rA)/oligo(dT) 
[3H]dTTP  
Poly(rI)/oligo(dC) 
[3H]dCTP 
 MgCl2 MnCl2  MgCl2 MnCl2  MgCl2 MnCl2  MgCl2 MnCl2 
PMEO-
DAPym-DP > 200 16 ± 3.3  N.D.b 0.26 ± 0.10  > 200 > 200  > 200 > 200 
PMEA-DP > 100 75 ± 21  N.D.b 0.12 ± 0.06  > 100 > 100  > 100 > 100 
ddATP > 100 72 ± 13  N.D.b 0.23 ± 0.17  > 100 > 100  > 100 > 100 
ddTTP > 100 > 100  N.D.b > 100  0.053 ± 0.011 0.072 ± 0.001  > 100 > 100 
AZT-TP > 100 > 100  N.D.b 67 ± 7  0.024 ± 0.020 0.006 ± 0.004  > 100 59 ± 7 
 
a Concentration (µM) required to inhibit the RT reaction by 50%. The concentration of MgCl2 or MnCl2 in the reaction mixture was 5 
mM. Data are the means ± standard deviations of 2 to 3 independent experiments. 
b N.D., not detectable. 
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were required at 257- and > 385-fold higher concentrations, respectively, to inhibit these 
reactions in the presence of this T/P (Table 3.1). Interestingly, whereas PMEO-DAPym-DP did 
not inhibit reactions on the poly(rA)/oligo(dT) or poly(rI)/oligo(dC) T/P substrates at 200 µM, 
the compound was found to exert a 62-fold weaker inhibition (IC50 = 16 μM) when 
poly(rC)/oligo(dG) and MnCl2-dGTP were used as substrates than when poly(rU)/oligo(dA) T/P 
was used. No inhibition was noticed at 100 µM when MnCl2 was replaced by MgCl2. PMEA-DP 
and ddATP did not show pronounced inhibitory activity (IC50 = 72-75 µM) under similar assay 
conditions (Table 3.1). Additional studies demonstrated that PMEO-DAPym-DP acted as a 
competitive inhibitor of MnCl2-[3H]dATP or MnCl2-[3H]dGTP binding, and as a linear mixed-
type inhibitor of  poly(rU)/oligo(dA) or poly(rC)/oligo(dG) binding (Figure 3.3). The steady 
state Michaelis-Menten binding (Km) and inhibitory (Ki) constants determined from these 
experiments are provided in Table 3.2. Taken together, these data demonstrate that HIV-1 RT 
recognizes and incorporates PMEO-DAPym-DP as an adenine nucleotide derivative. The fact 
that PMEO-DAPym-DP was also weakly incorporated by HIV-1 RT into the poly(rC)/oligo(dG) 
T/P substrates when MnCl2 was used as the divalent metal ion suggests that this nucleotide might 
also base pair with cytosine. Alternatively, it is well known that nucleotide misincorporation is 
more readily facilitated by MnCl2 in comparison with MgCl2, because MnCl2 can partially 
compensate for the rate-limiting chemistry step that governs misincorporation reactions (287).  
Also, homopolymeric T/P substrates represent more artificial reaction conditions than 
heteropolymeric T/P substrates, making the latter more relevant to the physiological situation. 
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Figure 3.3 Double reciprocal plots for HIV-1 RT inhibition by PMEO-DAPym-DP using 
poly(rU)/oligo(dA) and MnCl2-dATP or poly(rC)/oligo(dG) and MnCl2-dGTP as 
substrates. 
The assay conditions are described in the Materials and Methods. PMEO-DAPym-DP was 
determined to be a competitive inhibitor of dATP (A) and dGTP (B) binding and a linear mixed-
type inhibitor of poly(rU)/oligo(dA) (C) or poly(rC)/oligo(dG) (D) binding. The Ki values 
determined from these experiments are provided in Table 3.2. 
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Table 3.2 Km and Ki values for PMEO-DAPym-DP and PMEA-DP against HIV-1 RT on homopolymeric T/Ps. 
 
 Competing entity  Competing entity 
Inhibitor Poly(rU)/oligo(dA) dATP  Poly(rC)/oligo(dG) dGTP 
 Km (μM) a Ki (μM) a Km (μM) Ki (μM)  Km (μM) Ki (μM) Km (μM) Ki (μM) 
PMEO-
DAPym-DP 1.2 ± 0.1 
b
 0.41 ± 0.10 16 ± 5 0.29 ± 0.22  17 ± 10 12 ± 2.2 2.7 ± 0.5 5.8 ± 1.2 
PMEA-DP 1.2 ± 0.4 0.12 ± 0.05 10 ± 2 0.10 ± 0.06  17 ± 10 46 ± 1.0 3.0 ± 0.7 39 ± 5.7 
 
a Km and Ki values were calculated from the kinetic data in Figure 3.3 using linear regression analysis. 
b Data are the means ± standard deviations of 2 to 3 independent experiments. 
 
72 
3.5.2 Inhibition of HIV-1 RT-mediated DNA synthesis by PMEO-DAPym-DP in the 
presence of heteropolymeric T/Ps 
In order to determine the incorporation profile of PMEO-DAPym-DP, we next examined 
inhibition HIV-1 RT-mediated DNA polymerization on heteropolymeric DNA/DNA and 
RNA/DNA T/Ps with MgCl2 as the divalent metal cation (Figure 3.4). In these experiments, 
TFV-DP and PMEA-DP were included as controls. Consistent with the studies described above, 
we found that HIV-1 RT recognized PMEO-DAPym-DP as a purine but not a pyrimidine 
nucleotide analog and incorporated it opposite to thymine in the DNA template or uracil in the 
RNA template. As expected, its incorporation resulted in chain-termination of DNA synthesis. 
The concentration of PMEO-DAPym-DP required to inhibit HIV-1 RT-catalyzed DNA synthesis 
by 50 % (IC50) was calculated to be 3.5 µM and 15 µM on the DNA/DNA and RNA/DNA 
template/primer substrates, respectively. By comparison, the IC50 values for TFV-DP and 
PMEA-DP were calculated to be 0.79 µM and 0.78 µM  for the DNA/DNA, and 1.83 µM and  
1.21 µM for the RNA/DNA T/P substrates, respectively. In these assays, PMEO-DAPym-DP 
was not incorporated opposite to the alternative pyrimidine cytosine, even when MnCl2 was used 
as the divalent metal ion (data not shown).  
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Figure 3.4 Incorporation of PMEO-DAPym-DP as an adenosine analog by WT HIV-1 RT 
in DNA/DNA (panel A) or RNA/DNA (panel B) T/P. 
The sequences of the DNA/DNA and RNA/DNA T/P are indicated above each autoradiogram.   
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3.5.3 Pre-steady-state incorporation of PMEO-DAPym-DP by WT, K65R, K70E, and 
M184V HIV-1 RT 
Pre-steady-state kinetic analyses were carried out to elucidate, in detail, the interactions between 
PMEO-DAPym-DP and the polymerase active site of HIV-1 RT (Table 3.3). Because PMEO-
DAPym-DP behaves as an adenine nucleotide analog, we again included TFV-DP and PMEA-
DP as controls. In addition, we examined the activity of PMEO-DAPym-DP against RTs 
containing the K65R and K70E mutations that are associated with TFV and PMEA resistance, 
respectively (288, 289). The M184V mutation, which may confer hypersusceptibility to TFV, 
was also examined. The results (Table 3.3) show that the catalytic efficiency of incorporation 
(kpol/Kd) of PMEO-DAPym-DP for WT HIV-1 RT is approximately 2- to 3-fold less than the 
kpol/Kd values determined for PMEA-DP or TFV-DP. This decrease in the kpol/Kd value for 
PMEO-DAPym-DP (relative to PMEA-DP and TFV-DP) is driven predominantly by a slower 
rate of nucleotide analog incorporation (kpol) and not by a diminished binding affinity (Kd) for 
the DNA polymerase active site of RT. As reported previously, the catalytic efficiency of 
incorporation of TFV-DP is decreased 12.4- and 2.5-fold by the K65R and K70E mutations in 
RT (122, 161). Consistent with previously published cross-resistance data (288, 289), both the 
K65R and K70E mutations in HIV-1 RT also conferred resistance to PMEA-DP. Similar to 
TFV-DP, this resistance was driven primarily by a selective decrease in the rate of PMEA-DP 
incorporation (kpol) and not by a decrease in the nucleotide binding affinity (Kd).
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Table 3.3 Pre-steady state kinetic incorporation values of PMEO-DAPym-DP for WT and drug-resistant HIV-1 RT. 
 dATP  ANP  
 kpol (s-1) Kd (µM) 
kpol/Kd  
(µM-1 s-1)  kpol (s
-1) Kd (µM) 
kpol/Kd  
(µM-1 s-1) Selectivity 
b Resistance c 
PMEO-DAPym-DP 
WT 24.4 ± 3.9 a 3.2 ± 1.2 7.6  1.1 ± 0.3 2.3 ± 1.1 0.49 15.5 -- 
K65R 12.6 ± 1.9 3.2 ± 0.7 4.0  0.21 ± 0.04 3.5 ± 2.1 0.06 65.8 4.2 
K70E 18.0 ± 2.8 3.3 ± 0.9 5.5  0.18 ± 0.01 2.3 ± 0.6 0.08 69.3 4.5 
M184V 14.8 ± 6.4 2.5 ± 0.8 5.9  1.2 ± 0.08 4.3 ± 0.2 0.27 21.7 1.4 
TFV-DP 
WT 24.4 ± 3.9 3. 2 ± 1.2 7.6  6.16 ± 1.0 4.3 ± 1.0 1.44 5.3 -- 
K65R 12.6 ± 1.9 3.2 ± 0.7 4.0  0.45 ± 0.06 7.3 ± 2.7 0.06 65.8 12.4 
K70E 18.0 ± 2.8 3.3 ± 0.9 5.5  2.1 ± 0.1 5.1 ± 1.5 0.41 13.5 2.5 
M184V 14.8 ± 6.4 2.5 ± 0.8 5.9  2.0 ± 0.9 2.6 ± 0.3 0.76 7.8 1.5 
PMEA-DP 
WT 24.4 ± 3.9 3. 2 ± 1.2 7.6  5.1 ± 1.3 4.0 ± 1.5 1.26 6.0 -- 
K65R 12.6 ± 1.9 3.2 ± 0.7 4.0  0.52 ± 0.28 4.2 ± 1.8 0.12 32.9 5.5 
K70E 18.0 ± 2.8 3.3 ± 0.9 5.5  2.5 ± 0.5 4.3 ± 1.4 0.59 9.39 1.6 
M184V 14.8 ± 6.4 2.5 ± 0.8 5.9  1.95 ± 0.6 3.4 ± 1.3 0.57 10.3 1.7 
 
a Values represent the means ± standard deviations of three independent experiments. 
b Selectivity is (kpol/Kd)dNTP/(kpol/Kd)ANP. 
c Resistance (n-fold) is selectivitymutant/selectivityWT. 
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Both the K65R and K70E mutations in RT also conferred resistance to PMEO-DAPym-DP via a 
similar mechanism (i.e. selective decrease in kpol). However, PMEO-DAPym-DP displayed 
better incorporation activity against K65R RT than TFV-DP. In this regard, a previous study 
reported that PMEO-DAPym exhibited better antiviral activity (lower levels of phenotypic drug 
resistance) against a panel of clinical virus isolates that contained multiple drug resistance 
mutations, including K65R, than did either PMEA or TFV (262). Furthermore, these data 
highlight that subtle changes in the side chains and identity of the base have a marked impact on 
the ANP anti-HIV-1 activity spectrum. 
3.5.4 ATP-mediated excision of PMEO-DAPym by WT and mutant HIV-1 RT                   
HIV-1 RT has the intrinsic ability to rescue DNA synthesis from a blocked primer by ATP-
mediated phosphorolytic excision of the DNA chain-terminating nucleotide (130). This ATP-
mediated excision activity of HIV-1 RT is selectively increased by TAMs (131, 132), but can be 
diminished by other mutations, including K65R and K70E (122, 161). Accordingly, we next 
investigated the ability of WT, K65R, K70E and TAM-containing RT to excise PMEO-DAPym 
from a DNA chain-terminated template/primer. Two RT enzymes that contained different 
patterns of TAMs (i.e. M41L/L210W/T215Y (TAM41) and D67N/K70R/T215F/K219Q 
(TAM67)) were included in this study. In addition, TFV- and PMEA-chain terminated DNAs 
were included as controls. The results (Figure 3.5, Table 3.4) demonstrate that, in comparison  
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Figure 3.5 Autoradiograms (panel A) and rates (panel B) for ATP-mediated excision of 
PMEO-DAPym, TFV, and PMEA by WT and mutant HIV-1 RT. 
For panel B, data represent the means ± standard deviations of two independent experiments.  
 
78 
 
Table 3.4 Excision rates and dead-end complex formation by WT and mutant RT. 
 
RT 
Excision Ratea (min-1)   IC50 for DEC formation
b (µM) 
TFV PMEA PMEO -DAPym  TFV PMEA PMEO -DAPym 
WT 0.024 ± 0.00 0.014 ± 0.00 0.025 ± 0.01  30.1 ± 6.5 14.7 ± 2.7 14.6 ± 1.8 
TAM67c 0.088 ± 0.02 (3.7)e 0.043 ± 0.01 (3.1) 0.080 ± 0.01 (3.2)  79.0 ± 4.5 65.9 ± 1.6 67.4 ± 4.6 
TAM41d 0.086 ± 0.02 (3.6) 0.030 ± 0.01 (2.1) 0.065 ± 0.01 (2.6)  78.3 ± 5.4 50.0 ± 9.0 55.6 ± 7.5 
 
a Values represent the means ± standard deviations from two independent experiments. 
b Values represent means ± standard deviations from three independent experiments. 
c TAM67: D67N/K70R/T215F/K219Q 
d TAM41: M41L/L210W/T215Y 
e Values in parentheses indicate fold change compared to WT RT. 
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with the WT enzyme, both TAM41 and TAM67 HIV-1 RT exhibited increased capacities to 
excise all three ANPs. However, the excision of PMEA and PMEO-DAPym by TAM41 RT 
occurred less efficiently than that of TFV. In contrast to the RTs containing TAMs, the mutant 
K70E and K65R RT enzymes exhibited poor excision activity that was independent of the DNA 
chain-terminating nucleotide analog. Previous studies have shown that the next complementary 
nucleotide can inhibit ATP-mediated chain terminator removal (81). To determine the magnitude 
and nature of this inhibition against PMEO-DAPym, PMEA, and TFV, we determined the IC50 of 
the next complementary nucleotide for the ATP-dependent removal of each of the acyclic 
nucleoside phosphonate analogs. The results (Table 3.4) show that the inhibitory concentrations 
of the next complementary dNTP were found to be somewhat higher for TFV compared with 
either PMEA or PMEO-DAPym. Taken together, these data suggest that PMEO-DAPym is a 
less efficient substrate for ATP-mediated excision than TFV. These findings may suggest that 
PMEO-DAPym may eventually be superior to TFV as an antiretroviral drug in respect of 
phenotypic drug resistance levels. 
3.5.5 Molecular modeling 
A molecular model of PMEO-DAPym-DP bound at the DNA polymerase active site of HIV-1 
RT was generated by docking this compound into the RT-T/P-TFV-DP structure (PDB co-
ordinates 1T05) (85). The model (Figure 3.6A) shows that PMEO-DAPym-DP can reside in the 
DNA polymerase active site of RT without significant perturbation of its key residues (i.e. K65, 
R72, D110, Y115, D185, D186 and Q151). In fact, overlay of the RT-T/P-TFV-DP structure 
with our model suggests that the active site architecture is essentially unchanged including the 
YMDD motif that is essential for catalysis (Figure 3.6B). In addition, the model shows that the  
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Figure 3.6 A model of PMEO-DAPym-DP bound at the DNA polymerase active site of 
HIV-1 RT. 
PMEO-DAPym-DP was docked into the RT-T/P-TFV-DP ternary structure (PDB co-ordinates 
1T05; A). No significant disruption of the active site residues was observed. An overlay of the 
RT-T/P-PMEO-DAPym-DP model with the RT-T/P-TFV-DP structure (B) demonstrates that 
PMEO-DAPym-DP mimics an incomplete purine ring and allows canonical Watson-Crick base 
pairing. 
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C-6 phosphonate linkage allows the pyrimidine ring in PMEO-DAPym to mimic an open 
incomplete purine ring that allows the canonical Watson-Crick base pairing to be maintained. 
3.5.6 Inhibition of human DNA polymerase α-, β-, and γ-mediated DNA synthesis by 
PMEO-DAPym-DP 
We also examined the potential for PMEO-DAPym-DP to inhibit steady state DNA synthesis by 
the human DNA polymerases α, β, and γ (Figure 3.7 ). PMEO-DAPym-DP was recognized and 
incorporated as an A-analog by DNA Pol α, resulting in chain termination. DNA synthesis by 
Pol α was also inhibited by PMEA-DP but not by TFV-DP. Human Pol β DNA synthesis was 
inhibited by TFV-DP (IC50 = 20.3 μM) and PMEA-DP (IC50 =  28.8 μM) but was not inhibited 
by PMEO-DAPym-DP. PMEO-DAPym-DP, TFV-DP, PMEA-DP were not substrates for 
incorporation by DNA Pol γ.  
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Figure 3.7 Inhibition of human polymerase α (A), β (B), and γ (C) steady state DNA 
synthesis by PMEO-DAPym-DP. 
The DNA/DNA T/P used is indicated in each panel and the reaction conditions are provided in 
the Materials and Methods section.  
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3.6 DISCUSSION 
In the present study, we demonstrate that HIV-1 RT efficiently recognizes PMEO-DAPym-DP 
as a purine (i.e. adenine) nucleotide derivative but not as a pyrimidine nucleotide derivative. Our 
modeling and docking studies in HIV-1 RT confirm the similarities between PMEO-DAPym-DP 
and TFV-DP in terms of a mimetic of an incomplete purine ring (DAPym) and are in full 
agreement with the obtained kinetic data. This is a striking observation and the first 
demonstration that a pyrimidine nucleotide analog can be unambiguously recognized as an 
adenine nucleotide derivative for both binding and incorporation into the growing DNA chain by 
HIV-1 RT. Moreover, such a wrongly-incorporated nucleotide derivative shows a less efficient 
increase of excision from the terminated DNA chain by mutant RTs than TFV. Such drugs may 
make it more difficult for the virus to escape drug pressure and may eventually exert lower 
phenotypic drug resistance levels, as has been experimentally shown in cell culture when PMEO-
DAPym is compared to TFV (262). PMEO-DAPym-DP was also recognized as adenosine by 
human pol α for incorporation across from thymine, suggesting that the molecular mimicry 
phenotype extends beyond HIV-1 RT.  
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4.1 PREFACE 
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4.2 ABSTRACT 
GS-9148 is a novel adenosine analog phosphonate NtRTI that demonstrates potent antiviral 
activity and favorable toxicity and resistance profiles. In cell culture selection experiments, 
viruses with decreased susceptibility to GS-9148 harbored a novel set of resistance mutations.  
The RT mutation K70N was initially selected, which was later replaced with K70E followed by 
the addition of D123N and T165I.  The K70E/D123N/T165I combination represents a novel set 
of resistance mutations that are not selected by other NRTI and are infrequently observed in 
treatment-naïve and treatment-experience patients. We have used pre-steady state assays to 
determine the single nucleotide kinetic binding and incorporation parameters of GS-9148-DP by 
WT RT and RT containing the mutations K70N, K70E, D123N/T165I, and K70E/D123N/T165I. 
The results indicated that K70E/D123N/T165I RT has a decreased catalytic efficiency (kpol/Kd) 
of GS-9148-DP incorporation compared to WT RT. This decreased catalytic efficiency was 
driven by substantially weaker GS-9148-DP binding to the active site of K70E/D123N/T165I RT 
relative to WT RT (2.3-fold difference in Kd) with no effect on incorporation rate. This is 
different from the mechanisms of decreased catalytic efficiency toward TFV-DP; i) we observed 
changes in both TFV-DP binding and incorporation for K70E/D123N/T165I RT compared to 
86 
WT, ii) the previously characterized K65R and K70E mutations display predominantly decreased 
TFV-DP incorporation rates with little effect on binding. Our data indicate that the novel set of 
resistance mutations selected by GS-9148 confer decreased susceptibility to the drug by an 
alternative mechanism. Furthermore, these data reaffirm the importance of nucleotide base as a 
resistance determinant.  
4.3 INTRODUCTION 
GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosphonic acid] 
is a novel adenosine analog phosphonate NtRTI with a 2’,3’-dihydrofuran ring structure that also 
contains a 2’-fluoro group modification (Figure 4.1) (263). GS-9148 demonstrated potent 
activity against HIV-1 replication in multiple cell types and the active form GS-9148-
diphosphate (GS-9148-DP) was a competitive inhibitor of RT with respect to dATP (Ki = 0.8 
μM) resulting chain-termination of DNA synthesis. GS-9148-DP had poor activity against 
human DNA polymerases α, β, and γ with selectivity indices with respect to activity against RT 
(calculated as IC50 human polymerase / IC50 HIV-1 RT) of 19, > 76, and > 130, respectively (263, 266). 
GS-9148 demonstrated a favorable resistance profile against multiple NRTI-resistant HIV-1 
strains. The RT mutations K65R, L74V, and M184V individually or in combination did not 
reduce the antiretroviral activity of GS-9148. Additionally, viruses with multiple TAMs resulted 
in a smaller decrease in susceptibility to GS-9148 compared to most other NRTI. Furthermore, 
GS-9148 demonstrated encouraging biological properties, including a low potential for 
mitochondrial toxicity, minimal cytotoxicity in multiple cell types and synergistic antiviral 
activity in combination with other antiretrovirals (263, 264, 266, 290). 
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Figure 4.1 Structures of GS-9148, tenofovir (TFV), GS-9148-diphosphate (GS9148-DP), 
tenofovir-diphosphate (TFV-DP), and dATP. 
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Cell culture selection experiments with GS-9148 resulted in the emergence of two 
different resistance pathways: Q151L or the combination of K70E/D123N/T165I (267, 268, 
291). The Q151L mutation resulted in high-level resistance to GS-9148, but it was present 
infrequently due to a replication deficiency (291). In the alternative pathway, K70N was selected 
first which was later replaced with K70E and the additional mutations D123N and T165I (267, 
268). By the end of the selection 100 % of the sequenced clones contained the K70E mutation 
with 80 % and 90 % also containing D123N and T165I, respectively. The K70N and K70E 
mutations are present in NRTI-experienced patients with frequencies of 0.2 % and 0.3%, 
respectively (267, 268). D123N and T165I are polymorphisms that occur in approximately 9% 
and 5% of NRTI-experienced patients. However, the combination of K70E/D123N/T165I that 
was selected by GS-9148 has not been observed in treatment-naïve or treatment experienced 
patients. This suggests that GS-9148 selects a unique pathway to viral resistance that is selected 
by other NRTI and is not found in patient-derived clinical isolates. 
The K70N and K70E mutations alone did not confer decreased HIV-1 susceptibility to 
GS-1948, however the combination K70E/D123N/T165I resulted in 3.3-fold resistance 
compared to WT HIV-1 (267). This combination also showed low-level cross-resistance (2- 3-
fold compared to WT) to TFV, ddI, ABC, and D4T. Interestingly, the K70E/D123N/T165I 
mutations conferred 6.7-fold resistance to FTC but hypersusceptibility to AZT (0.4- fold) 
compared to WT HIV-1 (267). Steady-state kinetic analyses demonstrated that K70E, K70N, and 
K70E/D123N/T165I decreased the catalytic efficiency (Ki/Km) of GS-9148-DP incorporation by 
RT 2.4-, 2.6-, and 4.0-fold, relative to WT, respectively (267). These results suggest that these 
mutations, like K65R, confer resistance via a discrimination mechanism by decreased 
binding/incorporation of GS-9148-DP compared to WT. Also like K65R, the K70E, K70N, and 
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K70E/D123N/T165I mutations decreased the excision of NRTI-MP from chain-terminated 
primers. As described previously, the K65R mutation confers a discrimination phenotype toward 
TFV-DP and other NRTI-TP, primarily due to a decreased kpol with minimal changes in 
nucleotide binding (122, 160, 212).  
While K70E/D123N/T165I displayed a similar discrimination phenotype as K65R in 
steady-state assays, the specific contributions of incorporation rate or nucleotide binding affinity 
for this novel mutant combination is not known. Furthermore, it is unknown what role the 
previously unidentified mutations D123N and T165I might play. Accordingly, this chapter will 
describe the pre-steady state assays used to determine the single nucleotide kinetic binding and 
incorporation parameters of GS-9148-DP compared to TFV-DP by RT containing the mutations 
K70N, K70E, D123N/T165I, and K70E/D123N/T165I. 
4.4 MATERIALS AND METHODS 
4.4.1 Reagents 
The wild-type (WT), K70N, K70E, D123N/T165I, and K70E/D123N/T165I HIV-1 RTs were 
constructed, over-expressed in E. coli, and purified as described previously (284, 285). The 
protein concentration of these enzymes was determined spectrophotometrically at 280 nm using 
an extinction coefficient (ε280) of 260450 M−1 cm−1, and by Bradford protein assays (Sigma-
Aldrich, St. Louis, MO). The RNA- and DNA-dependent DNA polymerase activities of the 
purified WT and mutant enzymes were essentially identical (data not shown). Tenofovir 
diphosphate (TFV-DP) and GS-9148 diphosphate (GS-9148-DP) were provided by Gilead 
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Sciences, Inc. (Foster City, CA). dATP was purchased from GE Healthcare (Piscataway, NJ), 
and [γ-32P]ATP was acquired from PerkinElmer Life Sciences (Boston, MA). DNA 
oligonucleotides were synthesized by IDT (Coralville, IA).  
The sequences of the DNA template and primer were 5’-
CTCAGACCCTTTTAGTCAGAATGGAAATTCTCTAGCAGTGGCGCCCGAACAGGGACA
-3’ and 5’-TCGGGCG CCACTGCTAGAGA-3’, respectively. The DNA primer was 5′-
radiolabeled with [γ-32P]ATP and annealed to the template as described previously (141). 
4.4.2 Pre-steady-state assays 
A rapid quench instrument (Kintek RQF-3 instrument, Kintek Corporation, Clarence, PA) was 
used for pre-steady-state experiments with reaction times ranging from 50 ms to 60 s. 
Experiments were performed and data were analyzed in the same manner described in 
CHAPTER ONE under the section ‘3.4.4 Pre-steady-state assays’ except using GS-9148-DP and 
TFV-DP substrates and WT, K70N, K70E, D123N/T165I, and K70E/D123N/T165I HIV-1 RT. 
4.5 RESULTS 
Pre-steady-state kinetic analyses were carried out to elucidate, in detail, the interactions of GS-
9148-DP with the polymerase active site of HIV-1 RT. The natural nucleotide dATP and TFV-
DP were included as controls. The results (Table 4.1) show that the catalytic efficiency of 
incorporation (kpol/Kd) of GS-9148-DP for WT HIV-1 RT is ~32-fold less than the kpol/Kd value 
determined for dATP (selectivity with respect to dATP).  The decrease in the kpol/Kd value for 
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Table 4.1 Pre-steady state kinetic values for GS-9148-DP incorporation by WT and drug-resistant HIV-1 RT. 
 
 dATP  Nucleotide analog     
  Kpol (s-1) Kd (µM) 
Kpol/Kd  
(µM-1 s-1)   Kpol (s
-1) Kd (µM) 
Kpol/Kd  
(µM-1 s-1)   selectivity 
b   resistance c 
dATP/TFV-DP 
WT 29.6 ± 3.1 a 3.01 ± 0.9 9.84  6.11 ± 1.0 1.40 ± 0.3 4.36  2.26  --- 
K70E 25.7 ± 2.0 3.08 ± 0.5 8.35  2.87 ± 0.3 1.26 ± 0.2 2.28  3.66  1.6 
K70N 39.0 ± 3.1 2.60 ± 0.4 15.0  8.50 ± 0.6 3.14 ± 0.3 2.70  5.56  2.5 
D123N/T165I 16.5 ± 2.8 3.85 ± 0.2 4.29  3.53 ± 0.5 1.07 ± 0.2 3.31  1.30  0.6 
K70E/D123N/T165I 20.3 ± 2.3 3.02 ± 0.7 6.70  2.43 ± 0.4 2.31 ± 0.2 1.05  6.38  2.8 
dATP/GS-9148-DP 
WT 29.6 ± 6.1 3.01 ± 0.9 9.84  3.90 ± 0.3 12.5 ± 0.7 0.312  31.5  --- 
K70E 25.7 ± 3.4 3.08 ± 0.5 8.35  2.84 ± 0.6 14.5 ± 1.9 0.196  42.6  1.4 
K70N 39.0 ± 6.3 2.60 ± 0.4 15.0  4.07 ± 0.8 13.1 ± 0.3 0.310  48.4  1.5 
D123N/T165I 16.5 ± 4.8 3.85 ± 0.2 4.29  3.41 ± 0.5 13.2 ± 0.5 0.259  16.6  0.5 
K70E/D123N/T165I 20.3 ± 4.6 3.02 ± 0.7 6.70   3.82 ± 0.5 29.3 ± 1.9 0.131   51.1   1.6 
 
a Values represent mean ± SEM of at least 3 independent experiments. 
b Selectivity is (Kpol/Kd)dNTP/(Kpol/Kd)NRTI-TP 
c Resistance (n-fold) is selectivitymutant/selectivityWT 
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GS-9148-DP (relative to dATP) is driven by both a slower rate of nucleotide analog 
incorporation (kpol) and by a diminished binding affinity (Kd) for the DNA polymerase active site 
of RT. This is contrary to TFV-DP in that the decreased kpol/Kd value (compared to dATP) is 
driven primarily by slower incorporation. In fact, TFV-DP (Kd = 1.4 µM) demonstrated 2.2-fold 
stronger binding to the WT HIV-1 active site than dATP (Kd = 3.0 µM). The K70N RT showed 
no deficit in catalytic efficiency of incorporation (kpol/Kd) of GS-9148-DP compared to WT RT. 
The catalytic efficiency of TFV-DP incorporation by K70N RT, however was decreased 2-fold 
compared to WT. The D123N/T165I RT showed only a 1.2-fold decrease in the kpol/Kd value 
compared to WT RT. Importantly, the catalytic efficiencies of GS-9148-DP incorporation by 
K70E RT (kpol/Kd = 0.196) and K70E/D123N/T165I RT (kpol/Kd = 0.131) were 1.6-fold and 2.4-
fold lower, respectively, compared to WT RT (kpol/Kd = 0.312). The decreased catalytic 
efficiency of GS-9148-DP incorporation by K70E RT (compared to WT RT) is due to small 
changes in both incorporation rate and binding affinity. However, the decreased catalytic 
efficiency of GS-9148-DP incorporation by K70E/D123N/T165I RT relative to WT RT is driven 
strongly by decreased nucleotide binding affinity (Kd values of 12.5 μM and 29.3 μM for WT RT 
and K70E/D123N/T165I RT, respectively). Also of note, the K70E/D123N/T165I RT 
incorporated dATP 1.5-fold less efficiently than WT RT, primarily due to a slower rate of 
incorporation. This decrease in dATP incorporation rate was more pronounced with RT 
containing D123N/T165I alone, which also showed a slightly weaker dATP binding affinity 
relative to WT RT.  
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4.6 DISCUSSION 
Overall, the pre-steady state kinetic assays we performed in this study indicate low levels of 
resistance to GS-9148 by progressively increasing discrimination phenotypes towards GS-9148-
DP by K70N, K70E, and K70E/D123N/T165I RT, respectively. These results are consistent with 
the previously determined steady state kinetic data (267). Moreover, our results indicate that GS-
9148-DP discrimination by K70E/D123N/T165I RT is driven by a 2.4-fold decrease in 
nucleotide binding affinity (Kd), compared to WT RT, with little effect on incorporation rate 
(Table 4.1). This is contrary to the previously described mechanisms of discrimination toward 
TFV-DP by RT containing the K65R or K70E mutations, which is due primarily to decreased 
incorporation rate with little effect on nucleotide binding to the active site (122, 161, 213). We 
found that K70E/D123N/T165I RT also showed a decreased rate of TFV-DP incorporation but 
this was accompanied by a decrease in TFV-DP binding affinity for the active site. Together, 
these factors resulted in a K70E/D123N/T165I RT discrimination phenotype toward TFV-DP 
that was not observed in the prior steady state kinetic assays (267). Taken together, these data 
show that the novel combination of mutations selected by GS-9148, K70E/D123N/T165I, confer 
resistance to GS-9148 and TFV by different mechanisms. Moreover, the fact that GS-9148 and 
TFV both contain an adenine base but differ only in their “ribose sugar” (TFV contains an 
acyclic “pseudo-sugar”) structure, reaffirms that nucleotide sugar an important determinant for 
NtRTI resistance development. 
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5.2 ABSTRACT 
β-D-3’-Azido-2’,3’-dideoxyguanosine (3’-azido-ddG) is a potent inhibitor of HIV-1 replication 
with a superior resistance profile to zidovudine. Recently, we identified five novel 6-modified-
3’-azido-ddG analogs that exhibit similar or superior anti-HIV-1 activity compared to 3’-azido-
ddG in primary cells. To gain insight into their structure-activity-resistance relationships, we 
synthesized their triphosphate (TP) forms and assessed their ability to inhibit HIV-1 RT. Steady-
state and pre-steady-state kinetic experiments show that the 6-modified-3’-azido-ddGTP analogs 
act as adenosine rather than guanosine mimetics in DNA synthesis reactions, and are 
incorporated by HIV-1 RT opposite thymine (in DNA) or uracil (in RNA). The order of potency 
of the TP analogs was: 3’-azido-2,6-diaminopurine > 3’-azido-6-chloropurine; 3’-azido-6-N-
allylaminopurine > 2-amino-6-N,N-dimethylaminopurine; 2-amino-6-methoxypurine. Molecular 
modeling studies reveal unique hydrogen bonding interactions between the nucleotide analogs 
and the template thymine base in the active site of RT. Surprisingly, the structure-activity 
relationship of the analogs differed in HIV-1 RT ATP-mediated excision assays of their 
monophosphate forms, suggesting that it may be possible to rationally design a modified base 
analog that is efficiently incorporated by RT but serves as a poor substrate for ATP-mediated 
excision reactions. Overall, these studies identify a promising strategy to design novel nucleoside 
analogs that exert profound antiviral activity against both WT and drug-resistant HIV-1. 
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5.3 INTRODUCTION 
Most combination therapies used to treat antiretroviral-naïve and -experienced HIV-1 infected 
individuals include at least two NRTIs. NRTIs are analogs of 2’-deoxyribonucleosides that lack a 
3’-OH group on the ribose sugar/pseudosugar. Once metabolized by host cell kinases to their 
active -TP forms, they inhibit viral reverse transcription by acting as chain-terminators of HIV-1 
RT DNA synthesis (292). Although combination therapies that contain two or more NRTIs have 
substantially reduced mortality from HIV-1 associated disease, the approved NRTIs have 
significant limitations that include acute and chronic toxicity, and the selection of drug-resistant 
variants of HIV-1 that exhibit cross-resistance to other NRTIs. Accordingly, there is a need to 
develop potent and safe NRTIs that demonstrate activity against a broad-range of drug-resistant 
HIV-1. 
To date, most NRTIs were discovered by an empirical approach in which novel sugar-
modified nucleoside analogs were synthesized without a priori knowledge of their activity 
against WT or drug-resistant HIV-1. To specifically identify NRTIs that retain activity against a 
broad spectrum of drug-resistant HIV-1, our group adopted a rational discovery approach that 
utilized structure-activity-resistance relationships to identify NRTI base and sugar moieties that 
retain potent activity against drug-resistant HIV-1 (141, 212). Importantly, this approach 
identified 3’-azido-2’,3’-dideoxyguanosine (3’-azido-ddG) as a lead compound that exhibits 
potent activity against HIV-1 variants that contain the discrimination mutations K65R, L74V or 
M184V and against HIV-1 that contains multiple TAMs that enhance nucleotide excision (172). 
Furthermore, 3'-azido-ddG does not exhibit cytotoxicity in primary lymphocytes or epithelial and 
T-cell lines, and does not decrease the mitochondrial DNA content of HepG2 cells (172).  
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To further improve the antiviral activity of 3’-azido-ddG, we recently synthesized and 
characterized a series of novel base modified 3’-azido-2’,3’-dideoxypurine analogs (143). Of the 
26 analogs studied, five (namely, 3’-azido-2’,3’-dideoxy-2,6-diaminopurine (3’-azido-2,6-DA-
P), 3’-azido-2’,3’-dideoxy-2-amino-6-chloropurine (3’-azido-6-Cl-P), 3’-azido-2’,3’-dideoxy -2-
amino-6- N,N-dimethylaminopurine (3’-azido-6-DM-P), 3’-azido-2’,3’-dideoxy-2-amino-6-
methoxypurine (3’-azido-6-MX-P) and 3’-azido-2’,3’-dideoxy-2-amino-6-N-allylaminopurine 
(3’-azido-6-AA-P)) exhibited superior or equivalent activity to 3’-azido-ddG in primary 
lymphocytes (Figure 5.1). To gain additional insight into the structure-activity-resistance 
relationships of these compounds, we synthesized their TP forms and assessed their ability to 
inhibit DNA synthesis by recombinant purified HIV-1 RT. Importantly, we show for the first 
time that HIV-1 RT recognizes and incorporates these 6-modified-3’-azido-ddGTP nucleotides 
as adenosine analogs. These findings reveal new avenues for developing novel, ambiguous 
nucleoside analogs that could be used to treat HIV-1 infection.  
5.4 MATERIALS AND METHODS 
5.4.1 Reagents 
WT, K65R, L74V, M184V, A62V/V75I/F77L/F116Y/Q151M (Q151M complex, Q151Mc), 
M41L/L210W/T215Y (TAM41) and D67N/K70R/T215F/K219Q (TAM67) HIV-1 RTs were 
purified as described previously (284, 285). The protein concentration of the purified enzymes 
was determined spectrophotometrically at 280 nm using an extinction coefficient (ε280) of 
260450 M−1 cm−1, and by Bradford protein assays (Sigma-Aldrich, St. Louis, MO). The RNA-  
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Figure 5.1 Structures of 6-modified-3’-azido-dideoxyguanosine analogs. 
The molecular structures of zidovudine (ZDV), 3’-azido-2’,3’-dideoxyadenosine (3’-azido-ddA), 
3’-azido-2’,3’-dideoxyguanosine (3’-azido-ddG), 3’-azido-2’,3’-dideoxy-2,6-diaminopurine (3’-
azido-2,6-DA-P), 3’-azido-2’,3’-dideoxy-2-amino-6-chloropurine (3’-azido-6-Cl-P), 3’-azido-
2’,3’-dideoxy-2-amino-6-N,N-dimethylaminopurine (3’-azido-6-DM-P), 3’-azido-2’,3’-dideoxy-
2-amino-6-methoxypurine (3’-azido-6-MX-P) and 3’-azido-2’,3’-dideoxy-2-amino-6-N-
allylaminopurine (3’-azido-6-AA-P) are shown. The EC50 values, determined for WT HIV-1 in 
peripheral blood mononuclear (PBM) cells, were adapted from reference (143). 
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and DNA-dependent DNA polymerase activities of the purified WT and mutant enzymes were 
similar (data not shown). The triphosphate (TP) forms of each of the 6-modified-3’-azido-ddG 
analogs were synthesized and purified using the methods of Ludwig and Eckstein (250). 3’-
Azido-ddGTP, 3’-azido-ddATP, 3’-azido-ddCTP and zidovudine-TP (ZDV-TP) were purchased 
from TriLink Biotechnologies, Inc. (San Diego, CA).  [γ-32P]ATP was obtained from 
PerkinElmer Life Sciences (Boston, MA). All DNA oligonucleotides were synthesized by 
Integrated DNA Technologies (Coralville, IA). 
5.4.2 Inhibition of HIV-1 RT DNA synthesis under steady-state conditions by the 6-
modified-3’-azido-ddGTP analogs 
The ability of the 6-modified-3’-azido-ddGTP analogs to inhibit HIV-1 RT DNA- or RNA-
dependent DNA synthesis was determined using two different template/primer (T/P) substrates, 
as described below:  
(i) RT DNA synthesis was evaluated using a 214 nucleotide RNA or DNA template that 
corresponds to the HIV-1 sequence used for (–) strong stop DNA synthesis. The RNA and DNA 
templates were prepared as described previously (141). Both the RNA- and DNA-dependent 
DNA synthesis reactions were primed with the same 5’-end-32P-labeled 18 nucleotide DNA 
primer (5’- GTCCCTGTTCGGGCGCCA-3’) that corresponds to the HIV-1 primer binding site. 
DNA synthesis reactions (20 µL) were carried out in a 50 mM Tris-HCl (pH 7.5) buffer that 
contained 50 mM KCl, 10 mM MgCl2, 20 nM T/P, 0.5 µM of each dNTP and varying 
concentrations of the 6-modified-3’-azido-ddGTP analogs. Reactions were initiated by the 
addition of 200 nM WT HIV-1 RT, incubated at 37 °C for 30 min (DNA-dependent DNA 
synthesis) or 60 min (RNA-dependent DNA synthesis) and then quenched by addition of 20 µL 
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of gel loading buffer (98 % deionized formamide containing 1 mg/mL each of bromophenol blue 
and xylene cyanol). Samples were then denatured at 95 °C for 10 min and polymerization 
products were separated from substrates by denaturing gel electrophoresis using 14 % 
acrylamide gels containing 7 M urea. DNA synthesis was analyzed by phosphorimaging using a 
GS-525 Molecular Imager and Quantity One Software (Bio-Rad Laboratories, Inc., Hercules, 
CA).  
(ii) Inhibition of HIV-1 RT DNA synthesis was also evaluated to determine IC50 values 
using a 5’-end-32P-labeled 19 nucleotide DNA primer (5’-TTGTAGCACCATCCAAAGG-3’) 
that was annealed to one of three 36 nucleotide DNA templates that contained five consecutive 
thymine, cytosine, or adenosine bases. In this regard, inhibition of HIV-1 RT DNA synthesis by 
analogs with adenine, guanine, or thymine bases were evaluated using the templates  
(T1, 5’-CAGACTTTTTCAGACCTTTGGATGGTGCTACAAGCT-3’),  
(T2, 5’-CAGAGCCCCCGAGACCTTTGGATGGTGCTACAAGCT-3’),  
or (T3, 5’-CTGCTAAAAACTGCCCTTTGGATGGTGCTACAAGCT-3’), respectively. The T1 
template was used for inhibition of WT and mutant HIV-1 RT DNA synthesis by each of the 6-
modified-3’-azido-ddGTP analogs. Reaction conditions and gel electrophoresis were identical to 
those described above except 100 nM of WT or mutant HIV-1 RT was used to initiate the 
reaction. Reactions were quenched following incubation at 37 °C for 10 min. The amount of 
final product on the denaturing PAGE gels was quantified by densiometric analysis using 
Quantity One Software. The concentration of each 6-modified-3’-azido-ddGTP analog required 
to inhibit the formation of final product by 50 % was calculated using non-linear regression 
analyses (SigmaPlot Software Version 11, Systat Software, Inc., San Jose, CA) from at least 
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three independent experiments. Two-tailed homoscedastic T-tests were used to calculate the 
reported p-values. 
5.4.3 Pre-steady-state incorporation of 6-modified-3’-azido-ddGTP analogs                                 
A rapid quench instrument (Kintek RQF-3 instrument, Kintek Corporation, Clarence, PA) was 
used for pre-steady-state experiments. Experiments were performed and data were analyzed in 
the same manner described in CHAPTER ONE under the section 3.4.4 Pre-steady-state assays. A 
5’-radiolabeled primer (5’-TCGGGCGCCACTGCTAGAGA-3’) was annealed to one of two 
different templates. The sequence of the template used to evaluate the 6-modified-3’-azido-
ddGTP nucleotides as ‘A’ analogs was  
3’-
ACAGGGACAAGCCCGCGGTGACGATCTCTTAAAGGTAAGACTGATTTTCCCAGACTC
-5’.  
The sequence of the template used to evaluate the 6-modified-3’-azido-ddGTP nucleotides as ‘G’ 
analogs was  
3’-
ACAGGGACAAGCCCGCGGTGACGATCTCTCAAAGGTAAGACTGATTTTCCCAGACT
C-5’.  
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5.4.4 Excision of the 6-modified-3’-azido-ddG monophosphate (MP) analogs by WT or 
TAM-containing HIV-1 RTs 
The ability of WT or TAM-containing HIV-1 RT to facilitate ATP-mediated excision of the 6-
modified-3’-azido-ddG-MP analogs from a DNA/DNA chain-terminated T/P was assessed as 
described previously (141). Briefly, a 23-nucleotide DNA primer was 5’-radiolabeled with [γ-
32P]ATP, annealed to the appropriate 36-nucleotide DNA template, and then chain-terminated 
with the appropriate nucleotide analog. For excision of 3’-azido-ddGMP the T/P pair was 
T2/pr23G (pr23G: 5’-TTGTAGCACCATCCAAAGGTCTC-3’) whereas for the excision of 3’-
azido-ddAMP and each 6-modified-3’-azido-ddGMP analog the T/P pair was T1/pr23A (pr23A: 
5’-TTGTAGCACCATCCAAAGGTCTG-3’). Reactions were carried out in a 50 mM Tris-HCl 
(pH 7.5) buffer that contained 50 mM KCl, 10 mM MgCl2, 3 mM ATP and 1 μM dGTP/10 μM 
ddCTP (for the excision of 3’-azido-ddGMP) or1 μM dATP/10 μM ddGTP (for excision of 3’-
azido-ddAMP and each 6-modified-3’-azido-ddGMP analog). Reactions were initiated by the 
addition of 200 nM WT or mutant RT. Aliquots (5 µL) were removed at defined times, quenched 
with gel loading buffer, denatured at 95 °C for 10 min, and product was then resolved from 
substrate by denaturing polyacrylamide gel electrophoresis and analyzed, as described above.  
5.4.5 Molecular modeling  
Molecular models of incorporation were constructed using the X-ray crystallographic 
coordinates (PDB entry 1 RTD) for the RT-T/P-TTP ternary complex (77). The 3’-OH of the 
primer strand as well as the 6-modified-3’-azido-2’,3’-ddGTP analogs and complementary bases 
in the template strand were built into the model to generate a pre-initiation complex, as described 
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previously (84). Tautomerization and protonation potential of the entire system was calculated 
using the Generalized Born/Volume Integral (GB/VI) electrostatics method of Labute (293). 
Energy gradient minimization was carried out using MMFF94x force field in the Molecular 
Operating Environment (MOE 2008.02; Chemical Computing Group, Montreal, Quebec, 
Canada). Ligand interactions were quantified and images generated using the LigX interaction 
function in MOE. Structural models comparing incorporation and excision of specific nucleotide 
analogs used the PDB co-ordinates 3KLF and 3KLE that contain the excision product AZT 
adenosine dinucleoside tetraphosphate (AZTppppA) in complex with HIV-1 RT containing 
multiple TAMs (82). To eliminate the potential force field bias from alignment of bases, 
empirically derived angle relations were used for all analogs tested. 3KLF and 3KLE were fit to 
the p66 subunit of 1RTD using the Matchmaker function in Chimera version 1.51 (UCSF 
Chimera, Resource for Biocomputing, Visualization, and Informatics at the University of 
California, San Francisco). Aligned structures were opened in MOE and dihedral angles were 
measured from bases relative to the ribose ring O and C1 of both template and bound nucleotides 
for each complex. MOE’s builder function was used to modify each template/bound nucleotide 
base pair retaining the experimental dihedrals. Hydrogen bonding potential between the aligned 
base pairs was quantified using the “FindHBond” function in Chimera with default settings. Parts 
of the modeling workflow were automated using Pipeline Pilot 7.5 (Accelrys Corporation, San 
Diego, California). 
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5.5 RESULTS 
5.5.1 Steady-state incorporation of 6-modified 3’-azido-ddGTP nucleotides by HIV-1 RT 
To characterize the ability of WT HIV-1 RT to incorporate the 6-modified-3’-azido-ddGTP 
analogs, we first conducted steady-state DNA synthesis reactions using heteropolymeric 
DNA/DNA and RNA/DNA T/P substrates (Figure 5.2). The sequences of the RNA and DNA 
templates correspond to the HIV-1 sequence used for (–) strong stop DNA synthesis, and both 
reactions were primed with the same 18 nucleotide DNA primer that was complementary to the 
HIV-1 primer binding site (141).  3’-Azido-ddGTP, 3’-azido-ddATP, 3’-azido-ddCTP and ZDV-
TP were included as controls in these experiments. Unexpectedly, we found that HIV-1 RT 
recognized all of the 6-modified-3’-azido-ddGTP nucleotides as adenosine analogs and 
incorporated them opposite thymine in DNA (Figure 5.2A) or uracil in RNA (Figure 5.2B). As 
anticipated, their incorporation resulted in chain-termination of DNA synthesis. Under the assay 
conditions described in Figure 5.2, the 6-modified-3’-azido-ddGTP nucleotides were not 
incorporated into the nascent DNA opposite cytosine. However, if the dNTP concentration was 
lowered to 0.1 μM, chain-termination opposite cytosine was observed (data not shown). We also 
determined the concentration of 6-modified-3’-azido-ddGTP analog required to inhibit DNA 
synthesis (i.e. IC50) using a different heteropolymeric DNA/DNA T/P substrate, as described in 
the Materials and Methods (Table 5.1). Their order of potency against WT RT was determined 
to be: 3’-azido-ddATP, 3’-azido-ddGTP > 3’-azido-2,6-DA-P-TP > 3’-azido-6-Cl-P-TP, 3’-
azido-6-AA-P-TP > 3’-azido-6-DM-P-TP, 3’-azido-6-MX-P-TP.  
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Figure 5.2 The 6-Modified-3’-azido-ddGTP analogs are recognized and incorporated by 
WT HIV-1 as adenosine analogs. 
(A) Representative denaturing polyacrylamide gel showing chain-termination of HIV-1 RT DNA 
synthesis by each of the 3’-azido-ddGTPs on a heteropolymeric DNA/DNA T/P under steady-
state assay conditions. (B) Representative denaturing polyacrylamide gel showing chain 
termination of WT HIV-1 RT DNA synthesis by each of the 3’-azido-ddGTPs on a 
heteropolymeric RNA/DNA T/P under steady-state assay conditions. Reaction conditions are 
described in the Materials and Methods section. 
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Table 5.1 Inhibition of steady-state WT and mutant HIV-1 RT DNA synthesis by  
6-modified-3’-azido-ddGTP analogs. 
 
Nucleotide analog HIV-1 RT 
WT K65R L74V M184V Q151M a 
ZDV-TP      
IC50 (µM) b 
Fold-R c 
0.13 ± 0.04 0.66 ± 0.20 0.18 ± 0.10 0.12 ± 0.03 2.7 ± 1.0 
-  5.2 1.4 0.9 21.0 
3’-azido-ddGTP      
IC50 (µM) 
Fold-R 
0.15 ± 0.01 0.36 ± 0.02 0.25 ± 0.10 0.06 ± 0.02 0.30 ± 0.20 
-  2.5 1.7 0.4 2.1 
3’-azido-ddATP      
IC50 (µM) 
Fold-R 
0.16 ± 0.10 0.70 ± 0.10 0.42 ± 0.10 0.19 ± 0.10 1.44 ± 1.00 
-  4.3 2.5 1.2 8.8 
3’-azido-2,6-DA-P-TP      
IC50 (µM) 
Fold-R 
p-value d 
0.80 ± 0.10 2.5 ± 1.6 1.3 ± 0.4 0.34 ± 0.10 4.2 ± 3.6 
- 3.1 1.6 0.4 5.3 
- 0.36 0.08 0.02 0.45 
3’-azido-6-Cl-P-TP      
IC50 (µM) 
Fold-R 
p-value 
3.2 ± 0.8 9.1 ± 3.8 11.8 ± 3.9 2.5 ± 1.0 30.8 ± 6.1 
- 2.9 3.7 0.8 9.7 
- 0.12 0.15 0.22 0.81 
3’-azido-6-AA-P -TP      
IC50 (µM) 
Fold-R 
p-value 
4.10 ± 0.8 8.8 ± 0.8 10.3 ± 1.9 4.8 ± 0.6 21.8 ± 12.0 
- 2.2 2.5 1.2 5.3 
- 0.0006 0.97 0.94 0.43 
3’-azido-6-DM-P-TP      
IC50 (µM) 
Fold-R 
p-value 
23.4 ± 13.0 >50 >50 n.d. e >50 
- >2.0 >2.0  >2.0 
- - - - - 
3’-azido-6-MX-P-TP      
IC50 (µM) 
Fold-R 
p-value 
24.4 ± 7.0 80.1 ± 6.1 >100 32.9 ± 23.0 78.0 ± 34.0 
- 3.3 >4.0 1.3 3.2 
- 0.10 - 0.71 0.31 
 
a The Q151M RT contains the A62V, V75I, F77L, F116Y and Q151M mutations. 
b IC50 values are the concentration of drug required to inhibit 50% of DNA synthesis under 
steady-state assay conditions. Data are shown as the means ± standard deviations of at least three 
independent experiments. 
c Fold-resistance (Fold-R) values are calculated by IC50 mutant RT/IC50WT RT. 
d P-value compares the Fold-R values determined for the 6-modified 3’-azido-ddGTP analogs to 
the Fold-R value determined for 3’-azido-ddATP. 
e n.d. Not determined 
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5.5.2 Pre-steady-state incorporation of 6-modified 3’-azido-ddGTP nucleotide analogs by 
HIV-1 RT 
Pre-steady-state kinetic analyses were carried out to elucidate, in detail, the interactions between 
the 6-modified-3’-azido-ddGTP analogs and the polymerase active site of WT HIV-1 RT (Table 
5.2). Because the 6-modified-3’-azido-ddGTP analogs behave as adenine nucleotide analogs, we 
included 3’-azido-ddATP as a control. The results (Table 5.2) show that the catalytic efficiency 
of incorporation (kpol/Kd) of 3’-azido-2,6-DA-P-TP was similar to that of dATP and 3’-azido-
ddATP. Consistent with the steady-state kinetic experiments, 3’-azido-6-Cl-P-TP, 3’-azido-6-
AA-P-TP, and 3’-azido-6-MX-P-TP were all less efficiently incorporated by WT HIV-1 
compared to dATP. The observed decreases in catalytic efficiency for each of these substrates 
was driven by both a decrease in the rate of nucleotide incorporation (i.e. kpol) and a decrease in 
the affinity of the nucleotide for the polymerase active site (i.e. Kd). Due to limited quantities of 
the 3’-azido-6-DM-P-TP, we were unable to obtain pre-steady-state kinetic data for this analog. 
We also assessed the ability of the 6-modified-3’-azido-ddGTP analogs to be incorporated 
opposite cytosine (Table 5.2). The data show that, in comparison to dGTP, the 6-modified-3’-
azido-ddGTP analogs were inefficiently incorporated by HIV-1 RT. The only compound with 
reasonable activity as a G-analog was 3’-azido-6-Cl-P-TP; however its selectivity value versus 
dGTP (SI = 254) was ~ 7-fold less than its selectivity value versus dATP (SI = 35). 
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Table 5.2 Pre-steady-state kinetic values for incorporation of 6-modified-3’-azido-ddGTP 
analogs by WT HIV-1 RT. 
 
 
Incorporation as an “A” analog 
Nucleotide Analog kpol  (sec-1) Kd (µM) 
kpol / Kd 
(µM-1 sec-1) 
Selectivitya 
vs dATP 
dATP 17.0 ± 2.1b 0.33 ± 0.05 52 - 
3'-azido-ddATP 14.0 ± 5.6 0.32 ± 0.13 44 1.2 
3'-azido-2,6-DA-P-TP 14.0 ± 4.9 0.29 ± 0.05 48 1.1 
3'-azido-6-Cl-P-TP 2.7 ± 0.5 1.8 ± 1.0 1.5 35 
3'-azido-6-AA-P-TP 2.1 ± 0.2 4.8 ± 2.3 0.44 118 
3'-azido-6-MX-P-TP 2.8 ± 0.2 12.0 ± 1.2 0.23 226 
Incorporation as a “G” analog 
Nucleotide Analog kpol  (sec-1) Kd (µM) 
kpol / Kd   
(µM-1 sec-1) 
Selectivity 
vs dGTP 
dGTP 17.3 ± 1.4 0.17 ± 0.05 102 - 
3'-azido-2,6-DA-P-TP 0.16 ± 0.02 34 ± 14 0.005 20400 
3'-azido-6-Cl-P-TP 0.37 ± 0.04 0.92 ± 0.02 0.402 254 
3'-azido-6-AA-P-TP n.m.c > 50 n.m. n.m. 
3'-azido-6-MX-P-TP 0.22 ± 0.09 16.3 ± 4.3 0.013 7846 
 
a Selectivity is (kpol/Kd)dNTP/(kpol/Kd)3’-azido-ddNTP. 
b Values represent the means ± standard deviations of three to four independent experiments. 
c n.m. Not measurable. The rate of incorporation was so inefficient that accurate kinetic 
parameters could not be determined. 
 
 
 
110 
5.5.3 Activity of the 6-modified-3’-azido-ddGTP analogs against HIV-1 RT containing 
NRTI discrimination mutations 
The amino acid substitutions K65R, L74V, Q151M (in complex with A62V, V75I, F77L and 
F116Y) or M184V in HIV-1 RT improve the enzyme’s ability to discriminate between the 
natural dNTP substrate and an NRTI-TP. These substitutions are typically referred to as NRTI 
discrimination mutations. To determine whether NRTI discrimination mutations impacted the 
ability of RT to recognize and incorporate the 6-modified-ddGTP analogs, we determined the 
concentration of nucleotide analog required to inhibit 50% of the DNA polymerase activity (i.e. 
IC50) under steady-state assay conditions using the heteropolymeric DNA/DNA T/P substrates as 
described in the Materials and Methods (Table 5.1). 3’-Azido-ddATP, 3’-azido-ddGTP and  
ZDV-TP were again included as controls.  The 6-modified-3’-azido-ddGTP analogs were also 
incorporated as adenosine analogs by the mutant HIV-1 RTs (data not shown). In general, the 
mutant HIV-1 RTs exhibited fold-resistance values to each of the 6-modified-3’-azido-ddGTP 
analogs that were similar (i.e. less than 2-fold) to the fold-change in resistance values determined 
for 3’-azido-ddATP.  The only statistically significant exceptions (p < 0.05) included 3’-azido-6-
AA-P-TP and 3’-azido-2,6-DA-P-TP which exhibited better activity against K65R HIV-1 RT 
and M184V HIV-1 RT, respectively. Of interest, all of the 3’-azido-dideoxypurines exhibited 
greater activity than ZDV-TP against multi-NRTI resistant HIV-1 RT containing 
A62V/V75I/F77L/Y116F/Q151M. 
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Figure 5.3 ATP-mediated excision of 6-modified-3’-azido-ddGMP analogs by WT (A), 
TAM67 (B), or TAM41 (C) HIV-1 RT. 
Data are the means ± standard deviations from at least three independent experiments. Reaction 
conditions are described in the Materials and Methods section. 
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5.5.4 Excision of 6-modified-3’-azido-ddG-5’-MP analogs by WT and TAM containing 
HIV-1 RT 
HIV-1 RT has the intrinsic ability to rescue DNA synthesis from an NRTI-MP blocked primer, 
using ATP as a phosphate donor (130). This ATP-mediated excision activity of HIV-1 RT is 
selectively increased by TAMs (131). Accordingly, we investigated the ability of WT and TAM-
containing RT to excise the 6-modified-3’-azido-ddGMP analogs from a DNA chain-terminated 
T/P (Figure 5.3). Two RT enzymes that contained different patterns of TAMs (i.e. 
D67N/K70R/T215F/K219Q (TAM67) and M41L/L210W/T215Y (TAM41)) were studied. Our 
results showed that the WT, TAM67, and TAM41 RTs could unblock T/Ps chain-terminated 
with 3’-azido-ddAMP, 3’-azido-2,6-DA-P-MP and 3’-azido-6-AA-P-MP, although TAM41 RT  
and TAM67 RT were more efficient in this regard than was the WT enzyme. By contrast, both 
the WT and TAM-containing RTs could not efficiently unblock T/P substrates chain-terminated 
with 3’-azido-ddGMP, 3’-azido-6-MX-P-MP, 3’-azido-6-Cl-P-MP or 3’-azido-6-DM-P-MP. 
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5.5.5 Molecular models of 3’-azido-2,6-DA-P-TP and 3’-azido-6-Cl-P-TP in the active site 
of HIV-1 RT 
We used molecular modeling to gain structural insight into the binding interaction between the 6-
modified-3’-azido-ddGTP analogs and the thymine base in the DNA template in the active site of 
HIV-1 RT. Specifically, we modeled 3’-azido-2,6-DA-P-TP and 3’-azido-6-Cl-P-TP into the 
active site of HIV-1 RT using the co-ordinates (1RTD) from the RT-T/P-TTP complex (77).  
Both 3’-azido-2,6-DA-P-TP and 3’-azido-6-Cl-P-TP, were found to fit comfortably into the 
active site of HIV-1 RT and formed hydrogen bond interactions with the thymine base in the 
DNA template (Figure 5.4). However, the base hydrogen bonding characteristics differed for 
each analog. The base of 3’-azido-6-Cl-P-TP forms two hydrogen bond interactions through the 
nitrogen (NH) at position 1 and the amine (NH2) at position 2 with the template thymine (Figure 
5.4B). In addition to these two hydrogen bonding interactions, 3’-azido-2,6-DA-P-TP can form 
an additional hydrogen bond via the amino group (NH2) at the 6-position of the purine base 
(Figure 5.4D). Therefore, the 2,6-diaminopurine:thymine base pairing interaction mimics the 
canonical Watson-Crick guanine:cytidine interaction. 
5.5.6 Molecular models for ATP-mediated excision of the 6-modified-3’-azido-ddG-5’-MP 
analogs 
To gain structural insight into why the 6-modified-3’-azido-ddG analogs are differentially 
excised by HIV-1 RT containing TAMs, we modeled their excision products (6-modified-3’-
azido-ddG adenosine dinucleoside tetraphosphate) in the enzyme’s active site. These models 
reveal a hydrogen bonding network that is different from those observed for the TP forms.  
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Figure 5.4 Molecular models of 3’-azido-ddGTP (A), 3’-azido-6-Cl-P-TP (B), 3’-azido-
ddATP (C), and 3’-azido-2,6-DA-P-TP (D) in the DNA polymerase active site of WT HIV-1 
RT. 
 Each of the analogs was modeled into the ternary RT-T/P-TTP complex (pdb co-ordinates 
1RTD). A schematic representation of the hydrogen-bonding patterns between the incoming 
nucleotide analog and the template base is depicted below each model. 
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Figure 5.5 Molecular models of the excision products of 3’-azido-ddA (A), 3’-azido-2,6-DA-
P (B), 3’-azido-6-AA-P (C), and 3’-azido-6-Cl-P (D) in the DNA polymerase active site of 
HIV-1 RT containing TAMs. 
Each of the analogs was modeled into the ternary RT-T/P-AZTppppA complex (pdb co-ordinates 
3KLE). A schematic representation of the hydrogen-bonding patterns between the excised 
nucleotide analog and the template base is depicted below each model. 
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3’-azido-ddA forms hydrogen bonds from the 1 and 6 atoms to the 3 and 4 atoms of the 
complementary thymine template in both the incorporation (Figure 5.4C) and excision (Figure 
5.5A) models. By contrast, the hydrogen bond observed between the 2-amino substitution and 
the 2-carbonyl of the thymine template observed for the nucleotide triphosphate analogs (Figure 
5.4B, 5.4D) is lost in all related excision complexes (Figure 5.5B, 5.5C, 5.5D). 3’-azido-2,6-
DA-P (Figure 5.5B) and 3’-azido-6-AA-P (Figure 5.5C) retain an H-bond from the 6 atom 
position of the purine ring and the 4 atom position on the template thymine, whereas this 
interaction is not maintained for 3’-azido-6-Cl-P (Figure 5.5D), 3’-azido-6-DM-P and 3’-azido-
6-MX-P (data not shown). Taken together, these different hydrogen bonding patterns may 
explain why 3’-azido-2,6-DA-P  and 3’-azido-6-AA-P are more efficiently excised by HIV-1 RT 
than are 3’-azido-6-Cl-P, 3’-azido-6-DM-P and 3’-azido-6-MX-P. 
5.6 DISCUSSION 
In this study, we demonstrated that 6-modified-3’-azido-ddGTP nucleotides act as adenosine 
mimetics for DNA synthesis carried out by HIV-1 RT. Of the five analogs studied, 3’-azido-2,6-
DA-P-TP, which has a 2,6-diaminopurine base, was found to be the most efficient substrate for 
incorporation by HIV-1 RT. In pre-steady-state kinetic experiments, 3’-azido-2,6-DA-P-TP was 
recognized and incorporated by WT HIV-1 RT as efficiently as dATP and 3’-azido-ddATP. The 
analogs that contain the 2-amino-6-N,N-dimethylaminopurine (3’-azido-6-DM-P-TP) or 2-
amino-6-methoxypurine (3’-azido-6-MX-P-TP) bases, however, were poor substrates for 
incorporation by HIV-1 RT. Our molecular modeling studies suggest that 6-modifications with a 
branched side-chain (e.g. 3’-azido-6-DM-P-TP) or one with electronic incompatibility (e.g. 3’-
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azido-6-MX-P-TP) may alter the alignment of the bases and move their α–phosphate away from 
the primer 3’-OH thus impairing nucleotide incorporation. In contrast, 3’-azido-2,6-DA-P-TP, 
3’-azido-6-CL-P-TP, and 3’-azido-6-AA-P-TP form relatively planar base pairing interactions 
with the template thymine that enhance their α-phosphate interaction with the 3’-OH of the 
primer. Compared to the canonical A:T base pair, the additional hydrogen bond achieved by the 
3’-azido-2,6-DA-P:thymine base pair may further stabilize the α-phosphate, facilitating the 
favorable catalytic efficiency observed in pre-steady-state assays. In contrast, the 6-modified-3’-
azido-ddGTP nucleotide analogs are inefficiently incorporated by HIV-1 RT opposite cytosine 
bases. Taken together, these findings are consistent with those of Cheong et al., who reported 
that oligodeoxyribonucleotide duplexes containing 2,6-diaminopurine formed more stable base 
pairs opposite thymine than cytosine (294).  
The mutations K65R, L74V, Q151M (in complex with A62V, V75I, F77L and F116Y) or 
M184V in HIV-1 RT allow the enzyme to discriminate between the natural dNTP substrate and 
modified nucleotide analogs. In Table 5.2, we show that the K65R, L74V and Q151M mutations 
confer low levels of resistance to both 3’-azido-ddATP and 3’-azido-ddGTP at the enzyme level. 
Modification at the 6-position of the purine base does not appear to enhance this discrimination 
phenotype: the K65R, L74V or A62V/V75I/F77L/F116Y/Q151M HIV-1 RTs all exhibited fold-
resistance changes to each of the 6-modified-3’-azido-ddGTP analogs that were largely similar 
(i.e. less than 2-fold) to the fold-change in resistance values determined for 3’-azido-ddATP. 
Interestingly, the structure-activity relationship for the ATP-mediated excision of the 6-
modified-3’-azido-ddGMP analogs by WT or TAM-containing HIV-1 RT differed from the 
structure-activity relationship for their incorporation. For example, whereas 3’-azido-6-Cl-P-TP 
is a relatively good substrate for incorporation, it is not efficiently excised by either WT or 
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TAM-containing HIV-1 RT. In this regard, our excision complex modeling data show that the 
hydrogen bonding pattern observed for 3’-azido-6-Cl-P-TP differs from that of 3’-azido-2,6-DA-
P  and 3’-azido-6-AA-P (Figure 5.5). As such, it is possible that the change in transition state 
geometry needed for excision is not sufficiently stabilized by the 6-Cl substituted guanine analog 
base paired with thymine. Taken together, these data suggest that the optimal conformation of 
the HIV-1 RT active site differs for incorporation and excision and further suggests that 6-
position modifications differentially effect these two reactions. This finding provides “proof of 
concept” that modified base analogs can be identified that are efficiently incorporated by HIV-1 
RT but serve as a poor substrate for HIV-1 ATP-mediated excision reactions. Further 
optimization of these divergent but favorable properties of purine analogs is in progress to 
develop novel, ambiguous NRTI that exert profound antiviral activity against WT and drug-
resistant HIV-1. 
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6.1 PREFACE 
The data described in this chapter were presented in part as a poster at The 17th Conference on 
Retroviruses and Opportunistic Infections February 16-19, 2010, San Francisco, CA USA. 
Abstract # 489. Herman, B. D., Obikhod, A., Asif, G., Zhang, H-W., Coats, S. J., Schinazi, R. F., 
Mellors, J. W. and N. Sluis-Cremer. RS-788, a Prodrug of β-D-3’-Azido-2,6-diamino-2’,3’-
dideoxypurine, Exhibits Potent Activity Against NRTI-Resistant HIV-1; and in part at The 18th 
Conference on Retroviruses and Opportunistic Infections February 27- March 2, 2011, Boston, 
MA USA. Abstract # 519. Herman, B. D., Zhang, H-W., Coats, S., Schinazi, R,, Mellors, J. and 
N. Sluis-Cremer. The 5’-triphosphates of 3’-azido-2’,3’-dideoxyguanosine and 3’-azido-2,6-
diamino-2’,3’-dideoxypurine act synergistically to inhibit wild-type and NRTI-resistant HIV-1 
reverse transcriptase. 
The work presented in this chapter is in partial fulfillment of dissertation Aim 2. Brian 
Herman performed all the experiments presented in this chapter. The detection of NRTI-TP 
metabolites in P4/R5 cells was performed by Brian Herman, along with Aleksandr Obikhod, and 
Ghazia Asif. 
6.2 ABSTRACT 
Although 3’-azido-2,6-DA-P-TP potently inhibited DNA synthesis by NRTI-resistant RT 
through incorporation and chain-termination as an adenosine analog in biochemical assays, 3’-
azido-2,6-DA-P is extensively metabolized to 3’-azido-ddG in cells. To further improve 3’-
azido-2,6-DA-P antiviral activity by increasing the intracellular delivery of its triphosphate form, 
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we synthesized RS-788, a novel phosphoramidate prodrug of 3’-azido-2,6-DA-P. RS-788 has 
potent anti-HIV-1 activity and is metabolized ~1:1 to both 3’-azido-2,6-DA-P-TP and 3’-azido-
ddG-TP in peripheral blood mononuclear (PBM) cells. Thus, RS-788 delivers two chemically 
distinct metabolites, each of which are potent HIV-1 RT chain terminators that are incorporated 
opposite different complementary bases; thymine for 3’-azido-2,6-DA-P-TP and cytosine for 3’-
azido-ddG-TP. In the current study, we further characterized the activity of this unique prodrug 
by examining the intracellular metabolism and antiviral cross-resistance profiles of RS-788, and 
its parent analogs, 3’-azido-2,6-DA-P and 3’-azido-ddG. We found that RS-778 exhibits a 
superior phenotypic cross-resistance profile against a broad range of NRTI-resistant viruses 
compared to 3’-azido-2,6-DA-P or 3’-azido-ddG. For example, against HIV-1 with the multi-
NRTI resistance mutation Q151M  (in complex with A62V/F77L/V75I/F116Y; Q151M 
complex) the potency of RS-788 was decreased only 2.3-fold compared to WT, whereas that of 
3’-azido-2,6-DA-P and 3’-azido-ddG were decreased 23- and 26-fold, respectively. Therefore, 
the potent inhibition of multi-drug resistant HIV-1 by RS-788 may be due to incorporation and 
chain termination at both thymine and cytosine positions by 3’-azido-2,6-DA-P-TP and 3’-azido-
ddG-TP, respectively. To evaluate this hypothesis, we examined the inhibitory activity of 
combinations of the active metabolites 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP against WT and 
multi-NRTI-resistant HIV-1 RT DNA synthesis. Drug synergy analyses by both the median-
effect and normalized isobologram methods indicated synergistic inhibition of multi-NRTI 
resistant HIV-1 RT DNA synthesis by combinations of 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP 
at the intracellular molar ratios detected in P4/R5 and PBM cells. Furthermore, the excision 
mechanism conferred by TAMs did not diminish the observed synergy. Taken together, our data 
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demonstrate that the combined intracellular delivery of 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-
TP by RS-788 provides synergistic inhibition of reverse transcription by NRTI-resistant RT.  
6.3 INTRODUCTION 
The rational design of a series of novel 3’-azido-2’,3’-dideoxypurine analogs led to the 
identification of 3’-azido-2’,3’-dideoxy-2,6-diaminopurine (3’-azido-2,6-DA-P) as a potent and 
selective inhibitor of HIV-1 replication in primary lymphocytes (Figure 5.1) (143).  3’-azido-
2,6-DA-P showed superior activity against WT and NRTI resistant HIV-1 replication compared 
to its parent analog 3’-azido-2’,3’-dideoxygaunosine (3’-azido-ddG) . The kinetic and molecular 
modeling studies described in the previous chapter indicated that the triphosphate form, 3’-azido-
2,6-DA-P-TP, was specifically recognized by HIV-1 RT as an adenosine analog and efficiently 
incorporated across from thymine in DNA or uracil in RNA, resulting in chain termination 
(Table 5.1, Figure 5.2, and Figure 5.4). Intracellular pharmacology analyses, however, revealed 
that 3’-azido-2,6-DA-P was extensively metabolized to 3’-azido-ddG in PBM cells, resulting in 
the production of 382-fold more 3’-azido-ddG-TP than 3’-azido-2,6-DA-P-TP (Figure 6.1) (295, 
296). Incubation with purified adenosine deaminase in vitro led to the efficient conversion of 3’-
azido-2,6-DA-P to 3’-azido-ddG (143). Therefore, the potent anti-HIV-1 activity of 3’-azido-2,6-
DA-P is primarily attributed to RT inhibition by 3’-azido-ddG-TP and not due to incorporation 
of 3’-azido-2,6-DA-P-TP as an adenosine analog. In order to further improve 3’-azido-2,6-DA-P 
antiviral activity by increasing the intracellular delivery of its triphosphate form, we synthesized 
a series of 5’-monophosphate prodrugs.   
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Figure 6.1 Structures and intracellular pharmacology in PBM cells of 3’-azido-2,6-DA-P 
and RS-788. 
PBM cells were incubated with 50 µM 3’-azido-2,6-DA-P or RS-788 for 4 hours and the 
resulting nucleotide-TP metabolites were detected using LC-MS/MS. Values are in pmol/million 
cells and are from references (295, 296).  
 
One such prodrug, RS-788, is a chemically shielded 5’-phosphoramidate prodrug of 3’-azido-
2,6-DA-P. In PBM cells, RS-788 was metabolized approximately 1:1 to both 3’-azido-2,6-DA-P-
TP and 3’-azido-ddG-TP, whereas the parent molecules 3’-azido-2,6-DA-P and 3’-azido-ddG 
were both converted to 3’-azido-ddG-TP as the major active metabolite (Figure 6.1). 
Consequently, RS-788 delivers two chemically distinct metabolites, each of which are potent 
HIV-1 RT chain terminators that are incorporated opposite different complementary  
bases: thymine for 3’-azido-2,6-DA-P-TP and cytosine for 3’-azido-ddG-TP. Intracellular 
delivery of two different chain terminating nucleotides from one parent prodrug has not been 
previously reported. 
RS-788 showed 60- and 17-fold more potent anti-HIV-1 activity in PBM cells than its 
parent molecules 3’-azido-ddG and 3’-azido-2,6-DA-P, respectively (Table 6.1) (295, 296). 
Importantly, RS-788 also showed a good cytotoxicity profile in PBM, CEM, and Vero cells. The 
selectivity index (SI; calculated as CC50/EC50) of RS-788 (CC50 = 17.6 μM) in PBM cells was  
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Table 6.1 Activity, cytotoxicity, and selectivity index of 3’-azido-ddG, 3’-azido-2,6-DA-P 
and RS-788 in peripheral blood mononuclear (PBM) cells. 
 
NRTI a  EC50 (µM) b  CC50 (µM) c  Selectivity Index d 
3’-azido-ddG  0.18  100  555.6 
3’-azido-2,6-DA-P  0.05  54.0  1080 
RS-788  0.003  17.6  5867 
 
a Data are from references (295, 296). 
b EC50 is the concentration required to inhibit 50 % wild-type (WT) HIV-1 replication. 
c CC50 is the concentration required to inhibit 50% cell growth. 
d Selectivity index is calculated as CC50/EC50. 
 
10.6-fold and 5.4-fold better than 3’-azido-ddG (CC50 = 100 μM) and 3’-azido-2,6-DA-P (CC50 
= 54 μM), respectively. Unlike the tenofovir prodrug (TDF) that delivers significantly higher 
concentrations of TFV-DP to cells than tenofovir alone, the increased potency of RS-788 was not 
due to increased delivery of active metabolite (206, 207). The total intracellular concentrations of 
3’-azido-ddG-TP/3’-azido-2,6-DA-P-TP in PBM cells treated with 50 μM of drug were 57.5 х 
106 and 38.3 х 106 pmol/million cells for 3’-azido-2,6-DA-P and RS-788, respectively (Figure 
6.1).  
The unique cellular pharmacology of RS-788 and the improved anti-HIV-1 activity over 
its parent analogs warranted further investigation of its activity and mechanisms of inhibition 
against WT and NRTI-resistant RT. Accordingly, this chapter describes the metabolism and 
antiviral cross-resistance profiles of RS-788, 3’-azido-2,6-DA-P, and 3’-azido-ddG in HIV-1 
reporter cell line P4/R5. We found that RS-778 exhibits a superior phenotypic cross-resistance 
profile against a broad range of NRTI-resistant viruses compared to 3’-azido-2,6-DA-P or 3’-
azido-ddG. The activity of RS-788 against HIV-1 with the multi-NRTI resistance mutation 
Q151M  (in complex with A62V/F77L/V75I/F116Y; Q151M complex) and the 69-insertion 
mutations (T69S-SS in the background of TAMs M41L/L210W/T215Y; T69SSS) was 
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particularly compelling. To gain mechanistic insight into the potent activity of RS-788 against 
multi-NRTI resistant HIV-1, we also evaluated the inhibitory activity of the active metabolites 
3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP and combinations of 3’-azido-2,6-DA-P-TP+3’-
azido-ddG-TP against WT and NRTI-resistant HIV-1 RT. 
6.4 MATERIALS AND METHODS 
6.4.1 Cells, viruses, and NRTI for intracellular metabolism and drug susceptibility 
studies 
The human T-cell leukemia MT-2 cell line (AIDS Research and Reference Reagent Program) 
was cultured in RPMI 1640 with 2 mM L-glutamine (Lonza, Walkersville, MD) supplemented 
with 10% fetal bovine serum (HyClone Laboratories, Inc., Logan, UT), 10 mM HEPES buffer 
(Gibco, Grand Island, NY), and 50 IU/ml of penicillin and 50 µg/ml of streptomycin (Gibco). 
The HeLa cell derived P4/R5 reporter cell line (provided by Nathaniel Landau, Salk Institute), 
which expresses the β-galactosidase gene under the control of the HIV-1 LTR that is 
transactivated by HIV-1 Tat, was maintained in phenol red-free Dulbecco’s modified Eagle 
medium (Gibco) supplemented with 10% fetal bovine serum, 50 IU/ml of penicillin, 50 µg/ml of 
streptomycin, and 0.5 µg/ml of puromycin (Clontech, Palo Alto, CA).  
The L74V, M184V, K65R, D67N/K70R/T215F/K219Q (AZT2),  
M41L/L210W/T215Y (AZT3), M41L/D67N/K70R/T215F/K219Q (AZT7),  
and M41L/D67N/K70R/L210W/T215Y/K219Q (AZT9) NRTI-resistant HIV-1LAI full-length 
proviral clones were kindly provided by Dianna Koontz (University of Pittsburgh). RT clones 
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containing the mutations A62V/F77L/V75I/F116Y/Q151M (Q151M complex, Q151Mc) and 
M41L/T69S-SS/L210W/T215Y (T69SSS) were generated by site-directed mutagenesis 
(QuikChange II site-directed mutagenesis kit; Stratagene, La Jolla, CA) using the p6HRT-MO 
plasmid. This plasmid contains the entire RT and protease coding sequence and four silent 
restriction sites (XmaI, MluI, XbaI, and NgoMIV from the 5’ to 3’ends of RT at codons 14, 358, 
490, and 554, respectively) (297). After site-directed mutagenesis, the mutated RT was ligated 
into pxxHIV-1LAI -MO, which contains the entire genome of HIV-1LAI and the same silent 
restriction sites in RT as p6HRT-MO plasmid provided by Jessica Brehm (University of 
Pittsburgh). All mutations in recombinant viruses were confirmed by sequencing. Stock viruses 
were prepared in MT-2 cells as described previously (212). Briefly, 5 -10 µg of plasmid DNA 
was electroporated into 1.3 × 107 MT-2 cells. Cell-free supernatants were collected 5 to 7 days 
post-transfection at peak cytopathic effect (CPE) and stored at -80°C. The infectivity of the virus 
stocks were determined by 3-fold end point dilution in P4/R5 cells, and the 50% tissue culture 
infectivity dose was calculated using the Reed and Muench equation (298). 
Zidovudine (AZT) was obtained from Sigma Chemical Corporation (St. Louis, MO) and 
3’-azido-ddG was obtained from Berry & Associates, Inc. (Ann Arbor, MI). 3’-azido-2,6-DA-P 
and RS-788 were synthesized as described previously and kindly provided by Raymond Schinazi 
(Emory University) (143). All NRTIs were prepared as 40 mM stock solutions in dimethyl 
sulfoxide and stored at -20°C. 
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6.4.2 Quantification of the intracellular metabolites of 3’-azido-2,6-DA-P, 3’-azido-ddG, 
and RS-788 in P4/R5 cells 
MT-2 cells (5 × 106) were incubated with 50 µM 3’-azido-2,6-DA-P, 3’-azido-ddG, or RS-788 
for 4 hours. The cells were then centrifuged for 10 min at 350 × g at 4 °C, and the pellet was 
resuspended and washed three times with cold phosphate-buffered saline (PBS). Nucleoside 
triphosphates were extracted by incubation overnight at -20 °C with 1 ml 60% methanol in 
water. The supernatant was collected and centrifuged at 16,000 × g for 5 min. After decanting 
the supernatant, an additional 200 µL of 60% methanol in water was added to the pellets, which 
were then incubated on ice for 1 hour followed by centrifugation at 16,000 × g for 5 min. The 
extracts were dried under a gentle filtered airflow and stored at -20°C. The dried residues were 
resuspended in 100 µL of water prior to liquid chromatography (LC)-tandem mass spectrometry 
analysis.  
The LC system was an UltiMate 3000 modular system (Dionex, Sunnyvale, CA) 
consisting of a quaternary pump, vacuum degasser, temperature-controlled autosampler (4 °C), 
and temperature-controlled column compartment (28 °C). An API5000 mass spectrometer 
(AB/SCIEX, Foster City, CA) was used as the detector. LC Analyst software version 1.4.2 was 
used to control both the LC and the mass spectrometer as well as for the data analysis and 
quantification. Phosphorylated nucleosides were quantified by ion exchange, with the separation 
performed on a 5µm particle-size Biobasic C18 (50-mm by 1.0-mm) column (Thermo Electron, 
Bellefonte, PA) using a gradient. The mobile phase consisted of A (10 mM ammonium acetate), 
B (ammonia buffer [pH 9.6]), and C, acetonitrile. Sample volumes of 5 µL were injected onto 
the column.  
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The flow was diverted to waste for the initial 1 min of the analysis. Initial composition of 
the mobile phase was 70 % A and 30 % C with a gradient at 3.5 min to 70 % B and 30 % C for 5 
min. The mass spectrometer was operated in positive ionization mode with a spray voltage of 5 
kV, gas 1 at 15 (arbitrary units), gas 2 at 20 (arbitrary units), and source temperature of 230 °C. 
A standard curve was prepared by spiking standards of synthesized 3’-azido-2,6-DA-P, 3’-azido-
ddG, or RS-788 in the range of 1 nM to 500 nM in control cell lysates. 
6.4.3 Drug susceptibility assays for WT and NRTI-resistant HIV-1 
The susceptibilities of WT and NRTI-resistant HIV-1 to 3’-azido-2,6-DA-P, 3’-azido-ddG, RS-
788, and AZT (as a control) were determined in P4/R5 cells as described previously (212). 
Briefly, 3-fold dilutions of inhibitor were added to P4/R5 cells in triplicate, and the cells were 
infected with an amount of virus that produced 100 relative light units (RLU) in control wells 
without drug. After 48 h, the cells were lysed (Gal-Screen; Tropix/Applied Biosystems, Foster 
City, CA) and the RLU were measured using a ThermoLab Systems luminometer (Waltham, 
MA). The concentration of drug required to inhibit viral replication by 50% (EC50) was 
calculated by linear regression from data points in the linear dose-response range. Data are 
reported as the mean EC50 ± standard deviations from 3-4 independent experiments. Fold 
resistance was calculated as the ratio EC50mutant/EC50WT.  
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6.4.4 Reagents for Steady RT DNA synthesis assays 
WT, T69SSS, and Q151Mc HIV-1 RTs were purified as described previously (284, 285). The 
protein concentration of the purified enzymes was determined spectrophotometrically at 280 nm 
using an extinction coefficient (ε280) of 260450 M−1 cm−1, and by Bradford protein assays 
(Sigma-Aldrich, St. Louis, MO). The RNA- and DNA-dependent DNA polymerase activities of 
the purified WT and mutant enzymes were similar (data not shown). The triphosphate forms of 
3’-azido-2,6-DA-P and 3’-azido-ddG were synthesized and purified using the methods of 
Ludwig and Eckstein (299). The dNTPs, ATP, [α-32P]dATP, and [α-32P]dGTP and Whatman® 
DE81 anion exchange paper were obtained from GE Healthcare (Piscataway, NJ). Activated calf 
thymus DNA was purchased from Sigma-Aldrich (St. Louis, MO). 
6.4.5 Steady-state RT DNA synthesis assays with 3’-azido-2,6-DA-P-TP, 3’-azido-ddG-
TP, and their fixed-ratio combinations  
Steady State DNA synthesis reactions with WT, T69SSS, or Q151Mc HIV-1 RT were carried out 
in a reaction buffer containing 50 mM Tris-HCl (pH 7.5), 50 mM KCl, and 10 mM MgCl2. All 
concentrations refer to the final concentration after mixing unless noted otherwise. Reactions 
were initiated by mixing solutions A and B, which were preincubated at 37 °C. Solution A 
contained 0.5 μM dATP and dGTP, 0.5 μCi/μL [α-32P]dATP or [α-32P]dGTP, 10 nM RT, and 
various concentrations of 3’-azido-2,6-DA-P-TP, 3’-azido-ddG-TP, or their fixed-ratio 
combinations in  reaction buffer. Solution B contained 100 ng/μL activated calf thymus DNA, 50 
μM dTTP, and 50 μM dCTP in reaction buffer. Reactions were incubated at 37 °C for 4 min and 
then 5 μL aliquots were spotted onto DE81 anion exchange paper. After successive washes with 
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Na2PO4 buffer (50 g/L, 3 × 5 min washes), dH20 (5 min), and EtOH (5 min) the paper was air 
dried, sealed in saran wrap, and then exposed to a phosphorimaging screen. Products were 
analyzed using BioRad Quantity One Software.  
3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP combinations were evaluated using a series of 
assays with increasing total drug concentrations at three fixed ratios. The 3’-azido-2,6-DA-P-TP: 
3’-azido-ddG-TP ratios of 2.4:1 and 1.1:1 were chosen because these are the intracellular molar 
ratios of 3’-azido-2,6-DA-P-TP: 3’-azido-ddG-TP detected in PBM and P4/R5 cells, 
respectively. The third series of assays used the experimental ratio of 1:3 3’-azido-2,6-DA-P-TP: 
3’-azido-ddG-TP. Assays using each of three 3’-azido-2,6-DA-P-TP: 3’-azido-ddG-TP ratios 
were performed using [α-32P]dATP as the reporter nucleotide and using [α-32P]dGTP as the 
reporter nucleotide. Experimental control combinations of 1:1 3’-azido-2,6-DA-P-TP:3’-azido-
2,6-DA-P-TP and 3’-azido-ddG-TP: 3’-azido-ddG-TP were also performed and, as expected, 
these combinations were always additive, regardless of whether [α-32P]dATP or  [α-32P]dGTP 
was used as the reporter nucleotide (data not shown). Lastly, assays using all three combination 
ratios and both reporter nucleosides were also performed with the addition of 3 mM ATP in 
order to examine steady state DNA synthesis in the presence of a functional excision mechanism. 
All assays were performed at least 3 times.  
6.4.6 Synergy analysis using the median-effect principle 
The degree of synergy or antagonism for inhibition of HIV-1 RT DNA synthesis by fixed-ratio 
combinations of 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP was evaluated based on the 
median-effect principal of Chou and Talalay (300). Using CompuSyn Software (ComboSyn, Inc, 
Paramus, NJ) the log (fa/fu) was plotted versus the log ([drug]), where fa is the fractional 
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inhibition of drug relative to no drug control and fu = (1-fa). The IC50 values were calculated from 
the antilog of the x-intercept. The combination index (CI) was calculated in a mutually exclusive 
model by the equation: CI = [(fa/fu)1 / (fa/fu)1,2] + [(fa/fu)2 / (fa/fu)1,2]; where 1 and 2 represent drugs 
1 and 2 individually, while 1,2 represents their combined activity. The CI values of < 1, = 1, and 
> 1 indicate synergy, additive effect, and antagonism, respectively. The degree of synergy is 
further categorized based on CI values as: very strong synergy (< 0.1), strong synergy (0.1 to 
0.3), synergy (0.3 to 0.7), moderate synergy (0.7 to 0.85), additive effect (0.85 to 1.20), moderate 
antagonism (1.20 to 1.45), antagonism (1.45 to 3.3), strong antagonism (3.3 to 10), and very 
strong antagonism (> 10).  
For each experiment, a set of CI values was determined at the 50 %, 75 %, 90 %, and 95 
% inhibition levels (i.e. IC50, IC75, IC90, and IC95, respectively). As recommended in the software 
manual, we report the average CI calculated from those at each of the four inhibition levels. On 
some occasions when the effect did not reach the 95 % inhibition level, the IC95 CI value was not 
included in the average CI calculation. Additionally, data points that were > 99 % inhibition 
were also excluded from analysis.  
6.4.7 Synergy analysis using normalized isobolograms 
In order to eliminate bias based on the analysis method, we also evaluated the data set by plotting 
normalized (equipotent) isobolograms (301, 302). These were constructed by plotting drug1 as 
[IC50]1,2/[IC50]1 and drug2 as [IC50]1,2/[IC50]2 on the x- and y- axes, respectively. The terms 
[IC50]1 and [IC50]2 represent the IC50 of each drug individually and [IC50]1,2 represents the IC50 of 
the combination. The diagonal line between coordinates (1,0) and (0,1) represents additivity. 
Data points that are above the additivity line represent antagonism between the compounds, 
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whereas data points below the additivity line represent synergy between the compounds. The 
relative strength of synergy or antagonism can be specified by average deviation from additivity 
(ADA), which indicates the statistical distance from dose-wise additivity line (302). ADA is 
calculated by the equation ([Σ(IC50a,IC50b)]-N)/N where N is the population size.  ADA 
significance (p-value < 0.05) was measured by a one-tailed homoscedastic t-test. If the ADA 
value is statistically significant, then negative values represent synergy. Values of -0.5 and lower 
indicate strong synergy.  
6.5 RESULTS 
6.5.1 Intracellular pharmacology of 3’-azido-2,6-DA-P, 3’-azido-ddG, and RS-788 in 
P4/R5 cells 
We quantified the levels of nucleotide triphosphate that accumulated in P4/R5 cells treated with 
50 µM 3’-azido-2,6-DA-P, 3’-azido-ddG, or RS-788 for 4 hours (Figure 6.2, Table 6.2,). As 
expected, 3’-azido-ddG-TP (20.8 × 106 pmol/million cells) was the only NRTI-TP species found 
in P4/R5 cells treated with 3’-azido-ddG. Consistent with data from PBM cells, almost all of the 
NRTI-TP quantified from 3’-azido-2,6-DA-P-treated P4/R5 cells was 3’-azido-ddG-TP (295, 
296). Cells treated with 3’-azido-2,6-DA-P contained 470-fold more 3’-azido-ddG-TP (23 × 106 
pmol/million cells) than 3’-azido-2,6-DA-P-TP (0.05 × 106 pmol/million cells). Conversely, cells 
treated with RS-788 accumulated 2.4-fold more 3’-azido-2,6-DA-P-TP (27 × 106 pmol/million 
cells) than 3’-azido-ddG-TP (11.4 × 106 pmol/million cells). Also of note, incubation with RS-
788, but not 3’-azido-ddG or 3’-azido-2,6-DA-P, reduced the intracellular levels of natural  
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Figure 6.2 Intracellular pharmacology of 3’-azido-2,6-DA-P and RS-788 in P4/R5 cells. 
P4/R5 cells were incubated with 50 µM 3’-azido-2,6-DA-P or RS-788 for 4 hours and the 
resulting nucleotide-TP metabolites were detected using LC-MS/MS as described in the 
Materials and Methods. Values are in pmol/million cells.  
 
 
Table 6.2 Levels of NRTI-TP and dNTP detected in P4/R5 cells incubated with 50 µM 3’-
azido-ddG, 3’-azido-2,6-DA-P, or RS-788 for 4 hours. 
 
drug 
incubated 
nucleotide triphosphates detected (×106 pmol/million cells) a 
3’-azido-
ddG-TP 
3’-azido-2,6-
DA-P-TP dGTP dATP dCTP dTTP 
None --- --- 33.4 ± 1.9 38.6 ± 1.5 29.4 ± 1.8 78.6 ± 1.3 
3’-azido-
ddG 20.8 ± 2.8 no peak 35.3 ± 5.9 40.0 ± 3.3 31.5 ± 4.2 76.3 ± 8.0 
3’-azido-
2,6-DA-P 23.3 ± 5.9 
b 0.05 ± 0.03 28.2 ± 1.2 36.0 ± 0.5 27.4 ± 1.0 71.6 ± 2.9 
RS-788 11.4 ± 2.2 b 27.0 ± 18 23.8 ± 0.8 18.4 ± 0.7 16.1 ± 0.5 70.9 ± 4.3 
a Values are means ± standard deviations from triplicate experiments performed as described in 
the Materials and Methods. 
b The actual concentration of 3’-azido-ddG-TP in cells treated with either 3’-azido-2,6-DA-P or 
RS-788 could be lower than reported due to interfering signal from 3’-azido-2,6-DA-P-TP in the 
LC-MS/MS analyses.  
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dGTP, dATP, and dCTP (but not dTTP) nucleotide pools. This is presumably due to competition 
for host nucleoside/nucleotide phosphorylating enzymes. These data show that RS-788 is 
efficiently metabolized in P4/R5 cells to both 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP, two 
structurally distinct active NRTI-TP metabolites that are recognized by HIV-1 RT as adenosine- 
and guanosine-analogs, respectively.  
6.5.2 Antiviral activity of 3’-azido-2,6-DA-P, 3’-azido-ddG, and RS-788 against WT and 
NRTI-resistant HIV-1 
The activities of 3’-azido-2,6-DA-P, 3’-azido-ddG, and the 3’-azido-2,6-DA-P-prodrug RS-788 
against WT HIV-1 replication were determined in P4/R5 cells (Table 6.3). The anti-HIV-1 
activity of AZT was also examined as a control. RS-788 potently inhibited WT HIV-1 
replication with an EC50 value of 0.12 µM. RS-788 had similar potency as AZT (EC50 against 
WT = 0.13 µM) against WT HIV-1 and was approximately 10-fold more potent than 3’-azido-
ddG and 3’-azido-2,6-DA-P that showed EC50 values of  1.1 µM and 1.2 µM, respectively. The 
phenotypic cross-resistance of a broad panel of NRTI-resistant HIV-1 to 3’-azido-2,6-DA-P, 3’-
azido-ddG, and RS-788 was also examined in P4/R5 cells (Table 6.3, Figure 6.3).  
As described above, 3’-azido-2,6-DA-P was almost entirely converted to 3’-azido-ddG-
TP in P4/R5 cells. Therefore, it was expected that 3’-azido-2,6-DA-P and 3’-azido-ddG would 
demonstrate similar activity against each virus. The data confirm that there was no statistically 
significant difference between the activities of 3’-azido-2,6-DA-P and 3’-azido-ddG against any 
virus examined. RS-788 potently inhibited the replication of every virus examined with EC50 
values between 0.05 µM and 0.28 µM (Table 6.3).  
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Table 6.3 Antiviral activity of RS-788, 3’-azido-2,6-DA-P, and 3’-azido-ddG against WT 
and NRTI-resistant HIV-1 in P4/R5 cells. 
 
Virus 
NRTI 
RS-788 3’-azido-2,6-DA-P 
3’-azido-
ddG AZT 
WT     
EC50 (µM) 0.12 ± 0.06 a 1.2 ± 0.3 1.1 ± 0.5 0.13 ± 0.06 
M184V     
EC50 (µM) 0.05 ± 0.03 0.8 ± 0.6 0.87 ± 0.3 0.10 ± 0.06 
Fold-R b 0.4 b 0.7 0.8 0.8 
L74V     
EC50 (µM) 0.07 ± 0.02 1.4 ± 0.4 1.6 ± 0.7 0.16 ± 0.06 
Fold-R 0.6 1.2 1.5 1.2 
K65R     
EC50 (µM) 0.11 ± 0.07 2.2 ± 0.7 2.3 ± 0.8 0.16 ± 0.06 
Fold-R 0.9 1.8 2.1 1.3 
AZT3 
41L/210W/215Y 
    
EC50 (µM) 0.19 ± 0.02 2.7 ± 0.5 3.0 ± 0.9 2.9 ± 0.06 
Fold-R 1.6 2.3 2.8 23 
AZT2 
67N/70R/215F/219Q 
    
EC50 (µM) 0.27 ± 0.07 3.7 ± 0.7 3.1 ± 1.1 11.1 ± 0.06 
Fold-R 2.3 3.2 3.0 88 
AZT7 
41L/67N/70R/215F/219Q 
    
EC50 (µM) 0.27 ± 0.05 6.0 ± 0.8 4.2 ± 0.1 >90 
Fold-R 2.3 5.1 4.0 >714 
AZT9 
41L/67N/70R/210W/215Y/219Q 
    
EC50 (µM) 0.25 ± 0.09 3.9 ± 1.3 3.8 ± 0.4 >90 
Fold-R 2.1 3.3 3.6 >714 
69SSS 
41L/69SSS/210W/215Y 
    
EC50 (µM) 0.44 ± 0.15 11.2 ± 5.2 8.7 ± 3.8 >90 
Fold-R 3.7 9.5 8.3 >714 
Q151Mc 
62V/75I/77L/116Y/151M 
    
EC50 (µM) 0.28 ± 0.07 26.6 ± 10 27.3 ± 7.3 >90 
Fold-R 2.3 22.6 26 >714 
 
a Values represent the EC50 means ± standard deviations determined from 3-4 independent 
experiments. 
b Values represent fold-change (Fold-R) compared to WT HIV-1. 
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Figure 6.3 Fold-change in the susceptibility of NRTI-resistant HIV-1 to RS-788, 3’-azido-
2,6-DA-P, and 3’-azido-ddG compared to WT HIV-1. 
Bars represent the mean fold-resistance values ± standard deviations of drug-resistant HIV-1 
compared to WT HIV-1 calculated from EC50 values determined from 3-4 independent 
experiments. Asterisks indicate p-value <0.05 compared to 3’-azido-ddG. 
 
 
HIV-1 containing the NRTI discrimination mutation M184V was slightly more 
susceptible to inhibition by 3’-azido-2,6-DA-P and 3’-azido-ddG than WT virus and the L74V 
and K65R mutations conferred only low level resistance (up to 2.1-fold over WT) to 3’-azido-
2,6-DA-P and 3’-azido-ddG (Figure 6.3). Similarly, the M184V and L74V mutations conferred 
hypersusceptibility to RS-788 with fold-resistance values of 0.4 and 0.6, respectively, compared 
to WT virus. RS-788 inhibited HIV-1 containing the K65R discrimination mutation to a similar 
degree as WT virus. Viruses containing 3 to 6 TAMs showed decreased susceptibility to 3’-
azido-2,6-DA-P and 3’-azido-ddG with fold-resistance values between 2.3-fold and 5.1-fold as 
compared to WT HIV-1 (Table 6.3, Figure 6.3). The same TAM-containing viruses were less 
resistant to inhibition by RS-788 with fold-resistance values between 1.6- and 2.3-fold relative to 
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WT HIV-1. Resistance to 3’-azido-2,6-DA-P, 3’-azido-ddG and RS-788 conferred by TAMs 
generally increased with increasing number of TAMs present in the virus. 
Importantly, RS-788 was substantially more potent than 3’-azido-2,6-DA-P or 3’-azido-
ddG against viruses harboring the Q151M complex or 69-insertion multi-NRTI resistance 
combinations (Table 6.3, Figure 6.3). Against HIV-1 with the Q151M complex, the potency of 
RS-788 was decreased relative to that of WT virus only 2.3-fold (EC50 = 0.28 µM), whereas that 
of 3’-azido-2,6-DA-P (EC50 = 26.6 µM) and 3’-azido-ddG (EC50 = 27.3 µM) were decreased 23- 
and 26-fold, respectively. Similarly, the potency of RS-788 against HIV-1 with the 69-insertion 
mutations (EC50 = 0.44 µM) was decreased from that of WT virus 3.7-fold compared to 9.5- and 
8.3-fold for 3’-azido-2,6-DA-P (EC50 = 11.2 µM) and 3’-azido-ddG (EC50 = 8.7 µM). Taken 
together, these data show that RS-788 has superior activity and a better cross-resistance profile 
than 3’-azido-2,6-DA-P or 3’-azido-ddG.  
6.5.3 Inhibition of HIV-1 RT DNA synthesis by combinations of 3’-azido-2,6-DA-P-TP 
and 3’-azido-ddG-TP 
As described in the previous chapter, the inhibition of WT and NRTI-resistant HIV-1 RT DNA 
synthesis by 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP has been extensively characterized. 
These data however, do not fully explain the exceedingly superior activity of RS-788, compared 
to 3’-azido-2,6-DA- or 3’-azido-ddG, against multi-drug-resistant HIV-1 containing the Q151M 
complex or 69-insertion mutations. First, 3’-azido-2,6-DA-P-TP was significantly less potent 
than 3’-azido-ddG-TP against the Q151M complex RT with IC50 values of 4.2 µM and 0.3 µM, 
respectively (Table 5.2). Secondly, 3’-azido-2,6-DA-P-MP was a better substrate than 3’-azido-
ddG-MP for excision by M41L/L210W/T215Y RT (data not shown). Therefore, the potent 
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inhibition of drug-resistant HIV-1 by RS-788 may be due to an alternate mechanism, such as 
incorporation and chain termination at both T and C positions by 3’-azido-2,6-DA-P-TP and 3’-
azido-ddG-TP, respectively. To evaluate this hypothesis, we examined inhibition of WT, 
Q151Mc, and 69-insertion RT DNA synthesis by 3’-azido-2,6-DA-P and 3’-azido-ddG alone and 
in combination.  
Steady-state RT DNA synthesis was evaluated in the presence of increasing 
concentrations of total NRTI-TP at three fixed-ratio combinations of 3’-azido-2,6-DA-P-TP:3’-
azido-ddG-TP. The 3’-azido-2,6-DA-P-TP:3’-azido-ddG-TP ratios of 2.4:1 and 1.1:1 were 
chosen because these are the intracellular molar ratios of 3’-azido-2,6-DA-P-TP:3’-azido-ddG-
TP detected in PBMC and P4/R5 cells, respectively. A third, experimental ratio, of 1:3 3’-azido-
2,6-DA-P-TP:3’-azido-ddG-TP was also included for comparison. RT-mediated DNA synthesis 
was monitored by the incorporation of either [α-32P]dATP or [α-32P]dGTP radionucleotide, 
which compete with 3’-azido-2,6-DA-P-TP or 3’-azido-ddG-TP for RT incorporation, 
respectively. Consequently, one set of experiments used [α-32P]dATP as the reporter nucleotide 
and a second set of experiments used [α-32P]dGTP as the reporter nucleotide. Furthermore, 
experiments were performed in the absence and presence of 3 mM ATP to assess the effect of a 
functional excision mechanism on inhibition of DNA synthesis by 3’-azido-2,6-DA-P-TP and 3’-
azido-ddG-TP alone and in combination. 
The IC50 of single drug or total drug, calculated using Compusyn Software from median-
effect plots (described in the Materials and Methods), are reported in Table 6.4. The IC50 values 
for inhibition of WT RT of 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP were 0.86 µM and 1.2 
µM, respectively when [α-32P]dATP was used as the reporter, and 2.3 µM and 0.28 µM, 
respectively when [α-32P]dGTP was used as the reporter.  
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Table 6.4 Inhibition of steady state WT, T69SSS, and Q151Mc RT DNA synthesis by 3’-
azido-2,6-DA-P-TP, 3’-azido-ddG-TP, and their combinations. 
 
 
 IC50 (μM) against HIV-1 RT DNA Synthesis b 
drug/ 
combination a 
[α-32P]dATP  [α-32P]dGTP 
WT T69SSS Q151Mc  WT T69SSS Q151Mc 
3’-azido-2,6-
DA-P -TP 0.86 ± 0.1 1.1 ± 0.2 3.0 ± 1.7  2.3 ± 0.8 3.7 ± 1.0 15 ± 2.8 
3’-azido- 
ddG-TP 1.2 ± 0.8 3.4 ± 0.2 2.4 ± 0.9  0.28 ± 0.04 0.35 ± 0.02 1.2 ± 0.2 
P4R5 (2.4:1) 0.55 ± 0.02 0.71 ± 0.03 2.4 ± 0.3  0.61 ± 0.1 0.71 ± 0.2 2.4 ± 0.6 
PBM (1.1:1) 0.51 ± 0.1 0.70 ± 0.2 1.9 ± 0.7  0.41 ± 0.2 0.58 ± 0.2 1.6 ± 0.4 
1:3 0.70 ± 0.1 0.90 ± 0.2 2.7 ± 0.4  0.27 ± 0.02 0.43 ± 0.1 0.96 ± 0.2 
 IC50 (μM) against HIV-1 RT DNA Synthesis with Excision c 
drug/ 
combination 
[α-32P]dATP  [α-32P]dGTP 
WT T69SSS Q151Mc  WT T69SSS Q151Mc 
3’-azido-2,6-
DA-P -TP 1.6 ± 0.4 5.1 ± 1.0 11 ± 2.7  4.2 ± 0.7 48 ± 13.2 30 ± 8.5 
3’-azido- 
ddG-TP 1.4 ± 0.4 53 ± 8.0 7.8 ± 0.4  0.33 ± 0.1 1.0 ± 0.1 1.7 ± 0.3 
P4R5 (2.4:1) 0.71 ± 0.1 3.6 ± 1.3 3. 6 ± 1.0  0.64 ± 0.1 2.4 ± 0.5 2.9 ± 0.7 
PBM (1.1:1) 0.73 ± 0.1 4.9 ± 0.3 3.3 ± 1.4  0.45 ± 0.1 1.6 ± 0.4 2.1 ± 0.5 
1:3 0.71 ± 0.1 5.9 ± 0.7 2.8 ± 0.9  0.34 ± 0.02 1.4 ± 0.4 1.8 ± 0.2 
 
 
a Drug combinations are displayed as the ratio 3’-azido-2,6-DA-P-TP:3’-azido-ddG-TP. 
b Values are the mean 50% inhibitory concentration (IC50) of single drugs or total drug for 
combinations ± standard deviations from at least 3 independent experiments. IC50 values were 
calculated from median-effect plots using CompuSyn Software. 
c Experiments of DNA synthesis with a functional excision mechanism included 3 mM ATP. 
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6.5.4 Median-effect analysis indicates synergistic inhibition of RT DNA synthesis by 3’-
azido-2,6-DA-P-TP+3’-azido-ddG-TP combinations 
We first analyzed inhibition of RT DNA synthesis with a combination of 3’-azido-2,6-DA-P-TP 
and 3’-azido-ddG-TP, using the median-effect principal of Chou and Talalay (300). Median-
effect analysis indicates the degrees of synergy or antagonism by a combination index (CI) 
value, where CI values < 1 indicate synergy, CI value = 1 indicate an additive effect, and CI 
values > 1 indicate antagonism. The average CI values determined from the 50%, 75%, 90%, and 
95% inhibition levels are reported in Table 6.5 and plots of the CI value versus fraction affected 
(fa, inhibition level) are shown in Figure 6.4.  
Combinations of 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP demonstrated moderately 
synergistic inhibition of WT RT with the P4/R5 (2.4:1) and PBM cell (1.1:1) ratios, regardless of 
which reporter radionucleotide was used. Interestingly, the 1:3 experimental 3’-azido-2,6-DA-P-
TP: 3’-azido-ddG-TP ratio (i.e. an arbitrary ratio not observed in cells) demonstrated slightly 
lower synergy for inhibition of WT RT when either reporter radionucleotide was used. 
Importantly against T69SSS RT, strong synergy was indicated by each of the three 3’-azido-2,6-
DA-P-TP+3’-azido-ddG-TP combinations when [α-32P]dATP was used (CI values = 0.72, 0.63, 
and 0.63 for the P4/R5 cell, PBM cell, and experimental ratios, respectively). Synergy was also 
indicated for the P4/R5 ratio 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP combination against 
T69SSS when [α-32P]dGTP was used but weaker synergy was observed for the other two ratios. 
For inhibition of Q151Mc RT, strong synergy was only indicated for combinations in the P4/R5 
and PBM cell ratios with the [α-32P]dGTP reporter. All other 3’-azido-2,6-DA-P-TP+3’-azido-
ddG-TP combinations were additive for inhibition of Q151Mc RT. 
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Table 6.5 Average combination index (CI) values for inhibition of WT, T69SSS, and 
Q151Mc RT DNA synthesis by combinations of 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP. 
 
 
 HIV-1 RT DNA Synthesis 
 [α-
32P]dATP  [α-32P]dGTP 
RT P4R5 (2.4:1) a 
PBM 
(1.1:1) 1:3  
P4R5 
(2.4:1) 
PBM 
(1.1:1) 1:3 
WT 0.79 ± 0.2 b 0.73 ± 0.2 0.86 ± 1.0  0.69 ± 0.11 0.75 ± 0.02 0.92 ± 0.2 
T69SSS 0.72 ± 0.1 0.63 ± 0.2 0.63 ± 0.1  0.65 ± 0.11 0.77 ± 0.08 0.93 ± 0.02 
Q151Mc 1.1 ± 0.3 1.0 ± 0.1 1.2 ± 0.4  0.61 ± 0.04 0.73 ± 0.01 1.1 ± 0.4 
 HIV-1 RT DNA Synthesis with Excision 
c 
 [α-
32P]dATP  [α-32P]dGTP 
RT P4R5 (2.4:1) 
PBM 
(1.1:1) 1:3  
P4R5 
(2.4:1) 
PBM 
(1.1:1) 1:3 
WT 0.50 ± 0.1 0.51± 0.1 0.53 ± 0.1  0.59 ± 0.04 0.61 ± 0.04 0.68 ± 0.1 
T69SSS 0.68 ± 0.2 0.74 ± 0.04 1.3 ± 0.4  0.51 ± 0.1 0.23 ± 0.02 0.09 ± 0.02 
Q151Mc 0.48 ± 0.2 0.47 ± 0.2 0.55 ± 0.3  0.47 ± 0.1 0.52 ± 0.02 0.67 ± 0.1 
  
a Drug combinations are displayed as the ratio of 3’-azido-ddG-TP-TP:3’-azido-ddG-TP. 
b Data are the average CI values from the 50%, 75%, 90%, and 95% inhibition levels. Data are 
the means ± standard deviations from least 3 independent experiments. 
c Experiments of DNA synthesis with a functional excision mechanism included 3 mM ATP. 
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Figure 6.4 Fraction-affected versus combination index plots for 3’-azido-2,6-DA-P-TP+3’-
azido-ddG-TP combinations. 
The Fa-CI plots for inhibition of WT (blue circles), T69SSS (red squares), and Q151Mc (green 
triangles) HIV-1 RT DNA synthesis in the absence (top panels) and presence (bottom panels) of 
nucleotide excision. The blue line at CI = 1 represents additive effect. Data are the means of 3 
independent experiments using [α-32P]dATP. The excision mechanism (bottom panels) was 
facilitated by the addition of 3 mM ATP. 
 
 
For reactions in which ATP was included to facilitate NRTI-MP excision, every 
combination, regardless of which reporter radionucleotide was used, demonstrated strong or very 
strong synergy for inhibition of WT, T69SSS, and Q151Mc RT (the one exception was the 1:3 
3’-azido-2,6-DA-P-TP:3’-azido-ddG-TP combination with the [α-32P]dATP reporter). The CI 
values for all 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP combinations from assays with a 
functional excision mechanism (i.e. ATP included) were almost always lower than those of the 
same combination for assays without ATP, although these were not statistically significant. 
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Figure 6.5 Normalized 50% effect isobolograms for of 3’-azido-ddG-TP-TP+3’-azido-ddG-
TP combinations. 
The plots show the ratios observed in P4R5 cells (2.4:1, circles), PBM cells (1.1:1, triangles), 
and a 1:3 ratio (squares) against WT (black symbols), 69SSS (red symbols), and Q151Mc (green 
symbols) HIV-1 RT in the absence (A) and presence (B) of nucleotide excision. The diagonal 
blue line indicates additivity where data points below the line indicate synergy and data points 
above the line indicate antagonism. Data are the means ± standard deviations of three 
independent experiments obtained using [α-32P]dATP.  
 
6.5.5 Normalized isobologram plots indicate synergistic inhibition of RT DNA synthesis 
by 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP combinations 
In order to eliminate bias based on the synergy analysis method, we also plotted normalized 
isobolograms from the same inhibition dataset. Isobologram analysis is a graphical approach to 
synergy determination that has been used since the eighteenth century as a time-tested and 
widely accepted method (301). Isobolograms are created by plotting the normalized doses of 
drug 1 and drug 2 on the x- and y-axes, respectively. A diagonal line connecting the points (0,1) 
and (1,0) is the line of additivity. Data points for combinations below the line are synergistic and 
those above the line are antagonistic. The isobolograms (Figure 6.5) showed that most 
combinations of 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP were synergistic for inhibition of WT, 
T69SSS, and Q151Mc RT DNA synthesis, regardless of which reporter radionucleotide was 
used. The relative degree of synergy from isobolograms can be indicated as an average deviation  
144 
Table 6.6 Normalized 50% effect average deviation from additivity (ADA) values of 3’-
azido-2,6-DA-P-TP+3’-azido-ddG-TP combinations against WT, 69SSS, and Q151Mc RT 
DNA synthesis. 
 
HIV-1 RT DNA Synthesis 
RT 
[α-32P]dATP  [α-32P]dGTP 
P4R5 
(2.4:1) a 
PBM 
(1.1:1) 1:3  
P4R5 
(2.4:1) PBM (1.1:1) 1:3 
WT -0.39 b,c -0.49 -0.36  -0.18* -0.21* -0.25* 
T69SSS -0.47 -0.57 -0.59  -0.26* -0.13* -0.04* 
Q151Mc -0.14* -0.27 0.09*  -0.28* -0.28* -0.36* 
HIV-1 RT DNA Synthesis With Excision d 
RT 
[α-32P]dATP  [α-32P]dGTP 
P4R5 
(2.4:1) 
PBM 
(1.1:1) 1:3  
P4R5 
(2.4:1) PBM (1.1:1) 1:3 
WT -0.53 -0.51 -0.52  -0.32* -0.28* -0.2* 
T69SSS -0.49* -0.46* -0.65*  -0.28* -0.23* 0.04* 
Q151Mc -0.64 -0.65 -0.67  -0.44* -0.38* -0.2* 
  
a Drug combinations are displayed as the ratio of 3’-azido-ddG-TP-TP:3’-azido-ddG-TP. 
b Data are the ADA values calculated as described in the Materials and Methods where N ≥ 3 
independent experiments. 
c All values were statistically significant as determined by one-tailed homoscedastic T-tests. 
d Assays of DNA synthesis with a functional excision mechanism included 3 mM ATP. 
*Indicates p < 0.05, all other values p < 0.01. 
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from additivity (ADA) value, which is a calculation of the statistical distance of a combination 
data point from the additivity line (302). As long as the values are statistically significant (p-
value < 0.05), negative ADA values indicate synergy and lower values indicate stronger synergy. 
The ADA values for 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP combinations are presented in 
Table 6.6. The ADA values for every 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP combination 
were statistically significant and most combinations displayed synergy for inhibition of DNA 
synthesis WT, T69SSS, and Q151Mc RTs. Moreover, the degrees of synergy indicated by the 
isobologram ADA values and the median effect CI values are ostensibly identical, thus 
demonstrating good concordance between the two synergy analysis methods. 
6.6 DISCUSSION 
Our intracellular pharmacology studies show that RS-788, a novel phosphoramidate prodrug of 
3’-azido-2,6-DA-P, is metabolized in P4/R5 cells to both 3’-azido-2,6-DA-P-TP and 3’-azido-
ddG-TP, whereas 3’-azido-2,6-DA-P and 3’-azido-ddG are both converted to 3’-azido-ddG-TP 
as the major active metabolite. This pattern of intracellular metabolism in P4/R5 cells is 
consistent with RS-788 intracellular metabolism in PBM cells (254, 255). Of note, RS-788 
incubation resulted in the intracellular delivery of the same amount of total nucleotide-TP (38 × 
106 pmol/million cells 3’-azido-2,6-DA-P-TP/3’-azido-ddG-TP) to both P4/R5 cells and PBM 
cells. 3’-azido-2,6-DA-P, however, was metabolized 2.5-fold less efficiently to 3’-azido-ddG-
TP/3’-azido-2,6-DA-P-TP in P4/R5 cells (23 × 106 pmol/million cells) compared to PBM cells 
(58 × 106 pmol/million cells). Additionally, the reduction of natural dATP and dGTP pools in 
cells treated with RS-788 would presumably decrease the competition for 3’-azido-2,6-DA-P-TP 
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and 3’-azido-ddG-TP incorporation by HIV-1 RT, which may be one mechanism responsible for 
the increased potency of RS-788. The prodrug RS-788 delivers two chemically distinct 
metabolites, 3’-azido-ddG-TP and 3’-azido-2,6-DA-P-TP, each of which are potent HIV-1 RT 
chain terminators that are incorporated opposite different complementary bases (cytosine for 3’-
azido-ddG-TP and thymine for 3’-azido-2,6-DA-P-TP). The intracellular delivery of 2 different 
chain terminating nucleotides from one parent prodrug has not been previously achieved.  
Next we characterized the antiviral activity and phenotypic cross-resistance profile of 
RS-788 against a broad panel of NRTI-resistant HIV-1. RS-788 exhibited 10-fold more potent 
activity against WT HIV-1 replication than its parent analogs 3’-azido-2,6-DA-P and 3’-azido-
ddG. Furthermore, HIV-1 viruses carrying discrimination mutations were hypersusceptible or 
similarly susceptible as WT virus to RS-788 and HIV-1 containing multiple TAMs was only 
marginally decreased (2.3-fold) to RS-788 potency compared to WT HIV-1. RS-788 also had 
remarkable activity against multi-NRTI-resistant HIV-1compared to its parent analogs 3’-azido-
2,6-DA-P and 3’-azido-ddG. Against HIV-1 with the Q151M complex, the potency of RS-788 
was decreased relative to that of WT virus only 2.3-fold (EC50 = 0.28 µM), whereas that of 3’-
azido-2,6-DA-P (EC50 = 26.6 µM) and 3’-azido-ddG (EC50 = 27.3 µM) were decreased 23- and 
26-fold, respectively. Similarly, the potency of RS-788 against HIV-1 with the 69-insertion 
mutations (EC50 = 0.44 µM) was decreased from that of WT virus 3.7-fold compared to 9.5- and 
8.3-fold for 3’-azido-2,6-DA-P (EC50 = 11.2 µM) and 3’-azido-ddG (EC50 = 8.7 µM). Taken 
together, these date show that RS-788 has a far superior activity and cross-resistance profile than 
3’-azido-2,6-DA-P or 3’-azido-ddG. 
The excellent activity of RS-788 against multi-NRTI-resistant HIV-1 could not be fully 
explained by structure-activity studies of purified RT described in the previous chapter because: 
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1) 3’-azido-2,6-DA-P-TP is less potent than 3’-azido-ddG-TP against the Q151M complex RT; 
and 2) 3’-azido-2,6-DA-P-MP is a better substrate than 3’-azido-ddG-MP for excision by 
M41L/L210W/T215Y RT. Consequently, we hypothesized that inhibition of drug resistant HIV-
1 by RS-788 is due to an alternate mechanism, such as incorporation and chain termination at 
both T and C positions by 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP, respectively. To 
evaluate this hypothesis, we performed DNA synthesis assays with WT and multi-NRTI-resistant 
RT in the presence of combinations of 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP. Drug synergy 
analyses by both the median-effect and normalized isobologram methods indicated synergistic 
inhibition of HIV-1 RT DNA synthesis by combinations of 3’-azido-2,6-DA-P-TP+3’-azido-
ddG-TP at the intracellular molar ratios detected in P4/R5 and PBM cells. Moderate synergy was 
indicated for inhibition of WT and 69-insertion HIV-1 RT DNA synthesis, whereas weak 
synergistic or additive inhibition was seen against Q151Mc RT. Furthermore, the excision 
mechanism conferred by TAMs does not diminish the observed synergy. Taken together our data 
demonstrate that the combined intracellular delivery of 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-
TP by RS-788 provides synergistic inhibition of reverse transcription by NRTI-resistant RT. 
These findings help explain the superior activity of RS-788, compared to its parent analogs 3’-
azido-2,6-DA-P and 3’-azido-ddG, against highly NRTI-resistant HIV-1. 
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7.0  SUMMARY AND FINAL DISSCUSSION 
Combination antiretroviral therapy, commonly containing two or more NRTI, suppresses HIV-1 
replication and reduces patient morbidity and mortality (36).  However, the effectiveness of the 
currently FDA approved NRTI is limited by the rapid selection of drug-resistant viral variants 
that are often cross-resistant to other NRTI (242). Therefore, there is a critical need to develop 
novel NRTI that show little or no cross-resistance with existing NRTI. To address this need, our 
research group adopted a rational drug design approach using mechanistic knowledge of how 
NRTI structural components affect activity against drug-resistant RT to direct the synthesis of 
novel analogs with improved activity against NRTI-resistant viral variants.  
Shortly before this work began, Sluis-Cremer et al. and Parikh et al. described the initial 
structure-activity-resistance relationships that identified the 3’-azido-2’,3’-dideoxypurines as 
lead class of novel NRTI that demonstrate excellent activity against NRTI-resistant HIV-1 (141, 
212). Specifically, 3’-azido-ddG potently inhibited replication of HIV-1 containing the 
discrimination mutations K65R, L74V, and M184V, and against HIV-1 containing excision 
enhancing TAMs (172). Furthermore, 3’-azido-ddG had good specificity for inhibition of HIV-1 
RT with minimal toxicity in multiple cell lines and showed a low potential for mitochondrial 
toxicity or bone marrow depletion.  
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The research presented in this dissertation sought to expand on this work by investigating 
the structure-activity-resistance relationships for: i) two novel nucleotide analogs, PMEO-
DAPym and GS-9148; and ii) base-modified-3’-azido-2’,3’-dideoxypurine nucleoside analogs.  
i) PMEO-DApym and GS-9148 are both novel structural analogs of the NtRTI TFV. 
Preliminary studies showed that both PMEO-DAPym and GS-9148 had improved activity 
compared to TFV against clinical HIV-1 isolates containing discrimination mutations and those 
containing TAMs (262, 263). Additionally, cell culture selection experiments with GS-9148 
yielded resistant variants with the novel combination of resistance mutations 
K70E/D123N/T165I that are not selected by other NRTI and are infrequently observed in 
treatment-naïve and treatment-experience patients (268). The encouraging activity and resistance 
phenotypes of each of these novel analogs warranted a detailed characterization of the molecular 
mechanisms of WT and NRTI-resistant RT inhibition. 
ii) Given that natural base identity can influence NRTI activity towards drug-resistant 
RT, it is expected that base modification will also impact NRTI activity. However, the molecular 
interactions of base-modified analogs with WT or NRTI-resistant HIV-1 RT have not been 
extensively studied. Accordingly, we synthesized a series of novel base modified 3′-azido-2′,3′-
dideoxypurine analogs (143). The specific molecular interactions of these analogs with HIV-1 
RT were characterized in order to identify base modifications that may further improve 3′-azido-
2′,3′-dideoxypurine activity against NRTI-resistant HIV-1.  
The running hypothesis of the work in this dissertation was that acquiring specific 
knowledge of how NRTI structural components (such as base and sugar/pseudosugar) influence 
NRTI activity against WT and NRTI resistant RT, will inform the rational design and 
development of new analogs that demonstrate excellent activity and resistance properties. This 
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hypothesis was investigated in the context of the novel nucleotide and nucleoside reverse 
transcriptase inhibitors described above. The concluding chapter will summarize the important 
structure-activity-resistance findings from this research and highlight how they may influence 
future antiretroviral research and development. 
7.1 PMEO-DAPym: A PURINE DISGUISED AS A PYRIMIDINE 
The novel acyclic nucleoside phosphonate PMEO-DAPym differs structurally from the prototype 
analog TFV in both the pseudosugar and base components (261). With PMEO-DAPym a 2,6-
diamino-pyrimidine base is linked to an ethoxy pseudosugar at the C6-ring position, whereas, 
with TFV the purine base (i.e. adenine) is linked to a propoxy pseudosugar at the traditional N-9 
ring position. Using a combination of steady-state and transient kinetic RT DNA synthesis and 
molecular modeling analyses we characterized the molecular interactions between the active 
sites of WT and NRTI-resistant RT and PMEO-DAPym-DP.  
We show that PMEO-DAPym-DP acts as a purine analog mimetic in that it is recognized 
by HIV-1 RT as an adenosine analog and specifically incorporated across from thymine in DNA 
templates or uracil in RNA templates. The 2,6-diamino-base substitutions and the novel linker 
position allow the PMEO-DAPym pyrimidine base to mimic an incomplete purine ring. 
Molecular modeling studies show that PMEO-DAPym-DP forms a similar base pairing 
interaction with thymine and assumes a similar conformation in the active site HIV-1 RT as 
TFV-DP. Our studies provide the first demonstration that a pyrimidine nucleotide analog can be 
selectively recognized as an adenine nucleotide derivative for binding and incorporation into the 
growing DNA chain by HIV-1 RT. It appears as though the molecular mimicry of an adenine 
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base by PMEO-DAPym is important for recognition by HIV-1 RT because the PME-pyrimidine 
derivatives (same ethoxy linker but the pyrimidine base linkage is at the traditional N-1 position) 
do not possess antiviral activity (274, 280). PMEO-DAPym-DP was also recognized as 
adenosine and incorporated across from thymine by human DNA polymerase α.  
Although TFV and PMEO-DAPym are both recognized as adenosine, the efficiency with 
which PMEO-DAPym and TFV can be incorporated or excised across from thymine by WT and 
drug-resistant RT differs. HIV-1 RT containing the K65R mutation incorporated PMEO-
DAPym-DP 3-fold more efficiently than TFV. Additionally, PMEO-DAPym-MP was a less 
efficient substrate than TFV-MP for ATP-mediated excision by RT containing TAMs. These 
divergent resistance characteristics may make it more difficult for the virus to escape drug 
pressure and may eventually exert lower phenotypic drug resistance levels. This is supported by 
lower phenotypic resistance of HIV-1 clinical isolates in cell culture for PMEO-DAPym 
compared to TFV (262). Additional studies, such as cell culture selection experiments and 
phenotypic cross-resistance analysis, should be performed for PMEO-DAPym to further 
elucidate the potential resistance advantages displayed by this nucleotide.  
It is not known to what extent the differing pseudosugar linkers of PMEO-DAPym (i.e. 
ethoxy) and TFV (i.e. propoxy) affect the observed phenotypes. The PMPO-DAPym analog (i.e. 
identical DAPym base but with a propoxy linker like TFV) has slightly decreased activity against 
HIV-1 clinical isolates compared to PMEO-DAPym but its activity against NRTI-resistant HIV-
1 or RT has not been thoroughly characterized (280). A direct structure-activity comparison of 
the incorporation and excision efficiencies of PMEO-DAPym and PMPO-DAPym could 
elucidate the specific role of the ethoxy and propoxy linkers.   
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The studies of PMEO-DAPym inhibition of HIV-1 RT and human DNA polymerases 
described here identify a novel substrate mimicry mechanism in which a base modified 
pyrimidine derivative can be recognized for incorporation by a polymerase as a purine analog. 
Using the PMEO-DAPym structure as a starting point, novel pyrimidine nucleotide analogs may 
be rationally designed to mimic incomplete purine ring systems. For example, PMEO-DAPym 
derivatives with 5-methyl, 5-bromo, and 5-Cl substitutions have been shown to inhibit HIV-1 
replication but have not been thoroughly characterized (262). Ostensibly, these 5-position 
substitutions are compatible with adenine mimicry. Molecular comparisons of RT inhibition by 
the 5-modified derivatives and PMEO-DAPym, like those described in this work, would expand 
the structure-activity understanding of this nucleotide class. Other 2- and 4-position pyrimidine 
base substitutions (e.g. 2,4-dicarbonyl and combinations of amino-, carbonyl-, chloro-, bromo-
modifications at each position) in the context of a C-6 sugar/pseudosugar may facilitate 
molecular mimicry of the guanine and hypoxanthine purine ring systems. In addition to base 
modifications, these DAPym derivatives can be linked at the C-6 position to other pseudosugar 
linker structures as well as natural and modified ribose and 2’-deoxyribose sugars in both the D 
and L conformations. These analogs should be evaluated for antiviral activity (against 
retroviruses and DNA viruses such as herpesviruses, poxviruses and hepatitis B virus), as 
potential antimetabolites in purine and pyrimidine nucleoside/nucleotide metabolism, and for 
activity toward other DNA and RNA polymerases. 
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7.2 GS-9148: SUGAR MODIFICATION LEADS TO DIVERGENT RESISTANCE 
MECHANISMS 
Next, we used pre-steady state kinetic analyses to characterize the molecular mechanisms of 
discrimination resistance conferred by the previously unrecognized pattern of RT mutations, 
K70E/D123N/T165I which were selected by GS-9148, another investigational phosphonate 
NtRTI (268). GS-9148 and TFV both contain an adenine base and the same phosphonate 
structure but differ in their sugar/pseudosugar structure (263). TFV contains an acyclic propyl 
pseudosugar linker to the phosphonate, whereas GS-9148 contains a 2’-fluoro-3’-deoxy-2’,3’-
didehydroribose sugar linked to the phosphonate. Overall we observed low levels of resistance to 
GS-9148 by progressively increasing discrimination phenotypes towards GS-9148-DP by K70N, 
K70E, and K70E/D123N/T165I HIV-1 RT, respectively. The discrimination phenotype of 
K70E/D123N/T165I RT was driven by a 2.4-fold decrease in nucleotide binding affinity (Kd), 
compared to WT RT. This is contrary to the mechanism of resistance toward TFV-DP by RT 
containing the K65R or K70E mutations. Our studies and those in the literature showed that 
K65R and K70E resistance to TFV-DP is primarily due to decreased incorporation rate with little 
effect on nucleotide binding to the active site (160, 161). Furthermore, our results indicate that 
the K70E/D123N/T165I mutations confer resistance to GS-9148 and TFV by different 
mechanisms of discrimination between the natural nucleotide dATP and GS-9148 or TFV. 
Namely, GS-9148 showed deficits in both binding and incorporation rate compared to dATP, 
whereas TFV showed only a decreased incorporation rate in relation to dATP. The fact that GS-
9148 and TFV, differing only in their sugar/pseudosugar structure, develop differing resistance 
mutations which confer resistance through different mechanisms reaffirms that nucleotide sugar 
is an important determinant for NtRTI resistance development.  
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The molecular mechanisms by which the K70E, D123N, and T165I mutations modulate 
the binding and rate of incorporation of GS-9148 are unknown. GS-9148 binding affinity is 
likely modulated through interactions of the RT active site residues with the GS-9148 modified 
sugar because decreased binding affinity was not observed for TFV or dATP, that contain the 
same base and phosphonate structures as GS-9148. The decreased rate of nucleotide 
incorporation for RT containing K70E has been attributed to destabilization of the nucleotide 
gamma phosphate modulated through the K65 residue (161, 211). A similar mechanism may be 
partially responsible in the case of GS-9148 incorporation rate deficits, however another 
mechanism must also be responsible since RT containing the D123N/T165I mutations alone also 
incorporated GS-9148 slower than dATP. Crystallization and/or molecular modeling studies 
could shed further light on the molecular basis of GS-9148 discrimination by this novel 
combination of mutations.   
The K65R mutation, selected by TFV, and the K70E mutation are antagonistic to one 
another and are never found on the same genome (211). It would be interesting to examine 
whether significant phenotypic resistance could develop in the presence of both GS-9148 and 
TFV in cell culture selection studies. Additive or slightly synergistic anti-HIV-1 activity has 
already been demonstrated for the combinations of GS-9148 and TFV, and competition for 
activation by cellular enzymes was not observed for concentrations of TFV and GS-9148 
combinations above those required for HIV-1 inhibition (290).  
GS-9148 has a low potential for cross-resistance with existing NRTI due to its excellent 
activity against a broad panel of NRTI-resistant HIV-1 and the selection of a novel combination 
of infrequently observed resistance mutations (263, 268). Additionally, GS-9148 and its 
phosphonoamidate prodrug GS-9131 demonstrate favorable toxicity and pharmacokinetic 
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properties including a low potential for mitochondrial and renal toxicity, low possibility of 
pharmacokinetic interactions with other NRTI, and sufficient accumulation of active nucleotide 
triphosphate in lymphoid cells with a long intracellular half-life of 19 hours (263, 266, 290). 
These properties along with the novel mechanism of resistance described here suggest GS-9148 
should be further evaluated as a clinical NRTI candidate.  
7.3 BASE-MODIFIED ANALOGS OF 3’-AZIDO-2’,3’-DIDEOXYGUANOSINE: 
SUBSTRATE MIMICRY 
Applying the knowledge from Sluis-Cremer et al. that base identity, in the context of 3’-azido-
2’,3’-dideoxypurine NRTI, influences activity and resistance phenotypes we synthesized a series 
of novel 3’-azido-2’,3’-dideoxypurine analogs with base modifications (141, 143). Five of these 
analogs, all with 6-position guanine base modifications, showed similar or greater anti-HIV-1 
activity as 3’-azido-ddG in PBM cells. In the current work, we sought to expand the structure-
activity-resistance profile of 3’-azido-2’,3’-dideoxypurine NRTI through a mechanistic analysis 
of the activity of the 6-modified-3’-azido-2’,3’-dideoxyguanosine analogs against WT and 
NRTI-resistant HIV-1 RT.  
Steady state and transient kinetic RT DNA synthesis assays unexpectedly revealed that 
each of the 6-modified-3’-azido-ddG-TP analogs behaved as adenosine rather than guanosine 
mimetics for incorporation by HIV-1 RT across from thymine in DNA templates or uracil in 
RNA templates. The nature of the 6-modification, however, affected the efficiency of 
incorporation. In transient kinetic assays 3’-azido-2,6-DA-P-TP was incorporated by WT RT 
with similar efficiency as dATP (selectivity value versus dATP = 1.1). 3’-azido-6-CL-P-TP and 
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3’-azido-6-AA-P-TP were also efficiently incorporated into DNA by RT, however, were poor 
substrates for RT incorporation. Our molecular modeling analyses supported these results 
showing planer base pair interactions of the efficiently incorporated analogs with the template 
thymine. However, the poorly incorporated analogs, 3’-azido-6-DM-P-TP and 3’-azido-6-MX-P-
TP, had altered base pair alignments, ostensibly due to steric clash of the branched 6-DM moiety 
and electronic incompatibility of the 6-MX group, respectively. The favorable base pair 
conformations seem to position the nucleotide α-phosphate for chemical reaction with the primer 
3’-OH, whereas the α-phosphate is positioned further from the 3’-OH for analogs with 
misaligned bases. Furthermore, compared to the canonical A:T base pair (with two H-bonds), the 
additional hydrogen bond achieved by the 3’-azido-2,6-DA-P:thymine base pair may further 
stabilize the α-phosphate and explain the excellent catalytic efficiency observed in pre-steady-
state assays.  
The  K65R, L74V and Q151M complex discrimination mutations conferred low levels of 
resistance to the 3’-azido-2’,3’-dideoxypurines, however, 6-position modification did not 
significantly affect the discrimination phenotype. The mutant HIV-1 RTs exhibited fold-
resistance values to each of the 6-modified-3’-azido-ddGTP analogs that were similar (i.e. <2-
fold) to the fold change in resistance values determined for 3’-azido-ddATP. The only 
statistically significant exceptions (P<0.05) included 3-azido-6-AA-P-TP and 3’-azido-2,6-DA-
P-TP which exhibited better activity against K65R HIV-1 RT and M184V HIV-1 RT, 
respectively. 
Assays of ATP-mediated excision revealed a different structure-activity relationship than 
that for 6-modified-3’-azido-ddG-TP incorporation. RT containing TAMs could unblock T/Ps 
chain-terminated with 3’-azido-ddAMP, 3’-azido-2,6-DA-P-MP, and 3’-azido-6- AA-P-MP. By 
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contrast, 3’-azido-6-Cl-P-MP, 3’-azido-6-MX-P-MP, and 3’-azido-6-DM-P-MP were poor 
substrates for ATP-mediated excision by RT containing TAMs. Consistent with the altered 
patterns of incorporation and excision observed in biochemical assays, our molecular models of 
the excision products of 6-modified-3’-azido-ddG analogs reveal different hydrogen bonding 
patterns than those observed in the models for nucleotide-TP incorporation. For example, 3’-
azido-6-Cl-P-MP has lost a hydrogen bond in its excision model compared to the model for 3’-
azido-6-Cl-P-TP incorporation. Together, these data suggest that the optimal conformation of the 
HIV-1 RT active site differs for the incorporation and excision reactions and further suggest that 
6-position modifications differentially effect these two reactions. Therefore, our data support the 
hypothesis that it may be possible to rationally design new analogs that are efficiently 
incorporated by RT but poorly excised from blocked primers. For example, 3’-azido-6-Cl-P-TP 
is a relatively good substrate for incorporation, but it is not efficiently excised by either WT or 
TAM-containing HIV-1 RT. Analogs with these favorable but divergent qualities may exhibit 
more potent inhibition of drug-resistant HIV-1 replication, thus resulting in lower levels of 
phenotypic drug-resistance. Further optimization of these qualities might be achieved by 
structure-activity-resistance analyses of additional 3’-azido-2’-3’-dideoxypurine analogs 
modified at both the 2- and 6-positions of the purine ring system.  
It remains to be seen whether the non-traditional base pair interactions observed with 6-
position purine modifications would also facilitate efficient incorporation of NRTI with sugar 
structures other than 3’-azido-2’,3’-dideoxy-ribose. Synthesizing a series analogs containing the 
6- modified-guanosine bases (especially the 2,6-DA-P base) with a diverse set of modified 2’,3’-
didoxyribose sugars in order to more fully evaluate the antiviral benefits of this artificial base 
pair is tempting. Preliminary studies show that 3’-azido-2’-3’-dideoxypurine analogs are also 
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recognized as adenosine mimetics by human DNA polymerases suggesting the adenosine 
mimetic phenotype is not unique to incorporation by HIV-1 RT (unpublished, data not shown). 
Therefore, linking these modified bases to other sugars (such as ribose) may extend their activity 
to other polymerases (such as RNA polymerase).  
 
7.4 RS-788: COMBINATION THERAPY FROM ONE PRODRUG? 
Although, 3’-azido-2,6-DA-P-TP potently inhibited DNA synthesis by NRTI-resistant RT 
through incorporation and chain-termination as an adenosine analog in biochemical assays, it 
was extensively metabolized to 3’-azido-ddG in PBM and P4R5 cells (295, 296, CHAPTER 
FOUR). Therefore, the potent anti-HIV-1 activity of 3’-azido-2,6-DA-P is primarily attributed to 
RT inhibition by 3’-azido-ddG-TP and not due to incorporation of 3’-azido-2,6-DA-P-TP as an 
adenosine analog. In order to further improve 3’-azido-2,6-DA-P antiviral activity by increasing 
the intracellular delivery of its triphosphate form, we synthesized RS-788, a 5’-monophosphate 
prodrug of 3’-azido-2,6-DA-P-TP. Intracellular pharmacology studies in P4/R5 and PBM cells 
showed RS-788 is metabolized approximately 1:1 to both 3’-azido-2,6-DA-P-TP and 3’-azido-
ddG-TP (295, 296, CHAPTER FOUR). Therefore, RS-788 delivers two structurally distinct 
active metabolites, each of which is a potent chain terminating inhibitor that is incorporated 
across from a different complementary base (thymine for 3’-azido-2,6-DA-P-TP and cytosine for 
3’-azido-ddG-TP). The intracellular delivery of two different NRTI from a single prodrug has 
not been previously demonstrated. 
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In PBM cells, RS-788 was 60- and 17-fold more potent against WT HIV-1 replication 
than its parent analogs 3’-azido-ddG and 3’-azido-2,6-DA-P. RS-788 also demonstrated a far 
superior cross-resistance profile compared to 3’-azido-ddG and 3’-azido-2,6-DA-P against a 
broad panel of NRTI-resistant HIV-1 in P4/R5 cells. Importantly, RS-788 was substantially more 
potent than 3’-azido-2,6-DA-P or 3’-azido-ddG against viruses harboring the Q151M complex or 
69-insertion multi-NRTI resistance mutations. For example, the potency of RS-788 against HIV-
1 with the Q151M complex was decreased relative to that of WT virus only 2.3-fold, whereas 
that of 3’-azido-2,6-DA-P and 3’-azido-ddG were decreased 23- and 26-fold, respectively. 
Similarly, the potency of RS-788 against HIV-1 with the 69-insertion mutations was decreased 
from that of WT virus 3.7-fold compared to 9.5- and 8.3-fold for 3’-azido-2,6-DA-P and 3’-
azido-ddG, respectively. The increased potency was not due to increased delivery of active 
metabolite because RS-788 delivered similar overall levels of 3’-azido-ddG-TP/3’-azido-2,6-
DA-P-TP as 3’-azido-ddG and 3’-azido-2,6-DA-P.  
To investigate whether the potent inhibition of drug-resistant HIV-1 by RS-788 may be 
due to additive or synergistic inhibition of RT resulting from incorporation and chain termination 
at both T and C positions by 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP, respectively we 
performed RT DNA synthesis assays with combinations of 3’-azido-2,6-DA-P-TP+3’-azido-
ddG-TP. Combinations of 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP at the molar ratios delivered 
in P4/R5 and PBM cells from RS-788 resulted in synergistic inhibition of RT DNA synthesis by 
incorporation of 3’-azido-2,6-DA-P-TP across from thymine and 3’-azido-ddG-TP across from 
cytosine. Synergy of 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP combinations was noted against 
WT as well as multi-NRTI resistant RT containing the Q151M complex or the T69SSS insertion 
mutations. Importantly, the excision mechanism did not impair drug synergy. These data suggest 
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that the low phenotypic levels resistance to RS-788 by multi-NRTI-resistant HIV-1 may be due 
to synergistic inhibition of RT DNA synthesis resulting from chain termination across from both 
thymine and cytosine template residues.  
One reason for including two NRTI in combination antiretroviral therapy is increased 
antiretroviral potency through additive or synergistic inhibition of DNA synthesis (36, 39). We 
have shown that the combinations of 3’-azido-2,6-DA-P-TP+3’-azido-ddG-TP in the molar 
ratios delivered to cells by RS-788 synergistically inhibit HIV-1 RT DNA synthesis and that this 
results in increased potency against HIV-1 replication. A second rationale for including two 
NRTI in combination antiretroviral therapy is increased potency against drug-resistant HIV-1 
variants or an increased barrier to resistance development by including NRTI with divergent 
resistance mechanisms (39, 242). In CHAPTER THREE we showed potent chain-termination of 
DNA synthesis by RT containing discrimination mutations and decreased chain-terminated 
primer unblocking by RT containing TAMs compared to AZT. In CHAPTER FOUR we showed 
that these favorable attributes translate to decreased phenotypic susceptibility in cells of drug-
resistant HIV-1 variants to 3’-azido-2,6-DA-P, 3’-azido-ddG, and their combination delivered by 
the RS-788 prodrug. The inclusion of two NRTI in combination antiretroviral therapy can result 
in a higher barrier to resistance development because HIV-1 RT must simultaneously develop 
mutations that decrease the incorporation and/or increase the excision of two different NRTI 
while maintaining the ability to complete reverse transcription (242). Whether the combined 
delivery of 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP from RS-788 also results in a higher 
barrier to resistance development was not examine in the current work.  However, cell culture 
selection experiments were recently performed with 3’-azido-ddG and 3’-azido-ddA (142). 
Interestingly, 3’-azido-ddG selected for a complex pattern of mutations that only conferred low-
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level resistance. Viruses resistant to 3’-azido-ddA could not be selected. By analogy, these 
results suggest that selection of resistance mutations in the presence of both 3’-azido-2,6-DA-P-
TP and 3’-azido-ddG-TP may not readily occur. To evaluate this hypothesis cell culture selection 
experiments with RS-788, 3’-azido-2,6-DA-P, and 3’-azido-ddG should be performed.  
Taken together, our data suggest that RS-788 may represent the first single prodrug that 
may achieve the same beneficial antiretroviral properties as two individual NRTI used in 
combination antiretroviral therapy. Such a prodrug would also improve patient adherence by 
decreasing patient pill burden as has been shown for fixed-dose NRTI combination pills. 
Consequently, RS-788 should undergo further pre-clinical evaluation. The kinetics of the 
intracellular accumulation, metabolism, and retention of the 3’-azido-2,6-DA-P-TP and 3’-azido-
ddG-TP active metabolites should be examined in detail. Pharmacokinetic properties including 
absorption, tissue distribution, metabolism, and excretion should be evaluated in mice and non-
human primates. Optimization of the unique metabolism and antiviral properties of RS-788 
should also be pursued. These efforts should focus first on modification of the RS-788 phosphate 
moiety as this component has great influence on cellular accumulation and metabolism to the 
active triphosphate forms. Modification of the phosphate chemical shielding groups may alter the 
kinetics and ratios of the active 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP metabolites 
produced in cells. Given that 3’-azido-2,6-DA-P-TP and 3’-azido-ddG-TP demonstrate different 
activities against WT and drug-resistant RT DNA synthesis, an altered intracellular ratio in favor 
of one triphosphate metabolite over the other may actually provide increased antiviral potency. 
Secondly, RS-788 analogs containing non-hydrolysable phosphate linkages should be 
considered. This could be a phosphonate linkage (C-P bond) like that of TFV and PMEO-
DAPym or another non-hydrolysable linkage such as an imidophosphate (N-P bond) or 
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phosphothiol (S-P bond). Since the adenosine deaminase enzyme has substantially decreased 
activity toward the RS-788 nucleotide compared to the 3’-azido-2,6-DA-P-TP nucleoside, it is 
expected that an RS-788 analog containing a non-hydrolysable phosphate group would be 
metabolized in cells almost entirely to 3’-azido-2,6-DA-P-TP (296). Such an analog would allow 
examination of the anti-HIV-1 activity specifically due to incorporation of 3’-azido-2,6-DA-P-
TP incorporation as an Adenosine analog. Finally, phosphate-containing prodrugs of 3’-azido-
2’,3’-dideoxypurine NRTI with bases other than 2,6-DA-P should be synthesized. These bases 
could include those described above that may alter the adenosine mimicry phenotype. 
 
7.5 GENERAL PERSPECTIVES AND FUTURE DIRECTIONS 
The structure-activity-resistance analyses presented in this dissertation unequivocally confirm 
that modifications to NRTI structural components (i.e. base and sugar/pseudosugar) affect 
activity against drug-resistant HIV-1. We have identified novel NRTI analogs (notably RS-788) 
that demonstrate improved activity against drug-resistant HIV-1 containing discrimination 
mutations or TAMs. These studies provide ‘proof of concept’ that a molecular understanding of 
how the structural components of NRTI affect RT enzyme sensitivity can direct the discovery 
novel NRTI analogs with potent activity against drug-resistant HIV-1.  
Though beyond the scope of this dissertation, the rational design of novel NRTI using 
structure-activity relationships should be expanded to include considerations for other NRTI 
limitations such as cellular toxicity and pharmacology. For example, NRTI structure may 
potentially be optimized for decreased mitochondrial toxicity through structure-activity studies 
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of polymerase γ inhibition. Similarly, improved NRTI-TP cellular accumulation and retention 
(i.e. intracellular half-life) might be achieved through optimization of NRTI affinity for the 
cellular kinases.  
PMEO-DAPym, GS-9148, 3’-azido-2,6-DA-P, and RS-788 all have improved activity 
compared to their parent analogs against the replication of HIV-1 containing discrimination 
mutations and TAMs. We have shown that these analogs also have improved incorporation 
activity and decreased excision activity with NRTI-resistant HIV-1 RT in vitro. Whether these 
favorable resistance characteristics against HIV-1 RT also provide a higher barrier to resistance 
development was not examined in this work. However, studies performed by others suggest that 
this is the case (142). Cell culture selection studies with 3’-azido-ddG and 3’-azido-ddA showed 
that resistance to these NRTI developed slowly and a complex combinations of mutations were 
required to develop low levels of phenotypic resistance (142).  
The novel N(t)RTI analogs described in this dissertation (chiefly PMEO-DAPym, 3’-
azido-2,6-DA-P, and RS-788) require further pre-clinical analysis. A more thorough examination 
of the cellular pharmacology should be performed including the kinetics of cellular accumulation 
and retention of the –MP, -DP, and –TP forms, identification of the kinases responsible, and 
kinetics of base metabolism (for 3’-azido-2,6-DA-P and RS-788). Given that any novel NRTI are 
likely to be used in combination with existing NRTI, the potential for synergy and antagonism 
for cellular phosphorylation and antiviral activity should be examined.  
The studies described herein identify substrate mimicry mechanisms in which a 
pyrimidine (i.e. PMEO-DAPym) or a base-modified purine (i.e. the 6-position-modified-3’-
azido-ddG analogs) are recognized by HIV-1 RT as adenosine analogs and are specifically 
incorporated across from thymine in DNA or uracil in RNA. This molecular mimicry phenotype 
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shows that HIV-1 RT and human DNA polymerases can recognize and incorporate nucleotide 
analogs with ambiguous base modifications. Our molecular modeling studies show these non-
traditional bases can mimic conical Watson-Crick base pairing to allow efficient nucleotide 
incorporation. For example, 3’-azido-2,6-DA-P could be incorporated by HIV-1 RT with equal 
efficiency as the natural 2’-deoxynucleotide dATP. Other purine ring modifications at the 2- and 
6-positions may facilitate incorporation across from cytosine thus mimicking a guanosine ring 
system. This molecular mimicry mechanism may represent a novel means of base-modified 
nucleotide analog design for the inhibition of microbial and human DNA and RNA polymerases 
that may have therapeutic use against viruses, bacteria, parasites, or cancer.  For instance, 
linkage of such an ambiguous base to a ribose sugar may endow the analog with activity against 
RNA polymerases, such as the viral RNA polymerases required for HCV and dengue virus 
replication. Analogs with ambiguous bases should also be evaluated as anti-metabolites against 
the cellular nucleoside/nucleotide synthetic enzymes for potential therapeutic use in metabolic 
disorders.   
The knowledge gained through this dissertation research has the potential to allow further 
optimization of lead analogs that may yield novel NRTI candidates for the treatment of highly 
drug-resistant HIV-1.  Such analogs are crucial for the continued success of the NRTI drug class 
in combating the HIV-1 epidemic.  
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